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ABSTRACT
This thesis describes research undertaken in peptidomimetic chemistry, concerned 
with stabilisation of peptide secondary structure.
The first section describes the successful synthesis of two triazepinediones for 
potential application as cis prolyl mimetics and/or (3-turn mimetics. The first 
triazepinedione 64, carrying an V-phenyl substituent, was subjected to reductive 
conditions in an unsuccessful attempt to generate a cis prolyl peptide. The second 
triazepinedione 72 was designed as a Gly-cw Pro-Phe peptidomimetic. Its synthesis 
proceeded in 8 steps, via a chiral a-hydrazino acid. Triazepinedione 72 was extended 
from both the N  and C termini, demonstrating that it could be incorporated into a 
peptide.
The second section describes the design and attempted synthesis of an iV-terminal 
template for stabilisation of a-helical structure in an attached peptide. Preliminary 
efforts to produce a Pro-Pro-Ala macrocycle 91 and a Pro-Pro-Pro ether macrocycle 
98 were unsuccessful. Attempts to synthesise a Pro-Pro-Pro thioether macrocycle 112 
resulted in formation of a cyclic dimer 122. The formation of this dimer was proposed 
to be due to excessive steric hindrance in the transition state to cyclisation. Attempts 
to stabilise the desired folded transition state by a-methylation of proline residues or 
hydrogen bonding did not allow synthesis of any of the desired monomeric cyclic 
material.
A monomeric cyclic compound was finally obtained by increasing the flexibility 
of the linear precursor, affording a Pro-(2R)-Ala-Pro thioether macrocycle 151. 
X-Ray crystallography and 2D NMR studies established that this macrocycle lacked 
the required arrangement of carbonyl groups conducive to initiation of an a-helix. 
Further NMR studies of macrocycle-peptide conjugates suggested that the macrocycle 
exerted a conformational influence only over the first residue of the attached peptide. 
The carbonyl groups of the macrocycle were found to adopt a significant degree of 
a-helical geometry upon attachment of a C-terminal cationic trialkylammonium 
group.
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1. INTRODUCTION
1.1 Biologically Active Peptides
Peptides are essential to almost every biochemical process, regulating diverse 
functions in the cai’diovascular, gastrointestinal, immunological, and central nervous 
systems. These crucially important molecules span a wide range of sizes from those 
with fewer than ten constituent amino acids up to proteins containing hundreds of 
residues. The function of these compounds varies as much as their size and structural 
complexity. Proteins may serve structural roles or act as enzymes to catalyse a myriad 
of complex chemical transformations.
This report will focus on structural aspects of peptides, especially those 
containing fewer than 50 residues. These compounds generally serve roles as 
chemical messengers, eliciting a physiological response in a cell by interacting with a 
membrane-bound receptor, thus acting as hormones and neurotransmitters in the 
regulation of a host of essential processes.
Important examples include the opioid peptides (endorphins, enkephalins and 
dynorphins) which possess analgesic properties;  ^ angiotensin II 1, which helps 
regulate blood pressure;  ^ bradykinin 2 , a vasodilator and bronchioconstrictor; 
oxytocin 3, responsible for uterine contraction;  ^ and somatostatin 4 which controls 
the release of growth factor from the hypothalamus, amongst other effects 
(Fig. 1.1).  ^ Whilst hardly critical for human function, the dipeptide sweetener
Aspartame™ 5 certainly possesses significant economic importance.
Peptides bind to their receptors in a particular conformation, the so-called 
bioactive conformation, even though they possess great conformatonal flexibility in 
solution. As such, the three-dimensional structure adopted by a peptide upon binding 
is crucial to its function. A description of the various structure types available to 
peptides and a discussion of the factors which determine the energetically accessible 
conformations adopted now follows.
AspArgValTyrlleHisProPhe AlaGlyCysLysAsnPhePheTrpLysThrPheThrSerCys
Angiotensin I I 1 Bradykinin 2
CysTyrlleGlnAsnCysProLenGly-NHz ArgProProGlyPheSerProPheArg 
Oxytocin 3 Somatostatin 4
AspPhe-OMe 
Aspartame 5
Figure 1.1: Some biologically important peptides
1.2 Peptide Structure
1.2.1 General Features
The description of peptide and protein structure is usually split into four groups, 
each reflecting a different level of complexity:
• Primary Stmcture, the sequence of amino acids;
• Secondary Structure, the folding of this sequence into basic motifs {e.g. 
a-helix, (3-sheet, (3-turn);
• Tertiary Structure, how these motifs pack together;
• Quaternary Structure, how large areas of tertiary structure interact between 
separate sub-units of a protein.
The interactions between individual residues, peptide chains or whole units of 
structure which govern the structures adopted may be covalent (disulfide bridges),
electrostatic (hydrogen bonds, salt bridges) or hydrophobic (clustering of non-polar 
groups) in nature.
In the case of the shorter peptides, only primary and secondary structures are 
important, the latter being especially critical in interactions with receptors. Each of 
the types of interaction listed above may be involved to a greater or lesser extent in 
determining stable conformations.
Secondary structure of peptides and proteins is described by a set of torsion 
angles for each residue within the chain (Fig. 1.2).
r
Figure 1.2: Dihedral angles used to describe peptide conformation
The important torsion angles are: Phi ((])), around the N—C“ bond;
Psi (\|/), around the C“—CO bond;
Omega (cd), around the CO—N bond;
Chi (x), around the C®^—CP bond.
Knowledge of each of these angles for the whole peptide describes its 
conformation; certain values for the residues within a sequence defines the peptide’s 
structure as a P-turn, P-sheet or an a-helix.
The angles (]), \j/ and % may cover a wide range, but co can only adopt values close 
to 0 ° (cis) or 180° (trans), due to the partial double bond character inherent in the 
amide bond.
The two most important parameters (|) and \]/ can be plotted on a Ramachandran 
Plot. This is a useful graphical representation of the low-energy (j) and y  values 
allowed for residues in a peptide, as depicted in Fig. 1.3. Less than half the area of the 
plot is accessible for the naturally-occurring L-series of amino acids, with each 
separate area corresponding to a certain structure type. The bottom left quadrant 
contains right-handed a-helices (Œr), the top left quadrant ^-structures, and the top 
right quadrant left-handed a-helices (ai).
180
120
-60
-120
-180
-180 -120  -60 0  60 120 180
4)
Figure 1.3 Ramachandran plot showing low-energy dihedral angles
These p-structures (turns and sheets) and a-helices account for the majority of 
conformations adopted by peptides and protein chains. The P-turn and a-helix in 
particular are the central areas of study in this thesis, and a detailed description 
follows.
1.2.2 The P-Turn
A p-tum (reverse turn or hairpin bend) is a sequence of the peptide chain where it 
folds back on itself (Fig. 1.4).
HN H J= 0  
V=0"""H“-N
>  X
Figure 1.4: General structure of a ^-tum
p-Turns contain four residues which each possess a different set of (<|), \j/) values, 
and a distance between the C“ atoms of the first residue i and the fourth residue 
{i + 3) of < 7Â. Most p-turns possess a stabilising hydrogen bond between the
carbonyl group of residue i and the NH of residue (i + 3), which closes a ten- 
membered ring. Model studies show that the ten-membered ring formed by the 
hydrogen bond is enthalpically favoured, with a near optimal hydrogen bond 
geometry, but entropically disfavoured, since chain flexibility is reduced.
P-Turns are classified into several groups according to the ((|), \j/) values for the 
middle two residues {i + 1) and {i + 2). The type VI turn is a special case which 
incorporates a cis peptide bond between residues {i+ 1) and {i + 2 ), residue (i + 2 ) 
being proline (Fig. 1.5).
Proline’s unique cyclic nature renders it common within P-turns, at positions 
(z + 1) (trans Pro) or (i + 2) (cis Pro). A P-turn is especially favoured in model 
peptides containing proline where the preceding residue has the D configuration. 
Glycine is also prevalent; due to its lack of a-substitution, it is more flexible and is 
able to adopt a wider range of dihedral angles, thus avoiding unfavourable
interactions which might disfavour the turn. The [{i + 1), (i + 2)] = (Pro, Gly)
sequence is very common; half of all proline residues followed by glycine are 
involved in a (3-turn.
/ + 2I +
HN
N
i + 3
Figure 1.5: A type VI p-turn
Reverse turns are often found at the surfaces of proteins, and are important for 
linking together sections of a-helix and p-sheet, especially in joining adjacent strands 
of an anti-parallel p-sheet.  ^ They have been implicated in initiation of protein 
folding ^  since they are integral to p-sheet structure and can help “start o ff’ a 
helix. Many biologically active peptides including bradykinin 2, somatostatin 
4, and tuftsin have been proposed to adopt a P-turn conformation in the receptor- 
bound form, especially when proline is a constituent residue.
A rather less common type of reverse turn exists which is closely related to the 
p-turn. This is the y-turn, which comprises three residues rather than four, usually 
with a hydrogen bond between the CO of residue i and the NH of residue (i + 2), 
forming a seven-membered ring. Model studies in isolation from other stabilising 
forces suggest this form to have lower enthalpic stability than the P-turn, but 
y-turns have been postulated to be present in the bioactive conformations of several 
peptides. ^5,31,32
1.2.3 The p-Sheet
P-Sheets involve interactions between two or more extended peptide chains which 
may be aligned in a parallel or anti-parallel manner relative to one another. An anti­
parallel P-sheet is shown in Fig. 1.6 .
R H 0  R H
H O R R O R  
O H R Ô H R
R O H R O ^
Figure 1.6; Two strands of an anti-parallel P-sheet
Each strand is “pleated”, with a-carbons successively a little above and a little 
below the plane of the sheet. The strands may be directly connected via a P-turn (anti­
parallel p-sheet) or further apart in a protein sequence (parallel P-sheet). This is a 
repetitive stmcture type, with ((]), \|/) values identical for each residue in the sheet. For 
the parallel P-sheet, (((), \|/) = (-119°, +133°), and for the anti-parallel p-sheet, ((j), \)/) = 
(-139°,+135°). 8
Hydrogen bonds between each P-strand stabilise these structures, and other 
longer-range hydrophobic and electrostatic forces are also important, which may 
explain why p-sheets are very rarely found in shorter peptides.
1.2.4 The a-Helix
1.2.4.1 Introduction
The a-helix (Fig. 1.7) was first proposed as a stable structure for a peptide chain 
in 1951 by Linus Pauling. Experimental proof of its existence followed shortly 
afterwards, and this structural motif is now recognised as being ubiquitous in 
proteins, comprising over 40% of their structure.
Figure 1.7: A section of a-helix incorporating a proline residue
Like the P-sheet, the a-helix is a repetitive structure, with each residue adopting 
identical (([), \|/) values of (-57°, -47°). These negative values correspond to a right- 
handed helix; the mirror-image left-handed helix, with ((j), \\r) = (+57°, +47°) is of 
higher energy for the naturally occurring L-amino acids and is seldom observed.
The a-helix is stabilised by hydrogen bonds between the carbonyl group of 
residue i and the NH group of residue (/ + 4). In the usual nomenclature for 
description of polypeptide helices this is a 3.613 helix, 3.6 being the number of 
residues per turn and 13 the number of atoms in the ring created by the (/ + 4) —> / 
hydrogen bond.  ^ In aqueous media, the actual enthalpic gain imparted by these 
backbone hydrogen bonds is disputed; little, if any, advantage exists over a fully
8
solvated, extended peptide, and there is an unfavourable loss of entropy upon 
restraining the conformation using a hydrogen bond. However, within the 
hydrophobic shell of the helix, no solvent is present and in this situation hydrogen 
bonds certainly have a stabilising influence, by occupying polar amide groups which 
do not suit this non-polar environment.
The regular repeating stmcture of the a-helix aligns all of the carbonyl groups of 
each peptide unit. Consequently, the helix as a whole possesses a significant dipole. 
This is a destabilising factor, but is offset by the enthalpic gain from hydrogen 
bonding and other stabilising factors. The positive end of the dipole is at the 
N-terminus of the helix, and the negative end at the C-terminus. This may be 
important in binding charged ligands (e.g. negatively charged phosphate groups at the 
N-terminus).
1.2.4.2 Preferred Residues Within an a-Helix
Certain amino acid residues play particular stabilising or destabilising roles 
depending upon their position within the helix. This position can be roughly described 
as internal (residues midway through the peptide sequence) or terminal (residues near 
the ends of the helix); residues which are favoured at the termini may be disfavoured 
internally, and vice versa.
Favoured internal residues often have hydrophobic side-chains. These side-chains 
can cluster together preventing access of water which may dismpt hydrogen bonding 
in the helix backbone. These hydrophobic interactions are thought to be extremely 
important in determining helix stability. Alanine is particularly suitable; it can 
provide some hydrophobic stabilisation but lacks a y-carbon, so less entropy is lost 
when its side-chain packs together with others. The least favoured residues 
internally are proline (see Section 1.3.1.2, p i8 ) and glycine. Glycine cannot 
contribute to hydrophobic interactions, and also loses more entropy when its dihedral 
angles are fixed to a-helical values, since it is more flexible.
Propensity for positioning at one of the helix termini is a quite distinct parameter. 
Preference for these positions depends primarily on the fact that the last 4 NH groups 
at the A-terminus and the last 4 CO groups at the C-terminus lack hydrogen bond 
partners within the backbone. Therefore, residues near the termini are preferred if 
their side-chains are able to supply hydrogen bond partners for unpaired main-chain 
NH and CO groups. ^
Residues with high A -^cap propensities (i.e. those which often appear in the last 
A-terminal turn) tend to possess small polar side-chains (e.g. Asn, Ser, Thr) which 
can provide hydrogen bonds to unsatisfied main chain NH groups. For the
same reason, these residues tend to be rather less common deeper within a helix, since 
their hydrogen bonding capabilities may disrupt essential backbone hydrogen bonds.
Residues with negatively charged side-chains (Asp, Glu) are also favoured at the 
N-terminus, since they can interact with the positive end of the helix macrodipole, as 
well as providing a hydrogen bond to an N-terminal amide proton which lacks a 
hydrogen bond partner.
Glycine is common at the A-terminus because of its small size; lacking a side- 
chain, it does not impede the access of solvent which can also form hydrogen bonds 
with unsatisfied main-chain donors.
Proline is another special case. Whilst highly disfavoured further into a helix, it 
fits very well into the first A-terminal turn because its torsion angle <j) is fixed to an a- 
helical value ((|) = -60  °), and it requires no hydrogen bonding partner since it is 
devoid of an NH group (see Section 1.3.1.2, p l8 ),
Although there is again a bias towards small, polar residues in the last C-terminal 
turn, the most significant preference is for glycine as the penultimate C-terminal 
residue in a-helices within proteins. a-Helices often end at the C-terminus with short 
sections of 3lo helix involving (i + 3) i hydrogen bonds (see Section 1.2.5, p i5). 
These sections are often followed by a residue in the left-handed a  -helical 
conformation (aL) (of lowest energy for glycine and asparagine), which forms a
10
“7C-turn”, with an (; + 5) -+ / hydrogen bond. This so-called Schellman forces 
termination of the a-helix.
Charged residues are also commonly found near C-termini of helices. At this 
position, the side-chains carry positive charges (Lys, Arg, His) which interact 
favourably with the negative end of the helix macrodipole. This stabilising
effect was demonstrated in a model study by Gellman et al. Schneider and 
DeGrado showed that C-capping auxiliaries supplying a cationic group and hydrogen 
bond donors for carbonyl groups at the helix C-terminus imparted a significant helix- 
stabilising influence.
1.2.4.3 Helix-Stabilising Pairs and Groups of Residues
In addition to the propensities of individual residues for various positions in a 
helix, certain pairs or groups of residues in defined positions relative to one another 
impart stability, a consequence of favourable side-chain —> side-chain interactions. 
These residues are usually placed three or four positions apart in the helix. This brings 
the interacting side-chains close to one another on the same face of the helix (Fig. 
1.8).
Side-chain of residue i
Side-chain of residue 
(i + 3) or (i + 4)
Figure 1.8: Stabilising interactions between side-chains in an a-helix
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These interactions may be hydrophobic or electrostatic in nature. Various non­
polar side-chains can pack together well [e.g. (/, / + 4) = (Tyr, Leu)]. The
stabilisation imparted depends on the loss of entropy involved, and also on tertiary 
interactions with other parts of the protein.
Salt bridges between oppositely charged side-chains [e.g. (i, / + 4) = (Glu, Lys)] 
are often found in stable helices, as are side-chain —> side-chain hydrogen
bonds [e.g. (/, / + 4) = (Phe, His) or (Gin, Asp), the former utilising the aromatic 
ring as the hydrogen bond acceptor from the NH of the histidine side-chain].
Groups of residues of similar polarity are often found on one face of a helix, 
enabling non-polar side-chains to cluster on the hydrophobic face (often buried in the 
protein interior), and polar side-chains to cluster on the hydrophilic face (often 
interacting with solvent) (Fig. 1.9). Such helices are termed amphiphilic or 
amphipathic helices.
hydrophobic
residuesLeu LeuLeu
Leu Leu
Sef Leu
Ser Leu
LeuGin
Ser
Leu'Ser
LeuGin Ginhydrophilic
residues
Figure 1.9: Helical wheel representation of a designed amphiphilic a-helix
Peptides designed to be amphiphilic have been shown to be a-helical in the 
presence of micelles, because the hydrophobic face present in the helical
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conformation can be shielded from the solvent upon interaction with the micelle. This 
stabilisation of structure is thought to be analogous to the binding of peptide 
hormones to membrane-bound receptors.
1.2.4.4 Calculation of Helix Stability
An algorithm for the calculation of helix stability relative to the random coil state 
was first suggested by Zimm and Bragg in 1959 and by Lifson and Roig shortly 
afterwards. Using the Zimm-Bragg parameters, helix stability is related to an 
initiation constant sigma (<j), which reflects the probability of aligning the first three 
residues in an a-helical conformation. Without stabilising hydrogen bonds, this is a 
highly disfavoured process, due to repulsive interactions between the aligned dipoles 
and the loss of entropy, so a  generally takes very low values of <10“ ,^ where a 
value of 1 would indicate that the first three residues were fixed in an a-helical 
conformation. The other important Zimm-Bragg parameter is the propagation 
constant s, which reflects the likelihood of an amino acid residue adopting a-helical 
((j), V|/) values when added to the end of a pre-existing helix. There is a different s 
value for each amino acid, and the value changes depending on the position within the 
helix (since some residues are more likely to be found at the helix termini, for 
example). Values for 5* of >1 indicate helix-making amino acids {e.g. Ala), values <1 
indicate helix-breaking residues {e.g. Pro).
Values of s have been determined experimentally, theoretically and by
analysis of protein crystal structure databases. Together, these Zimm-Bragg 
parameters a  and s give a useful quantitative indication of the helical propensities of 
each amino acid, which is important in understanding protein folding and structure.
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1.2.4.5 Prediction of Peptide and Protein Secondary Structure
The secondary structure of a peptide or protein is a function of the primary 
structure, but accurate prediction of the secondary structure of a given sequence is 
still difficult. A number of reasonably reliable methods are available, the most widely 
used being the rules developed by Chou and Fasman. These rules classify each 
amino acid as favouring either a  or p structures, as determined from analysis of 
protein crystal structure databases and s values for each amino acid. An algorithm 
based on the number of each type in the sequence determines whether the peptide is 
likely to form an a-helix or p-structure in a protein-like environment. This method 
gives a 60-70% success rate for prediction of the correct structure type, and is a 
useful guide in design of peptides where particular secondary structures are required, 
though it is intrinsically unable to take into account important longer range 
interactions which also have a crucial effect on the assumed stmcture.
1.2.4.6 a-Helices in Short Peptides
In general, the a-helix is not a stable element of structure in short peptides in 
aqueous solution, and peptides of fewer than about 2 0  residues usually exist as 
random coils. This is due to the competition for backbone hydrogen bonds by solvent, 
the low value of the initiation constant (J, and the lack of specific helix-stabilising 
interactions.
However, there are several examples of short peptides which do show a-helical 
structure in aqueous solution. The first of these to be studied in depth were the S- 
peptide and C-peptide, which are both part of an a-helical segment from the enzyme 
ribonuclease A. ^5,71,72 Baldwin et al. later showed these structures to be stabilised 
by charge-dipole interactions and salt bridges. Bombolitin I, a 17-residue peptide 
isolated from bumble-bee venom, is predominantly a-helical in the presence of 
micelles, and molitin, a 2 2 -residue gastrointestinal peptide hormone, is stabilised as 
an a-helix by charge-dipole interactions and salt bridges. A variety of other peptide 
hormones also show a-helical structure during interactions with receptors. These
14
peptides rely on amphiphilicity for their structural stability when associated with non­
polar surfaces.
In fact, virtually all short peptides which show observable helical structure in 
aqueous solution owe this feature to stabilisation contributed by amphiphilicity, 
charge-dipole interactions, salt bridges or involvement of helix-fortifying residues. 
These factors have been used in the de novo design of helical peptides, e.g. the 17- 
residue peptide of Marqusee and Baldwin which contains three (Glu —> Lys) salt 
bridges, charged groups of appropriate sign at both termini, and a high proportion of 
helix-stabilising alanine residues; and the 18-residue peptide of Zhou et al. which 
combines charge-dipole effects, salt bridges, high alanine content and amphiphilicity 
to generate helicity.
Although it is possible to synthesise helices by use of these stabilising forces, 
rigorous rules must be followed and there is consequently little opportunity for 
stmctural variation when using the proteinogenic amino acids.
1.2.5 Other Helix Types
The right-handed a-helix is the most stable helical form for oligomers of L-amino 
acids, but other forms do exist. A 7i-helix is possible, incorporating {i -h 5) —> i 
hydrogen bonds, but this requires distortion of backbone dihedral angles. Polymers 
of proline form helices which are not stabilised by hydrogen bonds. These are of two 
types; the PP I form contains all cis amide bonds whilst the PP II has all trans amide 
bonds. These helix types are still accessible when some of the residues are not 
proline, and may contribute to the bound form of some peptide ligands. The stmctural 
protein collagen adopts a PP II conformation in each of its three constituent 
strands.
Oligomers of (3-amino acids [H2NCH(R)CH2C0 2 H] show stable 314-helical 
structure in solution, which may switch to other helical forms under certain 
conditions.
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The only helix besides the a  form which is of appreciable significance in peptide 
and protein structure is the 3io helix, which has (({), \j/) = (-60°, -30°), and an 
(i + 3) —> i hydrogen bonding pattern, equivalent to an infinite series of type III 13- 
turns. This is closely related to the a-helix, and only small alterations are required to 
interconvert the two forms. The 9:1 ratio of a:3io helix observed in protein
structures in addition to theoretical calculations shows that the a-helix is the more 
stable of the two forms for proteinogenic amino acids. In mammalian systems, the 
310-helix is only found in short stretches, particularly at the C-termini of a- 
helices. ^
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1.3 Structurally Important Amino Acids
1.3.1 Proline
1.3.1.1 Introduction
Proline 6 is unique amongst proteinogenic amino acids because its amino group is 
secondary, a consequence of the side-chain cyclising back on to the nitrogen atom to 
create a pyrrolidine ring. This feature has direct consequences on the conformations 
available to this residue. The torsion angle (() is fixed to values close to -60° 
(corresponding to an a-helix), and the angle \j/ is restricted and can only assume 
values in two fairly narrow ranges around -40° and +140°. These values of \}/ 
correspond to a-helical and p-structure respectively, and are fairly equally
populated throughout peptide structure, depending on the nature of adjacent residues.
N H 
6
The pyrrolidine ring itself can exist in one of two conformations. These both have 
the C ,^ N, and CP atoms nearly co-planar, with the C7 atom displaced either to the 
same side as the carbonyl group (CY-endo) or the opposite side (CY-exo) (Fig. 1.10).
COoR' COgR'
> = ^oR
n :  h
endo exo
Figure 1.10: Pyrrolidine ring pucker in proline residues
Theoretical calculations suggest that the CY-exo form is slightly more stable than 
the CY-endo form, by about 1 kJ moFk
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1.3.1.2 Structural Role of Proline
The cyclic, V-alkylated nature of proline has profound effects on the types of 
secondary structures it can adopt. In peptides, its lack of an amide proton means that 
it cannot participate as a hydrogen bond donor in repetitive structural motifs. This 
fact, along with the unfavourable steric interactions associated with the pyrrolidine 
ring, and the constraint of the (j) angle to a-helical values, indicates that proline is 
highly disfavoured in p-sheets.
Its role in a-helical structure is more complex. It is certainly significantly 
disfavoured in the middle of a helical sequence, because it disrupts the hydrogen 
bonding within the backbone, and the pyrrolidine ring does not fit well into a helical 
structure, although it can be accommodated with a 20-30° bend in the
direction of the helix axis, as demonstrated by the helix in Fig. 1.7.
However, proline is actually favoured in the first iV-terminal turn of a helix, and 
89% of all proline residues in a-helices are found here. In this position, its lack of 
an NH group is advantageous, since it would otherwise lack a hydrogen bonding 
partner. It also prevents propagation of the helix in the A-terminal direction. The (j) 
angle is already fixed to an ideal a-helical value, so proline loses less freedom of 
movement when constrained in the first turn of the helix. The carbonyl
group of the residue directly preceding proline is more basic than for any other 
residue, since it is involved in a tertiary amide bond, and therefore forms stronger 
hydrogen bonds to stabilise the first turn of the helix.
The nature of the tertiary amide bond linking proline to the preceding residue has 
the additional consequence of imparting a relatively high polarity to these regions in 
peptides. Whilst also being another factor acting against burial within a helix, this 
results in proline residues often taking up positions at the surfaces of proteins, in 
loops and turns. Proline’s propensity to be involved in hydrogen bonding schemes 
and its constrained nature also lend themselves to these elements of secondary 
structure. In particular, there are many examples of peptides containing proline 
which adopt p or y-turn structures.
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1.3.1.3 Effect of Proline on Neighbouring Residues
The presence of a proline residue also constrains the conformations available to 
the adjacent residues within the peptide, especially that directly preceding it in the 
sequence. Steric clashes are possible between the pyrrolidine ring and the N  and CP- 
atoms of the preceding residue, if the preceding residue attempts to adopt an a-helical 
conformation. Consequently, its torsion angles are more likely to take up values 
corresponding to p-structure, again disfavouring formation of an a-helix in the 
vicinity of the proline residue.
The a-helical geometry of the residue prior to proline is almost always found 
when proline is also in the a-form and both are part of an a-helix with hydrogen bond 
stabilisation rendering the otherwise inaccessible structure feasible.
1.3.1.4 cisdrans Isomérisation of Prolyl Peptides
The amino acids in peptides are usually linked via secondary amide bonds. These 
are resonance stabilised and therefore have partial double bond character. 
Consequently, cis and trans isomers are possible. These interconvert with an energy 
barrier of -90 kJ mol"i, which corresponds to the resonance stabilisation of the amide 
bond. The cis form is destabilised by steric interactions, and the trans form is more 
stable by -11 kJ mol k Therefore, less than 0.1% of secondary amide bonds are found 
in the cis form; these tend to occur in cyclic peptides where the trans form is 
disfavoured, or where there are other external forces influencing the 
equilibrium.
O " R
cis Xaa-Pro trans Xaa-Pro
Figure 1.11; Cis-trans isomérisation o f Xaa-Pro peptides
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The amide bond directly preceding proline is tertiary in nature, which leads to 
differences in the cis-trans equilibrium process (Fig. 1.11). The trans form is now 
also destabilised by steric interactions involving the pyrrolidine ring, so the energy 
difference between the two configurations drops to only 1-6 kJ mol“L As a
result, this amide bond has a much increased frequency (10-40%) of being found in 
the cis form. The rate of isomérisation between the two forms is also increased, 
because the tertiary amide bond is longer (1.36Â versus 1.33Â for a secondary amide 
bond); the energy barrier for interconversion drops to 75-80 kJ mol~k
1.3.1.5 Factors Affecting Thermodynamics and Kinetics of cis-trans 
Isomérisation
The rate of isomérisation and the position of equilibrium for the process is 
dependent on several factors:
• a bulky side-chain on the residue preceding proline slows the process, and 
may also affect the ratio. If the residue following proline carries an aromatic 
group on its side-chain, the amount of cis isomer is increased due to a 
stabilisation of the cis form and/or a destabilisation of the trans form.
• if substituents are incorporated into the pyiTolidine ring, the ratio is affected. 
a-Methylproline peptides show no cis isomer at all, whilst ô-methylproline 
shows comparable amounts of cis and trans isomers. Electron- 
withdrawing substituents increase the rate of isomérisation by promoting 
pyramidalisation of the nitrogen atom, which reduces the double bond 
character of the amide bond. 0^0,102
• the solvent has some effect on the rate, which is slower in aqueous solution 
than in organic solution, since water interacts more strongly with the more
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polar planar ground state forms, thereby increasing the activation 
energy. 0^3-105 et al. showed that addition of lithium chloride to 
trifluoroethanol solutions of peptides containing tertiai-y amide bonds greatly 
increases the amount of cis isomer to -70%. 0^6
1.3.1.6 Peptidyl-Prolyl cis-trans Isomerases
The rate of isomérisation of the tertiary amide bond preceding proline is increased 
in vivo by a group of enzymes known as peptidy 1-proline cis-trans isomerases 
(PPIases), the first enzymes found to be specialised for catalysis of conformational 
changes. These enzymes exist because the uncatalysed rate is not fast enough to 
meet the biological demands of protein folding. 107-109
CHg /  O O
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The PPIases are also known as immunophilins, lo?. no since they are binding 
proteins for immunosuppressant drugs. The immunophilin cyclophilin binds the 
immunosuppressant cyclosporin A 7 whilst FKBP binds FK506 8 . 11 ( Therefore,
PPIases have sparked considerable interest as the targets for potential therapeutic 
agents.
1.3.1.7 Mechanism of cis-trans Isomérisation
The non-enzymatic process has been the subject of several mechanistic studies, 
one of the most important conclusions being that the activation barrier is almost 
entirely enthalpic, with no significant entropy of activation. m  This suggests a 
unimolecular reaction with no involvement of solvent, presumably proceeding via a 
transition state with a twisted amide bond (Fig. 1.12).
R O
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r \ c O R '
1 "O R
CIS
A
RT "C)
r ^ G O R '  
y H
O "  R
Figure 1.12: Mechanism for prolyl isomérisation via a transition state with a 
twisted amide bond
This theory is supported by the fact that the rate is increased by organic solvents, 
which can interact more favourably with the transition state than with the more polar 
ground states.
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The mechanism changes at the extremes of pH. In alkaline solutions, a tetrahedral 
adduct may be formed by attack of hydroxide at the amide carbonyl, removing double 
bond character and increasing the rate of rotation about the amide bond. In acidic 
solution, the rate also increases, due to A^-protonation which again destroys resonance 
stabilisation. 103, m
Exactly how the PPIases lower the activation barrier is still not certain. The 
transition state was originally proposed to be a tetrahedral adduct formed with thiol 
groups in the enzyme active site, but further research showed that no such groups 
were present. 103 it now seems more likely to be catalysis by distortion, where the less 
polar transition state structures are stabilised in a non-polar pocket in the enzyme 
active site. This effect may be enhanced by hydrogen bonding to the prolyl nitrogen 
atom which further enhances its sp3 character. *03, m , H3 'pjjjs effect has been 
demonstrated in a model peptidomimetic study. The immunosuppressant drugs 
cyclosporin A 7 and FK506 8 are thought to act by incorporating substructures which 
mimic a twisted amide bond, thus acting as transition state analogues.
1.3.1.8 Dynamic Role of Proline
In addition to its importance in structural aspects of peptides and proteins, the cis- 
trans isomérisation process which accompanies prolyl peptides is thought to have a 
role in dynamic events. Foremost amongst these is the part it plays in protein folding, 
being the rate-lim iting step in the folding pathways of many 
proteins. 6^,43, 86, 109,115-117 ij^  addition to its presence in structures which might 
initiate folding (beginning of a-helix, p-turns), this dynamic role underlines the 
central role that proline plays in the mechanisms of protein folding.
Even though it is a fairly polar residue, proline is found fairly frequently in 
transmembrane helices. This may be because it serves an active role; isomérisation 
between the cis and trans forms can exert a transient “pull” on the local protein 
segment, thus acting a switch. This could be involved in the function of membrane 
proteins, perhaps by opening and closing transport channels.
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1.3.1.9 Biologically Active Peptides Containing Proline
Many biologically active peptides contain one or more proline residues, including 
corticotropin, angiotensin II 1, bradykinin 2 and oxytocin 3.  ^Its
prevalence may be due to the constraints that its structure imposes upon these 
hormones and neurotransmitters. Being more constrained, the peptides can bind more 
effectively to their receptors, and are less likely to adopt peptidase-bound 
conformations, resulting in increased stability and bioavailability. Peptidases 
frequently will not cleave cis peptide bonds, another advantage conferred by the 
presence of proline.
The most abundant protein in vertebrates, collagen, is also rich in proline and 
hydroxyproline residues which reinforce its stable structure.  ^21,122
Proline is not the only //-alkyl amino acid found in biological systems. //-Methyl 
residues are prevalent in microbial peptides such as the fungal metabolite 
cyclosporin A 7. These have similar structural effects to those of proline, although 
thay lack the constraint on ({), so are somewhat more flexible. Cis-trans 
isomérisation also occurs in peptides containing //-methylated residues. 1^ 3,124
1.3.2 C‘^ “Disubstituted Amino Acids
The other common modification of amino acids besides //-alkylation is 
C®^-alkylation. This severely limits the conformational freedom of the residue, 
compressing the internal angle so that folded structures such as helices and turns are 
highly favoured over extended structures, 125
By far the most widespread of these amino acids is a-amino/5obutyric acid 
(Aib, 9). The dihedral angles for this residue are fixed to helical values, but its lack of 
chirality means that both right and left-handed helices are of equal energy for Aib 
oligomers. These form fully developed Bjo-helices at the octamer level, and
show high helicity even w ith only 4-7 residues in aqueous 
solution. 83, 125, 126, 128-132 \Yhen present in peptides containing L-amino acid 
residues, the right handed helical forms are promoted. a-Helices are preferred in
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these cases for peptides containing 9 or more residues, and for those with < 50% Aib 
content. Aib also favours type III p-turns (which are equivalent to a four-residue 
section of 3io helix).
NHg
9
Aib is commonly found in the pentaibol family of naturally occuning antibiotics 
which are produced by microbial sources. These alter the permeability of biological 
membranes by forming channels for ion transport. The presence of these 
structure-stabilising residues helps to direct folding of these molecules without other 
longer range forces, and may also be important in reduction of the entropie cost of 
receptor binding.
Other C®-disubstituted amino acids have come under study. Being chiral, (25)-a- 
methylvaline was found to favour right-handed helical forms. 
a-Methylglutamic acid, a-methylaspartic acid and a-methylproline were all found to 
promote P-turns in short sequences.
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1.4 Synthesis of Peptides Containing Hindered Residues
1.4.1 Difficulties Encountered in Coupling Hindered Residues
The synthesis of biologically active peptides and pseudopeptides such as 
cyclosporins and didemnins is an important area of research in the
development of potential therapeutic agents. As discussed, many of these compounds 
contain one or more unusual residues which are //-methylated, C®^-disubstituted 
and/or p-branched. These classes of amino acid share a trait with the proteinogenic 
amino acid proline; they are significantly more sterically hindered than other 
proteinogenic amino acids. Consequently, formation of amide bonds involving such 
residues can be problematic.
In these reactions, amide bonds are synthesised from an //-protected segment with 
a free carboxyl group, and a C-protected segment with a free amino group. The free 
acid is converted to an active species, usually by action of a peptide coupling reagent. 
This active species is used in the acylation of the amine, forming the amide bond with 
the release of a good leaving group (Scheme 1.1).
H activating H H R^
R ^ O  °  FT^O °  R ^ O  °
Scheme 1.1: General mechanism of formation of an amide bond
During the acylation of hindered residues, the presence of more than one 
substituent on the N, C“ or CP atoms appreciably diminishes the reaction rate. Whilst 
this in itself may only cause the minor inconvenience of a prolonged reaction, in some 
cases side reactions and racémisation processes which would otherwise be too slow to 
cause problems become competitive.
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The major concerns associated with these hindered residues include:
• Racémisation. The loss of chiral integrity at the a-carbon of //-protected 
residues involved in amide bond forming reactions generally occurs by one of 
two mechanisms, énolisation or via an oxazolonium salt.
Enolisation is not usually a problem, since most //-protected residues possess 
an amide proton which is more acidic than the a-proton and will be removed 
first. However, for A-alkyl residues there is no amide proton and therefore 
énolisation is more likely.
The oxazolonium salt 10 is produced by a side-reaction from the activated 
species (Scheme 1.2). This species can then undergo racémisation by 
énolisation (giving the mesoionic oxazolone 11) or tautomérisation.
" X i .  " i ' V - o -
r A  °  R ' ^  R -^ 0 ^
10 11
activated species oxazolonium salt pseudoaromaticmesoionic oxazolone
Scheme 1.2; Formation of oxazolone species during amide bond formation
Urethane protection is an effective way to reduce the degree of racémisation 
because urethanes are less readily converted to oxazolonium salts. This is a 
result of the reduced double bond character of the urethane bond, which 
results in reduced nucleophilicity of the carbonyl oxygen. 4^0
Fortunately, proline suffers from few of these undesirable side-effects, 
because the addition of another contiguous ring on to the pyrrolidine ring 
generates cyclic strain. Therefore, formation of an oxazolonium salt is only 
possible under highly forcing conditions (e.g. on treatment with perchloric 
acid). Consequently, proline is resistant towards racémisation.
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Dioxopiperazine Formation. This is a potentially serious problem when 
coupling a C-protected dipeptide which has an //-alkyl residue at the C- 
terminal position, as shown in Scheme 1.3.
P  
NH
R R
12
Scheme 1.3: Dioxopiperazine formation from a dipeptide ester
The greatly increased likelihood of a cis amide bond in such peptides 
facilitates cyclisation to form a six-membered dioxopiperazine ring 12 , which 
possesses two cis amide bonds. The rate of this process may not be fast 
enough to compete with intermolecular amide bond formation, but if the N- 
terminal residue is also //-alkylated or if the activated acid is hindered it can 
become an important consideration.
1.4.2 Peptide Coupling Reagents
Many of these undesirable processes would diminish in importance if a 
particularly effective acylating agent could be produced. With this goal in mind, a 
wide range of new reagents has appeared in the last 10-15 years specifically for 
reactions involving hindered residues. These are usually tested using the problematic 
residues Pro, A-methyl Ala, Aib and A-methyl Aib.
The older methods such as formation of mixed anhydrides via action of alkyl 
chloroformâtes, or use of carbodiimides are often ineffective. Rather more
successful as the acylating agent are pentafluorophenyl esters 13, symmetrical
anhydrides 14, and pivalic mixed anhydrides 15.
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Recently, Carpino has developed the use of acid fluorides 16 as highly active, 
stable acylating species. They are able to perform acylations of the extremely 
hindered //-methyl Aib residue with reasonable efficiency, and appear to be
superior to the less stable acid chlorides which are also used occasionally. 145-147 
Perhaps the most widely used families of reagents used in modern peptide 
synthesis are the uronium and phosphonium salts which include HBTU 17, TBTU 18 
and pyBOP 19. ^^ 8,149
X N M g2 _ I \
O ^ N M e 2  NIN
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X = PF6 17 
X = BF4 18
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19
These reagents initially react with the carboxyl group to produce an active 
oxyuronium or oxyphosphonium species.
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Hydroxybenzotriazole 20 or its anion is also present in the solution when these 
reagents are used, and this is thought to react with the oxyuronium or 
oxyphosphonium salt to give an oxybenzotriazolyl ester 21  which is the actual 
acylating agent for the amine, 149-151 Unfortunately, this is fairly stable and often 
lacks sufficient reactivity in difficult couplings. Noting this deleterious effect, Coste 
et al. introduced analogues which do not incorporate a hydroxybenzotriazole group, 
such as pyBroP 22.
-  o o'n
22
These reagents avoid formation of the benzotriazolyl ester, and as a consequence, 
pyBroP is preferable to pyBOP for difficult couplings.
The latest advance in this reagent family was the development of HATU 23, 
incorporating an azabenzotriazole group, by Carpino et al. in 1993.
PFe
+
Me2N;:^NMe2y;? !6 -  1
23 !i
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This gives increased reaction yields and a decrease in racémisation, even for very 
hindered couplings. Its efficacy was suggested to be due to a
favourable complex 24 between the azabenzotriazolyl ester and the incoming 
nucleophile, which brings it into closer proximity to the reaction centre.
R2 /
H OH
R,
N
n M N = \ T(I)
24 25
Such active esters can also be produced by using 7-azabenzotriazole 25 in 
conjunction with other coupling reagents such as carbodiimides.
Finally, mention should be made of BOP-Cl 26, a phosphinic chloride reagent 
first used for the formation of peptide bonds in 1985 by Rich et al. This
activates the carboxyl component by formation of a mixed phosphorus anhydride.
c > *
26
This reagent is best used with secondary amines, since it has a tendency to react 
with primary amines in preference to forming the anhydride. BOP-Cl is effective in 
sterically congested couplings and was used in a synthesis of cyclosporin A 7, 
though it does not tolerate bulky protecting groups or p-branched residues particularly 
well.
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1.5 Peptidomimetics
1.5.1 Introduction
The wide range of effects exerted by peptides suggests potential applications in 
the therapy of many disorders. This has proved to be possible in several cases, the 
best known of which is the administration of insulin, a two-strand 51 residue peptide, 
for the treatment of diabetes.
Unfortunately, the medical application of peptides as drugs has a number of 
limitations:
• they cannot usually be administered orally, since they are rapidly degraded in 
the stomach and gut and are poorly absorbed into the bloodstream, a 
consequence of their relatively high molecular mass and the lack of membrane 
transport systems;
• they are conformationally flexible. Their ability to adopt many different 
conformations in solution means that they are capable of binding to several 
different receptors, which can result in undesirable side-effects;
• the structure-activity relationship is not known in most cases. That is, the 
precise 3D conformation of the peptide which binds to the receptor remains a 
mystery. In some cases, this has been determined by NMR or X-Ray studies 
of ligand-receptor complexes, but these experiments are difficult and lengthy 
processes. Far more progress has been made in NMR studies of unbound 
peptides, although any stable structure found in solution does not
necessarily reflect the bound conformation.
An enormous research effort has gone into finding ways of overcoming these 
problems. Some approaches use the peptides themselves, but in a “masked”
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form which veils their true nature and increases bioavailability. For example, Bodor 
and Buchwald have synthesised a series of derivatives of neurotransmitter 
peptides such as enkephalins which can be transported across the blood-brain barrier 
into the brain, a process highly disfavoured for the peptides themselves. This was 
achieved by disguising the peptides by protection with large alkyl groups, which 
rendered them lipophilic enough to cross the membrane. Once there, endogenous 
brain enzymes are able to cleave the protecting groups to release the active 
neurotransmitter or hormone.
Whilst “smuggling” peptides into a target organ in this manner is a promising area 
of study, most efforts to overcome the innate problems of peptides as drugs focus on 
the design and synthesis of peptidomimetics, non-peptide molecules designed to 
simulate the biological action of endogeneous peptides.  ^Peptidomimetics should 
possess biological activity equal to or greater than that of the mimicked peptide, 
whilst lacking the aforementioned disadvantages inherent in the use of peptides as 
drugs.
This is universally achieved by designing conformationally constrained analogues 
which simulate the receptor bound conformation as shown in Fig. 1.13.
If the bioactive conformation is correctly mimicked, this approach offers several 
merits:
• increased receptor affinity, since the bound conformation is fixed in the 
mimetic and entropie losses are greatly reduced;
• increased stability to peptidases, which may be unable to bind this fixed 
conformation;
• minimal side-effects, since other receptors which trigger undesirable responses 
are unable to bind the mimetic. ^
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Figure 1.13: Comparison of the biological fates of a peptide and a constrained 
peptidomimetic
Such a peptidomimetic needs to supply the essential pharmacophoric elements 
from the primary sequence of the peptide in the correct three-dimensional 
positions. Knowledge of the biologically active conformation of the parent peptide 
would be a great advantage for this design, but is not usually known. Therefore,
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peptidomimetic design is often based on the predicted stable structure of the 
endogeneous peptide, which may be calculated from the Chou-Fasman rules.
Peptidomimetics cover a wide range of structural types, varying from those which 
differ from the parent compounds only by incorporation of a few unusual amino 
acids, to those which bear no readily apparent resemblance to the peptide whatsoever. 
One such example is morphine 27, which is a completely non-peptidic mimetic of 
endogenous opioids such as Leu-enkephalin 28. ^
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1.5.2 Constraints at the Amino Acid Level
Incorporation of more highly constrained analogues of naturally occurring amino 
acids into peptides can exert a significant influence over the conformation adopted, 
perhaps stabilising a certain element of secondary structure. This has already been 
discussed in the area of naturally occurring disubstituted and //-methylated 
residues (see Section 1.3.2, p24). Other changes are possible; substitution of D for L 
residues favours reverse turns, and increases stability towards peptidases. 
Incorporation of any of the above residue types alters the conformation of the 
backbone', other amino acids have been designed for control of the side-chain 
conformations, or topology of the peptide. ^ Such control has been exerted by Hruby 
et at. using cyclic amino acids such as 1,2,3,4-tetrahydroisoquinoline-3-carboxylate 
(Tic, 29), an analogue of phenylalanine with a constrained side-chain,  ^ or amino 
acids with p-substitution and/or substitution on aromatic rings,
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These substitutions severely restrict available values of the side-chain dihedral 
angles %i ând X2* Certain side-chain topologies may be present in the bound states of 
bioactive peptides, and this has been demonstrated by the incorporation of such 
residues into analogues of endogenous opioids which have high affinity and 
selectivity.
1.5.3 Dipeptide Analogues
The conformation of a peptide may be constrained at a slightly higher level by 
bridging neighbouring residues to control the structure of dipeptide units within the 
chain. This is often done by creating dipeptidomimetics containing lactam or 
piperazinone structures which in some cases can be substituted with appropriate side- 
chains to control the topology of the dipeptide sequence. Examples include the 6,5- 
fused bicyclic lactam 30, the Leu-Ala dipeptidomimetic 31, the diazepinone 
32, and the piperazinone 33;  ^ there are dozens of others, predominantly based
on fused 5,6 or 5,7 bicyclic skeletons. 171-174
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More global conformational constraint can be introduced in a similar manner by 
linking residues further apart in sequence via a variety of methods including disulfide 
bridges and larger lactam rings.
1.5.4 Mimetics of Cis and Trans Peptide Bonds
Cis amide bonds may be present in the bioactive conformations of prolyl peptides, 
often in type VI P-turns. In order to test such theories, cw-prolyl peptidomimetics are 
useful. Some of the aforementioned dipeptidomimetics incorporate this feature 
(e.g. mimetics 32 and 33); 1 9^.172 others are specifically designed to do so.
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Connection of the a-carbons of proline and the preceding residue with an ethylene 
bridge gives cw-prolyl peptidomimetic 34. The Phe-c/5-Pro mimetic
(R=CH2Ph) was incorporated into somatostatin 4 to produce a high-affinity ligand, 
which is suggestive of a possible P-turn conformation in the bound form of this 
peptide. Mimetic 35 connects the same two a-carbons using a lactam bridge.
Marshall et al. have designed tetrazoles 36 which are produced directly
from the amide bond and mimic its cis form. Other groups have produced mimetics of
37
trans prolyl amide bonds, such as the 5,7-fused bicycle 37 or the trans alkene 
38. 171.181
Piperazic acid derivative 39 was shown to have an increased bias towards the 
trans form compared to proline,
1.5.5 Modification of the Peptide Backbone
Altering the amide unit in some way usually produces a mimetic which has 
improved stability towards degradation, since it is no longer a substrate for 
peptidases. However, these compounds show no significant conformational constraint 
compared with the parent peptide, i* In many cases, completely new secondary 
structures may be formed which are inaccessible to the parent peptide. The types of 
modification possible include:
• Isosteric bond replacements; swapping the CONH unit for CH=CH, CF=CH, 
CH2CH or CH2S produces more stable analogues, but they are also more 
flexible; *83,184
• Peptoids; these are oligomers of A-substituted glycines (Fig. 1.14). They 
sample more conformational space than peptides themselves due to the lack of 
hydrogen bonding and chirality, but show improved stability;
• Retro-Inverso Isomers; these possess a reversed sequence of amino acids and 
a change in the chirality of each residue from L to D (Fig. 1.14). This 
maintains side-chain topology but increases resistance to peptidases. In some 
cases, such isomers have shown biological activity, ^^ 7 but in general their 
poor affinity suggests that the backbone sequence is also important in 
binding.
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Figure 1.14: Modification of the peptide backbone
1.5.6 Secondary Structure Mimetics
The majority of secondary structures adopted by peptides and proteins involve the 
P-turn, p-sheet and a-helix. Consequently, much effort has gone into the design of 
systems to simulate these motifs. These are known as secondary structure mimetics, 
and find uses not only in the design of bioactive compounds but also in studies of 
protein folding.
1.5.6.1 p-Turn Mimetics
The p-tum is a localised structural element and as such is much the easiest of the 
three main motifs to mimic. As discussed, p-turns can be stabilised simply by 
judicious use of turn-stabilising residues such as proline or C«-disubstituted amino 
acids. ^^7 . 134, 188 The majority of other mimetics involve cyclic scaffolds which 
simulate the 10-membered hydrogen bonded ring usually present in a p-turn. Ideally, 
these structures should also carry the relevant side-chains of the p-turn in the native 
peptide, 7^3,174 possess a C“/ — C“(i + 3) interatomic distance of < 7 Â, and cause a 
reversal in the direction of the peptide chain. A host of compounds have been 
synthesised to meet one or more of these conditions. Representative examples include 
the aforementioned type VI p-turn mimetic 34; 7^, 177 2,3-disubstituted
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azanorbornane 40; indolizoindole derivatives 41; the 14-membered macrocycle
42; and the 9-membered scaffolds 43.
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In some cases these have been incorporated into biologically active peptides to 
give analogues possessing reasonable affinity, but in most cases their application is 
unproven. The frequent incorporation of bulky artificial frameworks and 
insufficiently precise side-chain topologies may result in peptides incorporating these 
mimetics lacking activity upon application to biological systems.
Compounds designed to mimic other turn structures such as the y-turn mimetic 
44, or the Q-loop template 45 have also been suggested.
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1.5.6.2 Stabilisation of (5-Sheet Structure
Mimicry of larger, repeating structures is a more challenging task than that of 
localised motifs. The approaches towards |5-sheet stabilisation involve molecular 
scaffolds which provide attachment points for two or more peptide strands such that 
intramolecular hydrogen bonding is favoured (Fig. 1.15).
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Figure 1.15: Anti-parallel p-sheet nucleated from a template
Examples of these nucleating turn mimics include the benzofuran scaffold 46 of 
Skar et a l the diphenylacetylene 47 of Kemp et al. and the acetylene
derivative 48 of Hartzoulakis et al.
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In some cases mimics of the p-strands themselves are used to initiate formation of 
sheet structure, by acting as conformational templates to propagate a conformation 
from an ordered region (the template) to a disordered region (the peptide). Kemp et 
al used diacylaminoepindolidiones 49 to simulate a p-strand; in conjunction with 
known p-turn favouring Pro-D-Ala sequences, these mimics stabilise the p-sheet by 
hydrogen bonding to adjacent P-strands.
49
No wick et a l used a hydrazine P-strand template (upper chain in system 50) 
attached to a turn mimic to stabilise a P-sheet structure.
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1.5.6.3 Stabilisation of a-Helical Structure: Solvent Effects
The addition of 2,2,2-trifluoroethanol (TFE) or other alcohols to aqueous 
solutions of peptides is known to promote helix formation. This is due to the reduced 
dielectric constant which approximates to that of the protein interior; its less polar 
nature compared to water decreases the strength of peptide-solvent hydrogen bonding
42
found in random coil states, thus favouring the intramolecular hydrogen bonding of 
the helix. 0^3-205
The helicity induced correlates well with the helicity predicted by the Chou- 
Fasman rules; TFE does not stabilise helical structure in peptides which have little 
or no helix propensity. Its relatively hydrophobic nature is disruptive of tertiary 
structure, which may explain why it has no stabilising effect on p-sheets which 
depend on longer-range hydrophobic interactions rather more than do a- 
helices.
1.5.6.4 Stabilisation of a-Helical Structure: Side-Chain Constraints
Naturally occurring peptide and protein helices are often stabilised by favourable 
interactions between the overlapping side-chains of residues three or four apart in 
sequence, such as hydrogen bonds, hydrophobic interactions or salt bridges. This 
side-chain proximity has been used to similar effect by several groups who have 
found ways to force interactions between side-chains, thus enforcing a-helical 
conformation in the peptide, in an analogous way to the helix-stabilising interactions 
found between these side-chains in natural peptides (see Fig. 1.8, pi 1).
Various types of conformational constraint have been used. Co-ordination of the / 
and (i + 4) side-chains to metal ions has been accomplished using acid or amine and 
thiol groups. Similarly, aspartic acid residues at positions i and (i + 4)
co-ordinate a positively charged guanidinium receptor, enforcing the conformation as 
an a-helix.
Other methods use covalent linkages; [i to {i + 7)] disulfide bonds, [/ to 
(i + 4)1 or [r to {i 4- 7)] lactam bridges and [i to (/ + 7)] alkyl bridges have 
all been shown to enforce a-helical conformations in peptides. In one case, the i and 
(i+ 11) side-chains were connected to a porphyrin macrocycle, and the structure of 
the peptide between the attachment points was found to be an a-helix.
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1.5.6.5 Stabilisation of a-Helical Structure: Helix Templates
All the methods discussed to this point have been shown to stabilise a-helical 
structure to a greater or lesser extent. However, they all involve perturbation of the 
system by introduction of alien residues, organic solvents or “forcing” cyclisation 
strategies. In the study of protein folding processes and synthesis of analogues of 
bioactive peptides, such alterations may prove too drastic.
A preferable method is to bias the conformation towards an a-helix without 
changing its primary structure. This is possible by use of templates which initiate 
structure in attached peptides. ^^^This concept operates on two levels. Mutter’s 
template-assembled synthetic protein (TASP) approach uses macrocyclic templates 
for attachment of three or four peptide chains (Fig. 1.16). These fold into a-helices 
because of favourable inter-helical tertiary interactions which are present.
Figure 1.16: Template assembled synthetic protein approach to helix stabilisation
Other groups use different templates, such as porphyrins or transition metals, 
but they serve the same purpose of bringing the peptide chains into close proximity to 
allow tertiary interactions.
This kind of template allows study of the importance of inter-helix forces in 
stabilisation of these structures. They do not allow for study of the influence of 
residues within an isolated helix without longer range forces, nor for synthesis of 
potential bioactive analogues of endogenous peptides. This can only be done if an a-
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helix is stabilised in an isolated peptide chain. Without the tertiary interactions 
present in the TASP approach, the template itself must impart some stabilising 
influence upon the structure of the peptide (unlike the TASP templates, which are 
designed merely to bring the strands close together). These are further examples of 
conformational templates. In the case of the a-helix, the template must provide a set 
of carbonyl groups which are rigidly aligned in an a-helical conformation (Fig. 
1.17). 9^6.201
Figure 1.17: Stabilisation of an a-helix via an 1^-terminal template
An attached peptide can hydrogen bond to these carbonyl groups via its amide 
groups; if it does so, it will itself adopt an a-helical conformation. Such a template 
operates by a massive increase in the value of the initiation constant a  from -lO'^ to 
~1, by reduction of the entropie loss inherent in helix initiation. Design and synthesis 
of such a template with the correct structural features is far from trivial, but some 
success has been achieved by several groups.
Kemp and co-workers have led the work in this area, developing templates based 
on proline-containing macrocycles. 215-228 Most of this work has focussed on
template 51.
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Ideally, the three carbonyl groups present in this system should be aligned, and 
thus able to generate a-helical structure in an attached peptide. In the event, the 
macrocycle shows a degree of flexibility, interconverting between three 
conformations, only one of which is able to nucleate a helix. The amount of 
template present in this nucleating conformation (detectable by NMR spectroscopy) 
correlates with the degree of helicity of the attached peptide, and as such is a useful 
“reporter” on the conformation of the peptide. This has proved useful for 
quantification of amino acid s values, and for study of the helix-stabilising
effects of side-chains and TFE. However, the lack of rigidity significantly 
decreases the efficiency of the template as an a-helix initiator (a estimated at -0.15 in 
water, as compared to 1 for an exactly a-helical array of carbonyl groups). In an 
attempt to overcome this limitation, Kemp has also studied the triproline analogues 52 
and 53.
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Macrocycle 52 can supply three aligned carbonyl groups only if all three amide 
bonds within the ring possess the trans configuration (ttt). In solution, the macrocycle 
was found to exist as two conformers, cct and ctt, and did not have useful helix-
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initiating properties. Introduction of a methylenethio bridge to rule out the cis
configuration of the second amide bond gave macrocycle 53. However, the desired ttt 
conformer is still not present, the macrocycle favouring the ctt form. Preliminary 
results suggested that this template can generate a 3io-helix which may convert to an 
a-helix further along the peptide sequence, but these results require more
investigation. Whilst it apparently possesses greater initiating power than Kemp’s 
previous two templates 51 and 52, template 53 again lacks the required number of 
carbonyl groups for a-helix induction, and involves a laborious, inefficient 26-step 
synthesis.
Besides the Kemp group, three others have suggested a-helix templates based on 
different cyclic structures.
Bartlett et a i recently reported the hexahydroindol-4-one 54 as a so-called 
“aglet”, to prevent A^-terminal fraying of helices.
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This template requires the carboxyl group on the six-membered ring to be 
deprotonated in order to function, presumably using a charge-dipole interaction to 
stabilise the helix. The peptides must also be linked via a lactate residue to the other 
carboxylic acid. If these criteria are met, this template is able to generate an a-helix, 
as demonstrated by CD and NMR studies. The actual degree of helicity induced in the 
peptide is unclear; standard methods suggest around 30% helicity, but these methods 
were thought inappropriate for the short peptide sequence involved (six residues). 
Accounting for this factor produced an estimate of 50-75% helicity. Whilst this 
template clearly does have a stabilising influence over a-helical conformations, the 
extent of this stabilisation is unclear, since the peptide appended to the template 
already possesses high helical propensity (consisting largely of alanine residues, and
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initiating properties. Introduction of a thiamethylene bridge to rule out the cis
configuration of the second amide bond gave macrocycle 53. However, the desired ttt 
conformer is still not present, the macrocycle favouring the ctt form. Preliminary 
results suggested that this template can generate a 3io-helix which may convert to an 
a-helix further along the peptide sequence, but these results require more
investigation. Whilst it apparently possesses greater initiating power than Kemp’s 
previous two templates 51 and 52, template 53 again lacks the required number of 
carbonyl groups for a-helix induction, and involves a laborious, inefficient 26-step 
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Besides the Kemp group, three others have suggested a-helix templates based on 
different cyclic structures.
Bartlett et a l recently reported the hexahydroindol-4-one 54 as a so-called 
“aglet”, to prevent A^-terminal fraying of helices.
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This template requires the carboxyl group on the six-membered ring to be 
deprotonated in order to function, presumably using a charge-dipole interaction to 
stabilise the helix. The peptides must also be linked via a lactate residue to the other 
carboxylic acid. If these criteria are met, this template is able to generate an a-helix, 
as demonstrated by CD and NMR studies. The actual degree of helicity induced in the 
peptide is unclear; standard methods suggest around 30% helicity, but these methods 
were thought inappropriate for the short peptide sequence involved (six residues). 
Accounting for this factor produced an estimate of 50-75% helicity. Whilst this 
template clearly does have a stabilising influence over a-helical conformations, the 
extent of this stabilisation is unclear, since the peptide appended to the template 
already possesses high helical propensity (consisting largely of alanine residues, and
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incorporating a salt bridge). How much additional stabilisation does such a peptide 
need to form a helix? Studies using peptides with a lower helical propensity will help 
to determine the extent of the conformational influence exerted by the template.
Arrhenius and Satterthwait have also proposed an a-helix template in the form of 
the 13-membered macrocycle 55. However, this compound’s tempiating effect 
was only demonstrated in TFE, and the helix appeared to fray quite quickly moving 
away from the template.
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Finally, Müller et al. suggested several lactam derivatives as helix initiators, of 
which the cage compound 56 is representative. Peptide conjugates of these 
compounds show improved helicity compared to the untemplated peptides, but once 
again the experiments are performed in the presence of TFE and the peptides 
incorporate additional stabilising features. ,
Such templates have proven influence over peptide conformation. However, the 
energetic gain imparted is debatable, since in all cases other helix-favouring factors 
are present in the form of solvents or sets of residues with high helix propensities, so 
the energy required to convert these peptides from the random coil state to the helical 
state may be small. As such, the generality of their use is called into doubt; will the 
templates suggested to date only be applicable in certain favourable situations? The 
template approach has potential, and there is much scope for optimisation of these 
existing structures and design of new templates with substantial, proven influence 
over peptide stmcture.
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1.6 Protein Processing in Foot and Mouth Disease Virus
Peptidomimetics may assist in the elucidation of enzyme mechanism. One 
potential example is in polyprotein processing of the foot-and-mouth disease virus 
(FMDV).
Foot-and-mouth disease is an extremely contagious, acute viral condition of 
cloven-footed animals characterised by fever and formation of painful vesicles in the 
mouth and on the feet. Although a vaccine is available, it is expensive and a 
slaughter policy is often employed instead. In the case of farm livestock such as 
cattle, the disease prevents weight gain in beef animals and greatly reduces milk 
yields in dairy cows, resulting in substantial economic losses. Other significant 
expenditure goes into diagnosis of the condition, quarantine procedures, disposal of 
carcasses and compensation to affected farmers. The UK epidemic of 1967-68 cost an 
estimated £150 million.
The foot and mouth disease virus belongs to the picornavirus family of viruses. 
This family possesses four sub-classes, or genera, of viruses. These are the 
enteroviruses (which include the virus responsible for polio), the rhino viruses, the 
cardioviruses, and the apthovimses; it is this last genus to which FMDV belongs.
Picornaviruses are based on a single strand of positive sense ribonucleic acid 
(RNA) consisting of some 8400 base pairs, surrounded by an icosahedral capsid. This 
capsid has twenty faces, each consisting of sixty copies of each of four capsid 
proteins.
In order to replicate, the viral capsid must be discarded and the RNA strand 
passed into a host cell. Upon infection of the cell, the virus is able to suppress cellular 
protein synthesis, enabling more efficient production of viral proteins. Acting as 
messenger RNA (mRNA) on cellular ribosomes, the viral nucleic acid strand 
undergoes translation, resulting in the production of viral proteins. These include 
RNA polymerase, a replicative enzyme which catalyses synthesis of new RNA 
strands, using the genome of the viral RNA strand as a template. Translation from
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viral RNA strands also produces the various proteins required to synthesise the 
capsids of new virus particles. Together, these proteins produce new copies of the 
original virus particle which can then leave the cell. This procedure is very efficient, 
and can result in the formation of up to 100,000 new virus particles from a single host 
cell in only 4 hours.
The initial product of this replicative process is a laige polyprotein. This must be 
processed into the smaller encapsidative and replicative proteins via a series of 
cleavage reactions (Fig. 1.18). These are normally carried out by proteases within the 
polyprotein itself {e.g. L, 3C).
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Figure 1.18 Polyprotein processing of the foot and mouth disease virus
The most interesting aspect of FMDV viral polyprotein processing is the cleavage 
catalysed by the 2A region. In cardioviruses, this region is 143 residues long; in 
FMDV it contains only 16 amino-acids. Molecular biology studies have ruled out 
involvement of other regions of the polyprotein in this cleavage via creation of a new 
plasmid pCAT2AGUS which enabled synthesis of a polyprotein in which a sequence 
spanning the 2 A region of the FMDV poly protein was inserted between two unrelated
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proteins CAT and GUS. This resulted in the production of the cleavage products 
CAT2A and GUS, showing that the process does not require the presence of any other 
part of the FMDV poly protein.
Synthetic analogues of 2A show no ability to perform such cleavage reactions in 
aqueous solution. Initially, this was thought to be due to the lack of a defined 
secondary structure in this medium, as demonstrated by NMR and CD spectroscopic 
studies. It is now believed that the cleavage is not a proteolytic event akin to those 
catalysed by the L and 3C proteases, but instead occurs when the 2A region is still 
attached to RNA on the ribosome; i.e. the cleavage takes place at an ester bond and 
the 2A region is an esterase (Fig. 1.19). This conclusion was reached after 
observation that greater amounts of the CAT2A cleavage product were formed than 
the GUS product. This argues against proteolysis which would produce equal 
amounts of both products. This difference in the quantities of protein produced may 
serve a function in the reproductive process, since the virus requires more copies of 
encapsidative proteins (the region upstream of 2A) than of replicative proteins (the 
region downstream of 2A).
It is clear that the 2A region itself is involved in catalysing the reaction. This 
requires a particular reactive structure for the 2A region. Modelling studies by 
computational methods and structure prediction using the Chou-Fasman rules both 
strongly suggest the presence of an a-helix throughout the V-terminal region of the 
protein segment.
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Figure 1.19: Proposed a-helical conformation of the 2A region showing its 
amphiphilic nature and a possible mechanism of cleavage of the 
Gly^^-RNA bond
This a-helical structure is stabilised by a series of [i -» (i + 3)] or [i (i + 4)] 
side-chain interactions: a salt-bridge (Asp^ Lys^); hydrogen bonds (Lys^ Asp^^ 
and Aspio Asn^^) and a set of hydrophobic interactions. The helix is also 
amphiphilic in nature, with hydrophilic residues grouped on one face and 
hydrophobic residues on the other. The importance of these residues is supported by 
mutation studies; changes to residues which are proposed to stabilise the helical 
structure are not tolerated and the cleavage process fails to occur. Structural studies of 
synthetic 2A peptides in water/TFE mixtures also indicate a small degree of 
helicity.
Besides the a-helical region, cleavage also requires correct positioning of the 
scissile Gly^^-RNA ester bond underneath Glu^^ which might act as a nucleophile or 
as part of a general base mechanism in the cleavage reaction. This would be possible 
if a type VI {cis Pro) p-turn exists in the Ser^Asn^"^-Pro^^-Gly ^  ^sequence. If a helix-
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turn motif is present, the Gly^^-RNA bond scission could occur in preference to 
nucleophilic attack of the next amino acid (the first of the 2B region) at the Gly^6 
carbonyl; i.e. ester bond cleavage takes place instead of continued peptide synthesis. 
Significantly, the next residue is proline, the least effective nucleophile of the 
proteinogenic amino acids. The slow rate of Gly-Pro amide bond formation might 
allow the Glu  ^^ -catalysed ester bond cleavage to become competitive.
Molecular biology experiments are still in progress to elucidate further aspects of 
the 2A-mediated process. However, these studies will not be able to supply 
information on crucial structural aspects. Fortunately, the extraordinary small size of 
the 2A region renders it amenable to study by chemical methods.
It has already been demonstrated that isolated 2A peptides lack stable secondary 
structure in aqueous solution. We intend to produce analogues in which the proposed 
structure is stabilised using peptidomimetics, whilst maintaining maximum integrity 
of the primary structure of the 2A sequence. This is possible by the application of a 
type VI P-turn mimetic which is closely related structurally to the p-turn found in the 
putative bioactive structure, and by use of an V-terminal a-helix template which 
allows the proposed helical structure of the 2A peptide to be strengthened without 
perturbation of its primary stmcture. Such mimetics, which have minimal effect on, 
the primary stmcture of the sequence but a major stabilising effect on the secondary 
structure, will enable reliable conclusions to be drawn on the mechanism of action of 
this tiny enzyme. Our intention is to append RNA analogues to the end of a stmcture- 
stabilised 2A analogue to study the extent of ester bond cleavage in these systems, 
thus establishing if our proposed bioactive structure is accurate. If this proves to be 
the case, major advances can be made in the elucidation of the mode of action of this 
fascinating self-cleaving peptide.
This goal, along with the variety of other applications available in other areas of 
peptide chemistry, inspired us to begin work on the synthesis of peptidomimetics for 
the stabilisation of P-turns and a-helices.
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RESULTS AND DISCUSSION
2 Triazepinediones as cis-Prolyl Peptidomimetics
2.1 Introduction
The novel fused triazepinedione system 57 is a potential mimetic of cw-prolyl 
peptides.
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The fusion of the seven-membered triazepine-1,5-dione ring on to the proline ring 
fixes the amide bond preceding proline in the cis form. Incorporation of this mimetic 
into a peptide may lead to stabilisation of a type VI P-turn, which requires a cis- 
proline at position (/ + 2 ) and a distance between the C“ atoms of residues i and 
(i + 3) of < 7 Â. The molecular constraint imposed by the N-N bond in system 57 
ensures that both of these conditions are met for peptides containing this mimetic.
The initial objective in synthesising such compounds was to investigate their 
possible conversion to cw-prolyl peptides 58, useful for studying the cis to trans 
isomérisation process. This conversion could occur by scission of the N-N bond 
which is relatively weak (dissociation energy 37 kcal mol~i) (Scheme 2.1). The most 
common methods for this process are catalytic hydrogenolysis and dissolving
metal reductions.
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Scheme 2.1: Potential synthesis of a c\s-prolyl peptide from a triazepinedione
Unfortunately, synthesis of cw-prolyl peptides using this method by Lenman et al. 
did not prove possible. In all cases, the compound was either resistant to reduction 
(catalytic hydrogenolysis) or both N-N and C-N bond cleavage occurred (dissolving 
metal reductions). For example, the dimethyl analogue 59 gave (25)-propionylproline 
methylamide 61 upon treatment with sodium in liquid ammonia (Scheme 2.2).
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Scheme 2.2: C-N and N -N  bond cleavage during dissolving metal reduction of 
triazepinedione 59
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This reactivity can be explained if the carbonyl group a  to the cleaved C-N bond 
accepts an electron to give a radical anion 60. The C-N bond can then undergo 
homolytic cleavage, leading eventually to the undesired “double reduction” product 
61.
The aim of this work was twofold:
• synthesise a triazepinedione with the potential to stabilise a radical a  to the N-N 
bond, allowing this bond to cleave prior to the C-N bond to produce a cw-prolyl 
peptide 58;
• show that the triazepinedione system 57 can be incorporated into a peptide chain 
for use as a potential cw-prolyl peptidomimetic and/or a type VI p-tum mimetic.
Previous studies on these fused triazepinediones by Lenman et a l showed 
that either, or both, of the hydrazide nitrogen atoms could be substituted with a 
methyl group. We hoped to be able to use a similar methodology to synthesise a 
derivative 62 with an electron acceptor group X as substituent R^, enabling 
stabilisation of a radical a  to the N -N  bond which could allow this bond to be 
selectively cleaved under reductive conditions to give the desired cw-prolyl peptide 
63 (Scheme 2.3).
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Scheme 2.3: Generation of a radical a  to the N -N  bond
2.2 Synthesis of an W-Phenyl Triazepinedione Peptidomimetic
Our first target was the fused triazepinedione 64 (X = Ph in structure 62).
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The amide substituent on the phenyl ring can potentially destabilise an anion a  to 
it but stabilise a radical, the required situation for cleavage of the N-N bond.
Construction of the triazepinedione 64 was undertaken in a similar manner to that 
used by Lenman et al. for the N-methyl analogue.
Direct acylation of proline 6 with chloroacetyl chloride using the method of 
Ronwin gave (25)-chloroacetylproline 65 in good yield (Scheme 2.4).
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Reagents and conditions: i, chloroacetyl chloride, EtOAc, reflux, 50 min, 64%; 
ii, (BOQ2O, Et2 0 , 3 days, 8 6%.
Scheme 2.4: Synthesis of precursors to triazepinedione 64
The two remaining nitrogen atoms of the triazepinedione and its phenyl 
substituent were derived from phenylhydrazine 6 6 . In order to achieve the correct 
regiochemistry in the product, we required formation of an amide bond between the 
acid group of proline derivative 65 and (the nitrogen atom bearing the phenyl 
substituent). Direct coupling of the two species 65 and 66  would be unlikely to 
achieve this aim, since A-arylhydrazines tend to acylate on AP (the unsubstituted 
nitrogen). This is a consequence of. the low nucleophilicity of A« caused by the 
steric influence of the phenyl ring and the delocalising effect it has on the lone pair of 
A“ . This contrasts with acylation of alkylhydrazines which tends to occur 
predominantly on the substituted nitrogen.
The superiority of as a nucleophile was masked by treating hydrazine 66 with 
(B0 C) 2 0  to give the hydrazide 67, thus drastically reducing the nucleophilicity of AP, 
allowing A“ to be acylated without competition.
Formation of the required amide bond between species 65 and 67 proved to be 
relatively difficult, a consequence of the aforementioned poor nucleophilicity of the 
secondary amino group of hydrazide 67. The use of standard methods for the
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formation of amide bonds in peptide synthesis such as the carbodiimide EDCI or the 
uronium salt TBTU failed to promote any coupling between the two segments. In the 
event, a fairly crude method proved to be the most effective. This was the 
methodology of Matsuda et a l which involves activation of the acid
component as an acyl chloride or acyl pyridinium salt 6 8 , by action of thionyl 
chloride in the presence of pyridine and DMAP.
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These pyridinium salts possess high reactivity and are relatively unhindered. 
These properties render them ideal for acylation of unreactive and hindered 
nucleophiles such as hydrazide 67. Coupling of the two components using this 
method gave a 57% yield of the desired hydrazide 69 (Scheme 2.5).
Removal of the BOC protecting group using dry HCl gas gave hydrochloride salt 
70. Upon neutralisation with aqueous sodium hydroxide solution, cyclisation occurred 
via Sn2 displacement of chloride by the liberated primary amino group to give the 
fused bicyclic compound 64.
Whilst demonstrating that these mimetics can be elaborated with more complex 
substituents, we required to establish whether or not the dissolving metal conditions 
applied to triazepinedione 64 would give rise to the desired reduction product; i.e. 
does the phenyl ring allow creation of a radical a  to the N-N bond which can give 
rise to its fission?
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Reagents and conditions: i, SOCI2, pyridine, DMAP, CH2CI2, 3 days, 57%; 
il, HCl(g), EtOAc, 40 min; iii, 1 mol dm”  ^NaOH, H2O, 30 min, 68% (2 
steps).
Scheme 2,5: Synthesis o f triazepinedione 64
Therefore, triazepinedione 64 was treated with sodium in liquid ammonia. 
Unfortunately, the only product which could be obtained from this reduction process 
was that formed by cleavage of both N-N and C-N bonds, as before, to give {2S)-N- 
acetylprolinanilide 71 (Scheme 2.6).
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Scheme 2.6: Reductive cleavage of triazepinedione 64
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It appears that the carbonyl group a  to the C-N bond is still a better electron 
acceptor than the substituent a  to the N-N bond. Even though a radical anion could 
be generated in the phenyl ring, an electron is most likely to add to the carbonyl group 
first, leading to rapid fission of the C-N bond. Subsequent N-N bond cleavage leads 
to the undesired anilide. These dissolving metal conditions allow a radical to be 
generated at any position in the fused triazepinedione where it is relatively stable. If 
we can design a system where the radical is created exclusively a  to the N-N bond, 
then cleavage of the C-N  bond would not be possible. Work is currently under way 
with the aim of generating such a radical using a variety of methods.
Although it appears that these mimetics may not lead to a synthetic route to 
elaborate cis-prolyl peptides, it may soon be possible to create short mode/ systems 
containing a cis amide bond for study of the cis to trans isomérisation process.
2.3 Extension of cis Xaa-Pro Mimetics at the N- and C- Termini
Fused bicyclic compounds of type 57 may serve as effective mimetics of cis Xaa- 
Pro peptides. A primary requirement for a useful peptidomimetic is that it can be 
incorporated into a peptide sequence. For these triazepinediones, we must therefore 
show that extension is possible from both and N^.
Previous work in the group has showed that extension from M  (equivalent to the 
N-terminus of an open chain peptide) was straightforward, using standard mixed 
anhydride coupling methodology to add on further amino acid residues. Extension 
from is significantly more difficult, requiring synthesis of more complex 
substituted hydrazines for incorporation into the previously described synthetic route.
We chose to attempt the synthesis of the triazepinedione 72, a potential mimetic 
of H-Gly-cw-Pro-Phe-OMe.
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2.3.1 Synthesis of Protected (2S)-A-AminophenyIalanine
Chiral a-hydrazino acids 73 have received relatively little attention in the study of 
peptidomimetics due to difficulties in their synthesis and coupling reactions.
H R 
73
Few methods exist for the synthesis of these compounds. Some groups have 
utilised stereoselective aminations of chiral enolates using azodicarboxylates (Scheme 
2  7  ^ 244-246
9  R ^02C N = N C 02R ' O 2C , O  H O
R B ase /  H r '  H
R = chiral auxiliary
Scheme 2.7: Synthesis o f a chiral a-hydrazino acid via asymmetric amination
Whilst these methods can in principle supply any desired a-hydrazino acid, they 
all involve the manipulation of expensive chiral auxiliaries, potentially difficult low 
temperature reactions to produce the new stereogenic centre, and several synthetic 
steps. Less elegant methods also exist based on A-homologisation of amino 
acids. These avoid the generation of a new chiral centre, since the desired
stereocentre is already present in a starting material obtained from the chiral pool.
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a-Hydrazino acids find uses in the construction of hydrazino peptides 74 or N- 
amino peptides 75 for peptidomimetic studies. 183- 249-252
o  R H ^^^2 O 
NHg O H R NHgH R
74 75
We employed the two-step A^-homologisation procedure of Viret et al. for the 
synthesis of (25)-N-aminophenylalanine 78.
Accordingly, (25')-phenylalanine 76 was converted to the corresponding hydantoic 
acid 77 upon treatment with a basic aqueous potassium cyanate solution (Scheme 
2.8).
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Reagents and conditions', i, KOCN, H2O, 60 °C, 4 h, 86%; ii, KOCl, KOH, H2O, 
0 -> 70-80 °C, 90 min, 43%.
Scheme 2.8: Synthesis o f a-hydrazino acid 78
Conversion of the hydantoic acid 77 to the required a-hydrazino acid 78 was 
carried out using a Shestakov rearrangement, a transformation which converts a urea 
into a hydrazine. This is related to the better-known Hofmann rearrangement which 
transforms an amide into an amine. Action of a basic potassium hypochlorite 
solution on the hydantoic acid 77 resulted in formation of the hydrazine 78, in an 
optimised yield of 43%. Whilst these conditions enabled synthesis of the desired
63
compound, the relatively low yield and poor reproducibility prompted a study of 
alternative reagents which might improve the process.
The Hofmann rearrangement can also be brought about by the action of 
[/,/-bis(trifluoroacetoxy)iodo]benzene 79, a hypervalent iodine reagent which has 
proved useful for amides derived from peptides and acylamino acids.
FaC^O.i^O CF3T T Ï
79
However, action of reagent 79 on hydantoic acid 77 failed to give any of the 
hydrazino acid 78. It was apparent that the synthesis of the a-hydrazino acid was 
unlikely to be significantly improved without substantial further work, so no further 
efforts were made to increase the yield.
2.3.2 Synthesis of a Gly-cw-Pro-Phe Triazepinedione Peptidomimetic
We proposed to use the a-hydrazino acid in place of the simpler hydrazines used 
in previous syntheses of less complex triazepinediones. As for phenylhydrazine, this 
required selective protection of the unsubstituted amino group However, in this 
case the hydrazine is N^-alkylated rather than arylated, which might result in a 
different and undesirable regiochemistry of protection. Alkylhydrazines generally 
alkylate on the more nucleophilic substituted nitrogen except in cases where
the substituent imparts excessive steric hindrance. Fortunately, a-hydrazino acids 
possess sterically demanding substitution which significantly lowers the 
nucleophilicity of so Z-protection of the primary amino group of hydrazino
acid 78 proceeded in good yield with no detectable acylation of iV®, to give hydrazide 
80 (Scheme 2.9).
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Reagents and conditions: i, benzyl chloroformate, NaOH, H2O, 1 h, 79%; ii, SOCI2,
MeOH, reflux, 40 min, 87%.
Scheme 2.9; Synthesis o f protected a-hydrazino acid 81
As the next step is a peptide coupling reaction, the acid group of hydrazide 80 
also needed protection; this was done by the formation of a methyl ester using thionyl 
chloride in methanol in 87% yield, giving hydrazide 81.
Considering the difficulties encountered in the attempted coupling of BOC- 
protected phenylhydrazine 67, we predicted similar problems with the subsequent 
synthetic step in this sequence, the formation of an amide bond between of 
hydrazide 81 and the acid group of proline derivative 65 to give trisubstituted 
hydrazide 82 (Scheme 2.10).
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Reagents: i, IBCF; ii, EDCI; iii, pyBOP; iv, TBTU; v, DPPA; vi, pyBroP; 
vii, BOP-Cl.
Scheme 2.10: Failed attempts to couple acid 65 and hydrazide 81
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A greater range of coupling methods were employed here, covering every major 
family of reagents available, /.sobutyl chloroformate, EDCI, TBTU, DPPA and 
pyBOP all met with failure. Disturbingly, even BOP-Cl and pyBroP, usually so 
effective for difficult couplings, were unsuccessful in this case. Problems in coupling 
on to of hindered hydrazides have been encountered before. Lecoq et a l used 
strong activation via symmetrical anhydrides or acid chlorides, but yields for these 
processes were not quoted. Nugiel et a l required an acid chloride to acylate of 
their hydrazide in only 38% yield. Finally, Kim et a l utilised a double coupling 
procedure using the extremely powerful HATU reagent, in order to achieve a 
reasonably efficient reaction between Fmoc-Phe-OH S3 and protected {2S)-N- 
aminoleucine 84 to give hydrazide 85 (Scheme 2.11).
MeOaCMe02C HATU
DIEAFmoc
O Alloc
Fmoc
Scheme 2.11; Difficult coupling reaction of a N^-protected a-hydrazino acid
In the event, an acid chloride method proved to be effective in our synthesis. The 
potential of this methodology was shown by a test reaction between hydrazide 81 and 
acetyl chloride (Scheme 2.12).
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Scheme 2.12: Test acylation of hydrazide 81
This succeeded in acétylation of N^, giving the N“-acetyl derivative 8 6 , albeit in 
low yield. The success of this procedure indicated that the thionyl 
chloride/pyridine/DMAP methodology of Matsuda et al. which worked well
for the phenylhydrazine derivative 67, might also be applicable here. Fortunately, this 
was indeed the case and coupling between acid 65 and hydrazide 81 was achieved in 
yields of 40-53%, giving compound 82 (Scheme 2.13).
The standard method for removal of the Z protecting group is catalytic 
hydrogenolysis, but application of this technique to compound 82 resulted in 
reduction of the primary alkyl chloride as well, leading to A-acetyl compound 87. 
Acidolysis is an alternative method, and treatment of hydrazide 82 with a solution of 
HBr in acetic acid successfully cleaved the protecting group to give the hydrobromide 
salt 8 8 . Neutralisation of this with aqueous sodium hydroxide solution liberated the 
primary amino group which underwent cyclisation to give the fused triazepinedione 
72, in 8% overall yield for the 8 steps from proline, phenylalanine and chloroacetyl 
chloride.
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Reagents and conditions: i, SOCI2, pyridine, DMAP, CH2CI2, 3 days, 53%; ii, 
HBr, AcOH, 2 h; iii, 0.01 mol dm“  ^NaOH, H2O, 90 min, 91% (2 steps); iv, 
H2, Pd/C, MeOH, 12 h, 53%.
Scheme 2.13: Synthesis of triazepinedione 72
2.3.3 Further Studies of Triazepinedione 72
Compound 72 showed two sets of peaks in its ^H and NMR spectra in 
C%Cl3. This effect was also observed in some of the other triazepinediones in this 
series, ^^6 and is probably due to conformational isomérisation of the triazepine ring. 
This seven-membered ring may be in equilibrium between two sets of conformations, 
a chair family and a boat family (Fig. 2.1). Each of these families can undergo 
pseudorotations to more stable twist forms, in an analogous manner to 
cycloheptane. The two conformations will be discernable in NMR spectra if the 
interconversion is slow on the NMR timescale.
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Figure 2.1: Possible chair-boat conformational isomérisation of triazepinedione 72
Hydrazines may also show stereochemical isomérisation via nitrogen inversion. 
This process occurs at pyramidal nitrogen atoms, and consequently will not take place 
at the amide nitrogen of this hydrazide, which has a roughly planar configuration. 
However, this process is not usually observed at room temperature by NMR 
spectroscopy, making the chair-boat flip explanation more likely.
Another interesting feature of the ^H NMR spectrum of compound 72 is a 
substantial upfield shift of the triazepinedione methylene protons in one of the two 
conformations. These diastereotopic protons appear as two doublets at Ô 2.61 and 
3.09, well upfield of the shifts of the corresponding protons of the other 
conformation, which both resonate at around Ô 3.8.
This effect may be due to a shielding interaction, between the phenyl ring and the 
methylene protons, which only exists in one of the conformations. This shielding 
phenomenon has been observed in peptides containing the Gly-cw-Pro-Phe 
sequence. In these systems, the cis configuration of the Gly-Pro amide bond is 
stabilised, probably by an attractive interaction between the phenyl ring and the Gly 
carbonyl group which is not possible in the trans form (Fig. 2.2).
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Figure 2.2: Attractive interaction between phenyl ring and glycine residue in a 
Gly-cïs-Pro-Phe tripeptide
This brings the aromatic ring into close proximity with the glycine methylene 
protons, resulting in an upfield shift of their signals in the NMR spectrum.
A similar effect was observed in studies of dioxopiperazines by Kopple et al. 
and Vicar et al. These cyclic dipeptides have amide bonds fixed in the cis 
configuration, and resonances of protons in the piperazine ring show upfield shifts of 
over 1 ppm when an aromatic substituent is present which is capable of folding over 
the ring.
Our main objective here was to determine if this mimetic could be incorporated 
into a peptide chain. Extension from (the “C -terminus”) appears to be fairly 
straightforward, and all that remained was to couple another residue on to the 
secondary amino group of the triazepinedione 72. Yet again, this nucleophile is very 
hindered, and both BOP-Cl and HATU failed to promote coupling to Z-alanine 89. A 
final effort using wobutyl chloroformate succeeded in production of the desired 
peptide 90, albeit in very low yield (Scheme 2.14).
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Scheme 2.14: 'H-Terminal extension of triazepinedione 72
These fused triazepinediones differ from the mimicked peptide by only 
2 hydrogen atoms and an N-N bond. However, they still restrict the Xaa-Pro amide 
bond to the cis conformation, allow retention of all side-chains, and possess a 
C^i —> C«(,- + 3) interatomic distance of < 7 Â. These properties suggest that they may 
function as effective cw-prolyl mimetics and/or p-turn mimetics. The synthetic route 
is fairly straightforward and should prove general for any Xaa-Pro-Yaa sequence, 
which can be incorporated into a longer peptide.
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3 A^-Terminal a-Helix Templates
3.1 Attempted Synthesis of a Pro-Pro-Ala Macrocycle
We began our studies towards a macrocyclic V-terminal a-helix template by 
consideration of the necessary features required of such a compound and how these 
features could be incorporated into our design:
• it must provide three correctly oriented carbonyl groups;
• it should be conformationally rigid;
• it should lack hydrogen bond donors of its own to preclude other hydrogen 
bonded conformations;
• the synthesis should be reasonably concise.
With its restricted dihedral angles and A-alkylated nature, proline meets the first 
three criteria more effectively than any other proteinogenic amino acid. If the 
macrocycle could be constructed largely from proline residues, this would also 
simplify the synthesis. Accordingly, our first template design was the 11 -membered 
macrocycle 91, which consists of a Pro-Pro-Ala tripeptide sequence cyclised via a 
butyryl bridge between the Pro^ and Ala^ nitrogen atoms. This bridge further restricts 
conformational flexibility and rules out non-productive extended structures, thereby 
decreasing the entropie losses inherent in forming an a-helical conformation.
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In order to emulate an a-helical pitch of carbonyl groups, each of the three amide 
bonds within the ring must be in the trans configuration; molecular modelling 
suggested this to be an energetically accessible situation. The tertiary nature of each 
amide bond implies that cis isomers might be present, which would lead to ineffective 
templates.
The disconnection of the macrocycle (Scheme 3.1) suggested a similar Strategy to 
that used in the synthesis of the previously described triazepinedione mimetics.
HN
CH;
MeOaC
Scheme 3.1: Possible disconnection of macrocycle 91
Cyclisation could occur by Sn2 attack of a nitrogen nucleophile at an alkyl 
chloride. Synthesis of tripeptide 92 was achieved in five steps from commercially 
available starting materials. Proline 6 was directly acylated using 4-chlorobutyryl 
chloride to afford the A -^acyl derivative 93. (2S')-//-BOC-proline 94 was coupled to
73
(25')-alanine methyl ester 95 using mixed anhydride methodology to give dipeptide 96 
in moderate yield (Scheme 3.2).
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Reagents and conditions', i, 4-chlorobutyryl chloride, EtOAc, reflux, 75 
min, 94%; ii, IBCF, NMM, THF, DMF, -15 °C -> rt, 2 h, 65%; iii, 
HCl(g), EtOAc, 0 °C, 70 min, 99%; iv, 93, SOCI2, pyridine, DMAP, 
CH2CI2, 2 days, 39%.
Scheme 3.2: Synthesis o f linear precursor 92
Removal of the //-terminal protecting group with HCI afforded amine 
hydrochloride 97 in quantitative yield. The subsequent reaction of this amine with 
(2S')-//-(4-chlorobutyryl)proline 93 involved amide bond formation between two 
proline residues. This is one of the most hindered couplings possible when using the
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proteinogenic amino acids. Standard mixed anhydride methodology gave no 
detectable product; therefore the more powerful coupling reagents TBTU and pyBroP 
were utilised, but to no avail. These failures suggested the application of the thionyl 
chloride/pyridine methodology, which had already proven its utility for similar 
hindered systems. This produced a 25-39% yield of the desired tripeptide 92.
Compound 92 displayed three conformations in its and NMR spectra, in a 
ratio of approximately 2:1:1. A similar peptide studied by Venkatachalapathi and 
Balaram showed comparable conformational isomérisation by NMR spectroscopy. 
One or more of these conformations may incorporate a cis amide bond, preceding one 
or both of the proline residues. Hydrogen bonding between the Ala^ NH and one of 
the carbonyl groups may also be a factor in stabilising certain conformations. Such 
hydrogen bonding could form a 10-membered ring (P-turn/3 lo-helical turn) or 
7-membered ring (y-turn) (Fig. 3.1).
^/iGUgC H
p-turn y-turn
Figure 3.1: Potential conformations available to peptide 92
Cyclisation of compound 92 requires deprotonation of the Ala NH, since the 
amide nitrogen itself lacks sufficient reactivity. Analogous amide alkylations have 
been achieved using a variety of bases. 6^0-263 attempted this intramolecular 
amide alkylation using DBU, sodium hydride, potassium ferf-butoxide and LDA, but 
in no case could any of the desired macrocycle 91 be obtained (Scheme 3.3).
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Reagents: i, NaH; ii, DBU; iii, potassium tert-butoxide; iv, LDA.
Scheme 3.3: Attempted synthesis of macrocycle 91
This disappointing result must stem from the hindered nature of the nucleophile, 
and the conformations adopted by the acyclic compound. Any potentially useful 
conformation-directing effects of hydrogen bonding present in the linear precursor 
will be destroyed upon deprotonation of the amide group; without this stabilising 
factor, the tripeptide is liable to adopt a more extended conformation which precludes 
close proximity of the reactive centres, thus disfavouring the cyclisation. Efforts to 
perform the difficult iV-alkylation earlier in the synthesis in an intermolecular manner 
also proved fruitless.
Considering the significant problems we encountered in the synthesis of this 
macrocycle, we decided to refocus our efforts on a redesign of Kemp’s template 52 
(see p. 46). As it stands, this macrocycle fails to induce a-helicity, but we believed 
that prudent alterations to the structure and synthetic route might lead to an optimal 
a-helical template.
3.2 Attempted Synthesis of a Pro-Pro-Pro Ether Macrocycle
The Kemp macrocycle 52 adopts the unproductive ctt and cct conformations in 
solution. Molecular modelling indicates that the presence of the ttt form is the
primary requirement for correct alignment of the carbonyl groups. We chose to
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promote this conformer by use of a simple methyl substitution at the methylenethio 
bridge, which should destabilise the cis form of the first amide bond, thus 
disfavouring the undesired ctt and cct forms. In order to simplify the synthesis we 
also chose to avoid incoiporation of the sulfur atom. These two elements of redesign 
led to our target, macrocyclic ether 98.
CO2M©
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These structural alterations required a different synthetic route, since Kemp’s 
methodology does not allow for substitution at the intended position. Instead of 
ring closure via amide bond formation, we proposed a similar disconnection to our 
previous peptidomimetic syntheses (Scheme 3.4). This suggests cyclisation via Sn2 
displacement of chloride by an alcohol 99.
Me., Me
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Scheme 3.4: Disconnection of macrocycle 98
The synthesis of linear precursor 99 proceeded in eight steps from the amino acids 
(25)-proline 6 , cw-4-hydroxyproline 100 and (25)~alanine 103 (Scheme 3.5).
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(25)-Alanine 103 was converted to (25)-2-chloropropionic acid 104 via 
diazotisation-chlorination. Condensation of this acid with (25)-proline methyl ester 
102 using standard mixed anhydride methodology gave only 35-50% of the desired 
dipeptide 105, a conversion efficiency not improved by the use of the more 
specialised reagents BOP-Cl or PyBOP. Despite its somewhat hindered nature, the 
amine component of this coupling should not prevent any real difficulties, so the 
problem must lie in the activation and reaction of the a-chloro acid. The electron- 
withdrawing nature of the chloro substituent may render the active species rather 
unstable. In the case of the wobutyl chloroformate mediated reaction, significant 
amounts of a urethane 109 were formed. This arises from attack of the amine on 
unreacted chloroformate or at the carbonate carbonyl group of the mixed anhydride 
110. The a-chloro substituent must mediate this undesirable change in acid reactivity.
The methyl ester 105 was subsequently converted to the corresponding acid 106 
by alkaline hydrolysis without disturbing the chloro-substituted chiral centre; bromo- 
substituted analogues suffer racémisation during this process. Acid 106 was 
coupled to (25)-proline methyl ester 102  using the acid chloride method to afford the 
tripeptide 107 in 33% yield. Saponification gave acid 108 in almost quantitative yield.
The final residue to be attached to this sequence was cw-4-hydroxyproline, in the 
form of its methyl ester 101. Coupling of this with acid 108 gave a moderate 42% 
yield of the triprolyl peptide alcohol 99.
78
HQ
|\| COgH 
H 
100
COgMe 
H .HCI
101
rvl\I^^^COgMe 
H .HCI
102
HgN
CHg
A hCOgH Cl
103
ÇH3
A ’HCOgH
104
r v^Ivr^COaMe
M e-Y ^O
Cl 105
IV
O c COgH
Cl
o
106
VI
VII
Reagents and conditions: i, SOCI2, MeOH, reflux, 90 min, 100%; ii, NaN0 2 , HCI, 
KCI, H2O, 0-5 °C, 2 h, 73%; iii, IBCF, NMM, THF, DMF, -15 °C rt, 18 h; iv, 
1.0 mol dm”  ^NaOH, MeOH, H2O, 2 h, 36% (2 steps); v, 102, SOCI2, pyridine, 
DMAP, CHjClj, 4 days, 33%; vi, 1.0 mol dm”  ^NaOH, MeOH, HjO, 90 min, 
98%; vii, 101, SOCI2, pyridine, DMAP, CHjClj, 2 days, 42%.
Scheme 3.5: Synthesis of linear precursor 99 
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The proposed cyclisation of compound 99 is a variant of the Williamson ether 
synthesis, which involves reaction of an alkoxide with an alkyl halide. ^  The weaker 
amine bases pyridine and DBU failed to promote cyclisation even upon use of large 
excesses and prolonged reaction times. A similar lack of reactivity was found with 
stronger bases such as sodium methoxide, potassium rerr-butoxide, sodium hydride 
and potassium hexamethyldisilazide (KHMDS) in a variety of solvents either at 
ambient or elevated temperatures.
Compound 99 seems to suffer from similar drawbacks to amide 92 with regard to 
this cyclisation process. The nucleophilic and electrophilic sites are both at less 
reactive secondary centres. The carbon-oxygen bonds present in the proposed 
macrocycle 98 are shorter than the carbon-sulfur bonds found in Kemp’s macrocycle 
52; this could result in excessive strain in the molecule, precluding its formation. The 
linear precursor 99 may avoid the folded conformations which are required to bring 
the reacting centres together, instead favouring extended structures such as the 
polyproline II helix often found in oligoprolines, which minimise unfavourable 
steric interactions between the pyrrolidine rings.
The problems of low nucleophile reactivity and potential cyclic strain may be 
overcome by switching to a thioether macrocycle akin to that of Kemp. Thiolates are 
significantly better nucleophiles than alkoxides, and the longer carbon-sulfur bonds 
could help to relax cyclic strain.
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3.3 Studies of Pro-Pro-Pro Thioether Macrocycles
3.3.1 Molecular Modelling Studies
The substitution of sulfur for oxygen provides the new target molecules 111 and 
112:
Pro
R^  = Me,R  ^= H 111 
R' = H,R^ = Me 112
Pro^
Extensive molecular modelling studies were carried out on this macrocycle, 
assessing the isomers with both S (lll)and  R (112) stereochemistry at the new chiral 
centre compared to Kemp’s unsubstituted version 52.
The results are summarised in Tables 3.1 and 3.2, where the fifteen computed 
lowest energy conformations for each macrocycle are shown. Cis-trans isomérisation 
at each amide bond generates 8 possible configurational isomers. Only the ttt form is 
capable of a-helix initaition. Each of these 8 “parent” conformations of defined co 
values possesses a set of substates which differ in the <j) and \|/ dihedral angles for each 
proline residue and by flexibility in the thioether bridge.
The relative conformational energies of Kemp’s macrocycle 52 indicate that six 
isomeric forms exist which are of greater stability than the most likely a-helix- 
initiating ttt substate U. All but one of these contain a cis amide bond at position a, 
next to our proposed site of substitution. The modelling study correctly predicts the 
structure of this compound, which was experimentally determined by Kemp et a l to 
assume the ctt and cct forms. 219
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Table 3.1: Molecular mechanics energy calculations (in kcal mol~^) fo r 52 and 111
52 111
Code State Energy Code State Energy
G ctt 71.73 G ctt 93.02
B cct 71.92 AE ctt 95.20
AE ctt 73.44 AG ctt 95.73
R ctt 74.40 R ctt 96.09
K ctt 74.64 AB ctt 99.14
M ttt 75.95 A cct 100.21
u* ttt 76.24 u* ttt 101.34
S* ttt 77.49 D ctt 101.49
AA tct 77.60 I ttt 101.75
AB ctt 77.78 M ttt 101.78
G* ttt 77.97 Q tct 102.53
I ttt 78.23 G* ttt 103.21
N cct 78.96 A4 tct 103.34
A cct 78.98 S* ttt 103.65
Y tcc 79.46 P tct 103.67
Conformational energies were calculated using the AMBER all-atoms molecular 
mechanics force-field and the Insight II program?'^^ Energies are relative to an 
arbitrary minimum and are given in kcal mol~k “State” describes the configurations 
of the three amide bonds a, b, and c in the 12-membered ring. Conformers with the 
correct set o f dihedral angles for a-helix initiation are highlighted in bold and 
marked with an asterisk.
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Table 3.2: Molecular mechanics energy calculations (in kcal mol~^) fo r 112
112
Code State Energy
A cct 94.00
M ttt 96.99
ÀA tct 98.83
S* ttt 99.01
I ttt 99.95
u* ttt 100.30
G* ttt 100.93
Q tct 101.14
F ttt 101.47
N cct 101.54
G ctt 101.87
Y tcc 102.11
Z ttt 103.17
P tct 103.77
AG ctt 104.42
Surprisingly, methyl substitution at the methylenethio bridge with S 
stereochemistry in compound 111 seems to have a detrimental effect on the relative 
stability of a-helix initiating conformers. Isomers with amide bond a in the cis form 
are still of significantly lower energy. However, R stereochemistry appears to have a 
pronounced destabilising effect on the cis form. In general, isomers of the R form 112 
with amide bond a cis are now of significantly higher energy. This has the desired 
effect of increasing the relative stability of the a-helix-initiating ttt substates S, U and 
O. It should be noted that not all ttt states are capable of a-helix initiation. However, 
if another ttt state is present, the energy required to alter the conformation to an
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initiating state should be relatively small, involving changes to (j> and \|/ values rather 
than the large changes in co required for cis-trans isomérisation.
It is apparent from comparison of the sets of conformational energies for each 
compound that macrocycle 112, with R stereochemistry, is the most likely to afford 
a-helix-initiating properties, and this became our target. Three of the lowest energy 
modelled conformations are shown in Fig. 3.2. Conformer A is predicted to be the 
most stable of all, with a cct arrangement of amide bonds. Conformer M  is the lowest 
energy ttt substate, possessing no net dipole and lacking a-helix-initiating capability. 
Conformer S  is tbe most stable of the potentially a-helix-initiating ttt substates with a 
correctly aligned set of carbonyl groups and an associated dipole.
3.3.2 Synthetic Studies
Synthesis of macrocycle 112 required elaboration of the route for incorporation of 
the sulfur atom in place of oxygen. This could be done quite easily based on a similar 
strategy to the preceding synthesis. In this instance, rmm-4-hydroxyproline methyl 
ester 114 was required, and this was prepared from the amino acid 113 by action of 
thionyl chloride in methanol in almost quantitative yield. The amine 114 was coupled 
to acid 108, as for the cis analogue 1 0 1 , to give the triprolyl peptide alcohol 115 
(Scheme 3.6).
Our first attempt to incorporate sulfur began with tosylation of the secondary 
alcohol, which resulted in a disappointingly inefficient transformation to the desired 
material 116. The presence of two leaving groups in species 115 suggested an 
ambitious one-step conversion to the desired macrocycle 1 1 2 , via a double 
displacement of chloride and tosylate using sulfide (S%-) as the nucleophile. This 
method has been used in the preparation of symmetrical sulfides, giving almost 
quantitative yields even when using a secondary alkyl chloride as the electrophile.
In our hands, none of the desired macrocycle 112 could be obtained; and 
NMR spectra of the reaction products suggested that polymerisation had occurred, 
despite the high dilution conditions employed.
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Figure 3.2: Low energy modelled conformations o f macrocycle 112
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In view of the inefficient production of the tosylate and failure to achieve 
cyclisation, we decided first to convert the alcohol into a protected form of thiol 
which could then be unmasked in a controlled manner to undergo reaction with the 
alkyl chloride.
HO
H
113
108 + 114
HO
COoMe
IV
112
COaMe 
H .HCI 
114
9
COaMe
III
Cl O
116
Reagents and conditions: i, SOCI2, MeOH, reflux, 90 min, 98%; ii, 
SOCI2, pyridine, DMAP, CH2CI2, 3 days, 60%; iii, p-toluenesulfonyl 
chloride, pyridine, CH2CI2, 3 days, 15%; iv, Na2S, MeOH, reflux.
Scheme 3.6: Attempted synthesis of macrocycle 112
8 6
Conversion of alcohols to thiolethers or thiolesters with the required inversion of 
stereochemistry is well-established. 269-271 chose to use the Mitsunobu-type 
transformation of Volante, which was expected to convert the alcohol 115 directly 
into the corresponding thiolester of correct stereochemistry.
Me IN--."V115 HO^  117 Acs*'
Reagents and conditions: DIAD, PPh^, AcSH, THF, 0 °C, 2 h then rt, 4 h, 40%.
Scheme 3.7: Synthesis of thiolester 117
Treatment of alcohol 115 with diethyl azodicarboxylate (DEAD) or difjopropyl 
azodicarboxylate (DIAD) and triphenylphosphine in the presence of thiolacetic acid 
afforded 30-40% of the desired thiolacetate 117 (Scheme 3.7).
This yield was not considered sufficient at this late stage in the reaction sequence. 
We decided to adapt the synthesis so that the Mitsunobu reaction could be performed 
at an earlier point.
Accordingly, the original linear synthesis was superseded by a more convergent 
approach. Retrosynthetic analysis suggested amine 118 and acid 106 as intermediates 
(Scheme 3.8).
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Scheme 3.8: Disconnection of thiolester 117
Acid 106 was already available from the previous synthetic route, so we needed 
only to devise a synthesis of the amine fragment 118. In the event, this was possible 
in only three steps from intermediates in the previous synthesis (Scheme 3.9).
(25')-ferr-ButoxycarbonyIproline 94 and frfl«5-4 -hydroxyproline methyl ester 114 
were coupled using BOP-Cl in 62% yield to give the dipeptide 119. BOP-Cl proved 
to be the reagent of choice for coupling reactions involving proline residues.
Following this, the alcohol was converted to the thiolester 120 of opposite 
stereochemistry using Volante’s procedure. This transformation and subsequent 
acid-catalysed BOC group removal afforded 69% of the desired amine 
trifluoroacetate salt 118.
Using BOP-Cl, the acid 106 and amine 118 were coupled in very good yield to 
give the triprolyl thiolester 117. The yield of target compound 117 from acid 106 was 
thus increased four-fold in comparison with the previous less convergent route.
CO2H
HO
BO C
94
O 4 "N C 0 2 M e  
H .MCI 
114
T
|\j CO2H
S A c
III
Cl
106
IV
^ O M e
.C F 3 C O 2 H
118
S A c
120
C0 2 Me ?»=“ • 
« o
1 1 7  A c s 121 H S
Reagents and conditions: i, BOP-Cl, DIEA, CH2CI2, 0 °C —> rt, 6 days, 62%; ii, 
DIAD, PPI13, AcSH, THF, 0 °C, 2 h then rt, 15 h; iii, TFA, CH2CI2, 0 °C, 2 h, 
69% (2 steps); iv, BOP-Cl, DIEA, CH2CI2, 0-5 °C, 2 h then rt, 8 days, 90%; v, 
0.05 mol dm"’ KOH, MeOH, H^O, 4 h, 95%.
Scheme 3.9: Synthesis o f linear precursor 121
Cyclisation required the thiol to be unmasked. This was achieved in 95% yield by 
very mild alkaline hydrolysis of thiolester 117 to afford thiol 121 without affecting 
the methyl ester. A thiolate anion is generated during this process, but this underwent 
neither intramolecular nor intermolecular reaction with the alkyl chloride. Solutions 
of thiol 121  in various solvents were therefore subjected to a variety of other bases in
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an attempt to achieve cyclisation. Use of DBU, sodium methoxide or potassium tert- 
butoxide failed to produce any of the desired product. Only when solutions of thiol 
121 were heated in the presence of sodium hydride were significant changes seen in 
the NMR spectra of the crude product, indicating that some reaction had occurred. 
Column chromatography of the crude material allowed isolation of a compound in 
15-25% yield, the NMR spectra of which corresponded to those expected for the 
macrocycle 11 2 .
In the NMR spectrum, a striking 0.3 ppm upfield shift of the doublet 
attributed to the methyl group at the stereogenic centre was highly indicative of a 
change of substituent at that position. The NMR spectrum also showed two 
upfield shifts, of the methyl group carbon (by ~3 ppm) and the stereogenic carbon 
atom (by >10 ppm). These changes would be expected for the decreased 
electronegativity of the substituent upon exchanging chloride for sulfur. The single 
set of resonances in the NMR spectrum ruled out acyclic oligomers and polymers. 
The product lacked the S-H  stretch in the infra-red found for the starting material, 
supporting the NMR evidence that a sulfide rather than a thiol was now present.
These results gave a strong indication that the desired macrocycle 112 had 
formed. However, mass spectra of the compound failed to show the desired molecular 
ion (M+ = 409). Instead, a peak at mass 819 was observed, indicating that the reaction 
product was actually the cyclic dimer 122 containing a 24-membered ring 
(Scheme 3.10).
The dimeric product 122 was indistinguishable from monomeric compound 112 
by any of the other analytical techniques employed because it possesses C2 symmetry. 
Conformational analysis of the product in its acid form 123 by high-field 2D NMR 
experiments gave similarly ambiguous results. The set of ROESY cross-peaks 
observed is equally possible for both the monomer 112 (in the M  conformation) and 
the dimer 122 , with all amide bonds in the trans configuration.
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Reagents and conditions: i, NaH, THF, reflux, 2 h, 22%; ii, 1.0 mol dm“  ^NaOH, 
MeOH, H2O, 2 h, 65%.
Scheme 3.10; Cyclodimérisation upon attempted synthesis o f macrocycle 112
This disappointing result implies that the steric strain inherent in the folded 
conformations of thiol 121  which are required for intramolecular reaction prohibited 
cyclisation. Instead, only intermolecular thiol alkylation was possible. This produced 
an acyclic dimer which had sufficient flexibility to allow the reacting centres to 
approach one another without energetically prohibitive steric interactions between the 
pyrrolidine rings.
Formation of a macrocyclic template akin to 112 requires stabilisation of folded 
forms of thiol 121 which allow close intramolecular approach of the nucleophile and 
electrophile.
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3,4 Studies of a Pro^^-Pro-Pro Thioether Macrocycle
a-Alkyl amino acids such as Aib are known to favour folded 
conformations, and to promote cyclisation reactions via the gem-dimethyl
effect. If such an a-alkyl residue could be incorporated into the thiol 121, it could 
appreciably increase the time that such a molecule spends in folded conformations 
conducive to monomeric cyclisation. The minimum change which could be envisaged 
is the substitution of a-methylproline residue 124 for one of the proline residues in 
macrocycle 112
r \ C 0 2 H  
N ' mg
124
a-Methylproline (Pro^®) has received little attention to date. Those studies which 
have appeared indicate that the amide bond preceding an a-methylproline residue is 
exclusively t r a n s . Likewise, the cis configuration of the following amide bond 
is also destabilised. Substitution of Pro for Pro^«  ^at position (i + 1) in tetrapeptide 
sequences by Robinson and co-workers was found to restrict the conformational 
space available to the peptide so that it occupied turn-like conformations for longer 
periods of time, exactly the type of effect we hoped to utilise. The positioning 
of the Pro^G residue in Robinson’s sequences corresponds to Pro^ in the triprolyl 
peptide 112 Incorporation at this point affords new target 125.
Me
Me.
" COgMe
125
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Molecular mechanics simulations of the ttt substates of this molecule suggested a 
further advantage. The helix-initiating S substate is now predicted to be of lower 
energy than the non-productive M  substate, in contrast to the original thioether 
macrocycle 112 (Table 3.3).
Table 3.3; Energy differences (in kcal mol~^) between non-helical (M) and helical (Sj 
ttt conformations o f macrocycle 112 and analogue 125 containing an a-methylproline 
residue
Compound M S Difference
112 96.99 99.01 +2.02
125 118.95 117.39 -1.56
We envisaged using a very similar synthetic route towards macrocycle 125 to that 
used in the previous synthesis. First, we required a convenient synthesis of 
a-methylproline.
a-Alkyl amino acids can be made in a variety of ways, but we chose 
Seebach’s methodology for the synthesis of a-substituted proline derivatives as the 
most convenient (Scheme 3.11).
(2S)-Proline 6 was condensed with pivalaldehyde to give bicyclooctanone 126 in 
96% yield. Deprotonation a  to the carbonyl group using LDA at -78 °C followed by 
addition of methyl iodide gave 57% of the a-methyl derivative 127. The tert-hxHyX 
group directs the electrophile by controlling the conformation of the bicyclic enolate 
so that the alkylation must occur from the same side as deprotonation. Since the 
1,3-induction results in complete retention of configuration, this procedure is termed a 
“self-reproduction of chirality”. No trace of the (27?) diastereoisomer could be 
detected in the NMR spectra of compound 127.
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r v *CO2H
H
Cl
ÇH3
A ’-hCOgH
104
Me
C X^N^^COgMe
IV
H .HCI 
128
MervCOgMe
M e ^ O
Cl
129
126
-7 ?127
COgH
M e* Y ^  O Cl
130
Reagents and conditions: i, pivalaldehyde, pentane, reflux, Dean-Stark, 7 days; 
ii, LDA, THF, -78 °C, 1 h; then Mel, -78 -30 °C, 2 h, 55% (2 steps); iii,
SOCI2, MeOH, reflux, 2 h, 58%; iv, BOP-Cl, DIEA, CH2CI2, 0-5 °C, 4 h then 
rt, 15 h; V, NaOH, MeOH, H2O, 2 days, 43% (2 steps).
Scheme 3.11; Synthesis o f a-methylproline derivative 130
The bicyclic compound 127 was cleaved by action of thionyl chloride in methanol 
to give (2S)-2-methylproline methyl ester hydrochloride 128 in reasonable yield.
Coupling of the methyl ester 128 with (25)-2-chloropropionic acid 104 using 
wobutyl chloroformate or pyBroP gave yields of only 31% and 34% respectively of 
the dipeptide 129. BOP-Cl proved more effective; a slight excess of the activated acid
94
afforded a moderate 44% yield of the desired product. Although a three-fold excess 
increased the yield to 70%, this resulted in intolerable racémisation at the chloro- 
substituted chiral centre. Further optimisation established that a two-fold excess of 
activated acid gave a satisfactory 62% yield with no significant racémisation.
Alkaline hydrolysis of the methyl ester 129 to the acid 130 was sluggish, a 
consequence of the adjacent quaternary centre. With care, complete cleavage took 
place over 1-2 days. Increases in either alkali concentration or reaction time led to 
various degrees of substitution of chloride for hydroxide.
The next synthetic step required coupling of the acid 130 to the amine thiolester 
118, an intermediate in the previous synthesis. The powerful coupling reagent HATU 
afforded only 21% of the desired peptide 131, whilst BOP-Cl was more slightly more 
efficient, giving 31% yield. The slow acylation rate, related to the significant 
associated steric hindrance of both species, may have rendered dioxopiperazine 
formation from the amine fragment 118 competitive. This compound is particularly 
prone to this cyclisation process due to the presence of proline and hence its higher 
propensity to contain a cis amide bond. Such a side-reaction may be responsible for 
the low yield in this coupling reaction.
Nevertheless, useful quantities of the thiolester 131 could be obtained. This was 
converted to the thiol 132 using mild alkaline hydrolysis (Scheme 3.12).
In this case, caesium carbonate proved slightly more effective than sodium 
hydride for the subsequent cyclisation, affording 30% of a compound suggested by 
NMR to be cyclic in nature. Once again, mass spectral analysis confirmed formation 
of a cyclic dimer 133. It appears that incorporation of a Pro^^ residue failed to 
promote sufficiently the required folded forms of the acyclic precursor. However, 
NMR spectra of the cyclic dimer 133 do highlight the influence that the two Pro^^ 
residues have on the conformation of the macrocycle.
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132
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133
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Reagents and conditions’, i, BOP-Cl, DIEA, CH2CI2, 0-5 °C, 5 h then rt, 15 h; ii, 
0.05 mol dm'^ KOH, MeOH, HgO, 4 h, 29% (2 steps); iii, CsjCOj, DMF, 
80-90 °C, 2.5 h, 30%; iv, 1.0 mol dm“  ^NaOH, MeOH, HgO, 2 h, 78%.
Scheme 3.12: Synthesis of cyclic dimers 133 and 134
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Cyclic dimer 122 containing only ordinary proline residues showed 
predominantly one conformational state, with others accounting for <5% of the total 
in both chloroform and water. In contrast, the bis-(Pro^^) macrocycle 133 displayed 
solvent-dependent conformational isomérisation. In chloroform, three sets of peaks 
were observed in both and NMR spectra, in relative abundance 3:2:2. This 
may be due to the presence of three distinct C2-symmetric conformations which 
interconvert slowly on the NMR timescale, or alternatively one C2-symmetric 
conformation and one which lacks an axis of symmetry. In aqueous solution, only one 
set of NMR resonances was observed, suggesting that the interconversion between 
the various conformations was too rapid to be discernable in this medium.
The acid form of the dimer 134 showed isomérisation in aqueous solution, the 
NMR spectra showing three sets of peaks in relative abundance 81:13:6. High-field 
2D NMR experiments confirmed that the most populated conformer was the same as 
that found for macrocycle 123, with six trans amide bonds.
3.5 Attempted Synthesis of a ProM®-Pro'^®-Pro Thioether Macrocycle
Further promotion of folded forms of the linear precursor was clearly necessary to 
enable cyclisation to take place. Extension of the principles applied in design of the 
ProMe macrocycle 123 leads to the new target 135 which incorporates two Pro^® 
residues.
..Me
Me
Me
135
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Molecular mechanics simulations of compound 135 predicted a further advantage; 
an increased preference for the potential helix-initiating S ttt substate over the M  
substate (Table 3.4).
Table 3.4: Energy differences (in kcal mol~^) between non-helical (M) and helical (S) 
ttt conformations o f macrocycle 112 and analogues 125 and 135 containing one and 
two a-methylproline residues respectively
Compound M S Difference
112 96.99 99.01 +2.02
125 118.95 117.39 -1.56
135 178.43 175.34 -3.09
A second Pro^® residue would also have an additional destabilising effect on the 
cis configuration of the second and third amide bonds. Hence, if the 12-membered 
ring could be formed, a helix-initiating conformation is even more likely for this 
macrocycle. Unfortunately, the presence of two Pro^ ^® residues was certain to pose 
serious synthetic problems. i
This attempted synthesis of macrocycle 135 required a modification to the amine 
fragment 118. Accordingly, (25)-2-methylproline methyl ester hydrochloride 128 was 
converted to the corresponding BOC derivative 136 upon action of (B0 C)2 0  with 
DMAP catalysis and a prolonged reaction time. Alkaline hydrolysis then gave the free 
acid 137 in a satisfactory 61% yield over the two steps (Scheme 3.13).
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H .HCI 
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BOC
138
h t "  -^N^COaMe
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139
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COaMe 
H .CFaCOaH 
140
CAcSAc
MeMe VII137 + 140
OMeOMe
141 142
Reagents and conditions: i, (B0 C)2 0 , DIEA, DMAP, CH2CI2, 3 days; ii, 1.0 
mol dm“^NaOH, MeOH, H2O, 2 days, 61% (2 steps); iii, (BOC)2 0 , NMM, 
THF, 18 h, 79%; iv, DIAD, PPhg, AcSH, THF, 0 °C, 2 h then rt, 18 h; v, 
TFA, CH2CI2, 0 °C, 90 min, 72% (2 steps); vi, BOP-Cl, DIEA, CH2 CI2 , 
0-5 °C, 8 h then rt, 15 h, 55%; vii, TFA, CH2CI2, 0 °C, 90 min, 100%.
Scheme 3.13: Synthesis ofPro^^ thiolester dipeptide 142
We chose to incorporate the thiolacetate group prior to the coupling of the two 
proline residues in order to avoid manipulation of the precious Pro^®-Pro dipeptide. 
Accordingly, (2S)-4 -fra«5-hydroxyproline methyl ester hydrochloride 114 was 
converted to its N-BOC derivative 138 which was in turn converted to the thiolester 
139 using the Mitsunobu-type inversion. Trifluoroacidolysis of the amino protecting 
group afforded the amine trifluoroacetate salt 140. The acid 137 and amine 140 were 
coupled using BOP-Cl to give 55% of the Pro^®-Pro dipeptide 141. Removal of the 
N-terminal protecting group gave amine trifluoroacetate salt 142.
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The subsequent coupling reaction between two Pro^® residues proved to be most 
difficult yet, due to both fragments 130 and 142 possessing extreme steric hindrance. 
Although BOP-Cl had proved to be clearly superior to any other reagent in such 
hindered reactions, in this case it failed to produce any of the desired product. Instead, 
49% of the dioxopiperazine 143 was isolated (Scheme 3.14). The very slow rate of 
intermolecular acylation rendered intramolecular acylation the faster process, despite 
the presence of a Pro^® residue which disfavoured the required cis amide bond 
configuration of amine 142.
Q ^ c o , h  
N Me
Cl
SAc
^ OMe
.CF3CO2H
142
SAc
130  143
Reagents and conditions'. BOP-Cl, DIEA, CH2CI2, 0-5 °C, 9 h then rt, 14 h,
49%.
Scheme 3,14: Dioxopiperazine formation upon attempted coupling ofPro^^ residues
In order to overcome the problem of dioxopiperazine formation, we decided to 
pursue a linear synthetic route. We attempted to mediate amide bond formation 
between acid 130 and amine 128 using HATU (Scheme 3.15). Gratifyingly, this was 
partially successful, affording 21-30% of Pro^®-Pro’^® peptide 144. A second 
compound could also be isolated from the reaction mixture, and this appeared to be 
the azabenzotriazolyl ester 145. This acylating agent survived an aqueous work-up 
and silica column chromatography, demonstrating the extraordinary low reactivity 
that the a-methyl group imparts on the adjacent carbonyl group.
1 0 0
O ^ C O ^ H  
N Me
Cl
130
MeH e COaMe
H .HCI 
128
e > r ^ O °  H=n'
Cl
145
Reagents and conditions: i, HATU, DIEA, DMF, 0-5 °C, 4 h then rt, 40 h, 
30% (of 144) and 37% (of 145).
Scheme 3.15: Partially successful coupling o f two Pro^^ residues
Although it was possible to form the exceptionally difficult Pro^e-ProMe 
sequence, the yields to this point were low, and we did not envisage being able to 
produce useful amounts of more advanced intermediates. This view was supported by 
an attempt to hydrolyse the methyl ester of compound 144. This usually facile 
reaction did not go to completion even after a week in strongly alkaline conditions. 
Therefore, we decided to abandon synthesis of the bis-(Pro^e) macrocycle, and 
considered other ways of stabilising the required folded transition state of the linear 
precursor.
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3.6 Effect of Hydrogen Bonding on the Conformations of Linear Precursors
We have established that steric effects alone are insufficient to promote the 
necessary folding of the triprolyl sequence. In nature, folded structures in peptides 
and proteins are often stabilised by hydrogen bonding. Can we use this phenomenon 
to favour the cyclisation reaction?
Conversion of the methyl ester of the original linear precursor to a methylamide 
gives triprolyl peptide 146.
CONHMe
146 HS
The potential now exists for formation of intramolecular hydrogen bonds which 
could stabilise folded states approximating to the desired cyclic structure, thus 
assisting cyclisation. Possible hydrogen bonding schemes involve the terminal methyl 
amide in i —> (/ -  5) (a-helical turn), i —> (i -  4) (3%o-helical/p-turn) or i —> (/ -  3 ) 
(y-turn) interactions with preceding carbonyl groups (Fig. 3.3). Model studies on 
other peptide sequences have shown that the p-turn seems to be the most stable of the 
three in isolation.
These conformations may allow favourable geometry for intramolecular reaction, 
particularly if the a-helical turn makes a prominent contribution to the secondary 
structure of the linear precursor. Hydrogen bonding has found uses in favouring 
cyclisations in the past, for example in Wenger’s synthesis of cyclosporin A 7.
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Figure 3.3: Possible hydrogen bonded conformations o f linear precursor 146
Hydrogen bonding of this sort provides an enthalpic bias towards certain folded 
conformations, but the actual geometry adopted depends on a fine balance between 
this favourable effect and other forces which act against compact structures, such as 
loss of entropy upon formation of hydrogen bonded rings, torsional strain, and 
repulsive dipolar interactions. It remained to be seen whether the enthalpic
gain of a hydrogen bond would be enough to overcome the repulsive steric 
interactions which prohibited cyclisation of earlier linear precursors. Hydrogen 
bonding interactions in Pro-Pro-Ala tripeptides have been demonstrated to promote 
folded forms of this sequence. We hoped that this might also be possible in the 
similar Pro-Pro-Pro sequence.
The synthetic route to the linear precursor 146 used a very similar strategy to the 
previous synthesis (Scheme 3.16). To begin with, methyl ester 119 was converted to 
the corresponding methyl amide 147 in quantitative yield.
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BOCOBOCOO ' OMe 119
H
O '" 'NHMe 147
Cl
CONHMe IV
150 Acs
SAc
NHMe148
SAc
^ ° 0 "^  NHMe.CF3CO2H
149
CONHMe
I N — <y
146 HS
Reagents and conditions: i, NH2CH3, MeOH, 1 day, 100%; ii, DIAD, PPhg, AcSH, 
THF, 0 °C, 2.5 h then rt, 15 h, 50%; iii, TFA, CH2CI2, 0 °C, 2.5 h; iv, 105, BOP-CI, 
DIEA, CH2CI2, 0-5 °C, 2 h then rt, 2 days, 69% (2 steps); v, 0.05 mol dm“  ^KOH, 
MeOH, H2O, 4 h, 6 6%.
Scheme 3.16: Synthesis of linear precursor 146
The methyl ester 119 shows two conformations in single-dimensional NMR 
spectra in C^HClg. Examination of the proline CP and CY chemical shifts allows 
for designation of cis and trans isomers about the preceding urethane or amide bond.
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In ester 119, the conformations present are thus identified as trans trans (tt) and cis 
trans (ct), in 55% and 45% abundance respectively (Fig. 3.4).
O O OMe
trans trans 
55%
O O O OMe
cis trans 
45%
Figure 3.4: Conformations adopted by methyl ester 119
Cis and trans isomers of urethane bonds are of very similar energy due to the 
similar size of the carbonyl oxygen and the alkoxy substituent. The slight preference
for the trans configuration may be due to an O-H 0=C 10-membered ring
hydrogen bond which can form between the Pro^ y-hydroxy substituent and the 
urethane carbonyl oxygen. No trace of the cis configuration about the Pro-Pro amide 
bond could be found, indicating that it is of significantly higher energy than the trans 
form in the absence of external stabilising forces.
In contrast, the methyl amide 147 displays three conformational isomers. Since 
the only change is incorporation of a hydrogen bond donor, the additional 
conformation must be one stabilised by a hydrogen bond.
The NMR spectra reveal that the tc, tt, and ct configurations are present, in 
relative abundance 14:62:24 (Fig. 3.5).
The tc state is not found in the methyl ester, and must therefore be stabilised by an
N -H  0=C hydrogen bond involving the methyl amide NH and the urethane
carbonyl oxygen. The presence of a hydrogen bond is further indicated by a 0.4 ppm 
upfield shift of the amide proton resonance relative to the non-hydrogen bonded form; 
infra-red spectra in dichloromethane solution also show two N-H stretch bands at
105
3448 and 3342 cm“^ which correspond to non-hydrogen bonded and intramoiecularly 
hydrogen bonded N-H groups respectively.
o  0"'"H-N O O NHMe
OH
trans cis 
14%
trans trans 
62%
NHMe
cis trans
24%
Figure 3.5; Conformations adopted by methylamide 147
Alcohol 147 was converted to thiolester 148, and subsequent deprotection of the 
amino terminus gave amine trifluoroacetate salt 149 which showed only one 
conformation (Scheme 3.16). There is now only one isomerisable bond, and the 
removal of the urethane hydrogen bond acceptor site destroys any stabilising 
influence over the cis configuration, so only the trans form is now stable. Amine 
trifluoroacetate salt 149 was subsequently coupled to acid 105 to afford the thiolester 
150 in 69% yield. This thiolester shows two conformations, corresponding to ttt 
(45%) and ttc (55%), due to re-establishment of cis-trans isomérisation about the 
Pro2-Pro3 amide bond (Fig. 3.6).
H J L  O H CONHMe 
Cl i f )
Acâ
45%
Me^ \\
55%
SAc
Figure 3.6: Conformations adopted by thiolester 150
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Conversion of thiolester 150 to the free thiol 146 does not change the 
conformational equilibrium adopted in C^HClg. Spectra in ^H2 0  show only the ttt 
state because the intramolecular hydrogen bond found in the ttc state is replaced by 
intermolecular solvent-peptide hydrogen bonds.
It appears that addition of a hydrogen bonding group at the C-terminus will not be 
able to assist the thiol to adopt the required conformations involving close approach 
of the electrophile and nucleophile. A hydrogen bond is present in about half the 
molecules in chloroform solution and to some degree is able to overcome repulsive 
interactions which otherwise prohibit the folded form. However, the stabilised 
conformation is one in which the thiol group is held away from the intended site of 
reaction, and as such is of no use in assisting the cyclisation process.
3.7 Studies of a Pro-(2/2)-Ala-Pro Thioether Macrocycle
3.7.1 Design
Steric and hydrogen bonding effects both failed to promote the required folds of 
linear precursors to our desired macrocycles. This is largely due to the excessive non­
bonded interactions between the three pyrrolidine rings which greatly inhibit the 
backbone flexibility. Rather than trying to overcome such unfavourable steric effects 
in the transition state, a better method may be to increase the flexibility of the 
backbone. This can be done by substituting Pro^ by a less sterically demanding 
residue, thus removing undesirable interactions between Pro^ and the two adjacent 
Pro residues which preclude folded conformations. Of course, this substitution will 
also increase the conformational space available to the macrocycle.
Initially we chose to exchange Pro^ for Ala, a helix-favouring residue which will 
significantly increase the conformational space available to the sequence. We decided 
on a (2/?)-Ala residue because the Pro-(2R)-Ala sequence is well-established as an 
effective (I-turn inducer, 277-279 should therefore favour the elusive
conformations wherein the reactive centres are proximal.
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COaMe
151
Molecular mechanics modelling of the proposed template 151 has not yet been 
completed because of the large increase in accessible conformations resulting upon 
substitution of Pro^ for Ala. Although cis configurations of secondary amides have 
been found in cyclic peptides, 9b 93 can predict that ttt conformations of the 
macrocycle will be of relatively low energy because the secondary Pro^-Ala^ amide 
bond will have a significant bias towards the trans form.
3.7.2 Synthetic Studies
The synthesis followed the familiar pattern (Scheme 3.17). BOC-(2i?)-Ala-OH 
152 was coupled with (2S)-rra«5-4 -hydroxyproline methyl ester 114 using BOP-Cl to 
give dipeptide 153 in 55% yield. Mitsunobu inversion gave the thiolacetate 154, and
Iremoval of the BOC group gave amine trifluoroacetate salt 155 cleanly in 92% yield 
over the 2 steps.
These compounds all contain small amounts (10-20%) of a conformation with a 
cis Ala2-Pro3 amide bond, which was never present in Pro-Pro sequences without 
external stabilisation. Peptide bond formation between amine trifluoroacetate 155 and 
the ubiquitous acid 105 was mediated by BOP-Cl to give 6 8 % of the Pro-(2/?)-Ala- 
Pro peptide 156.
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H * T
NHBOC
152
^N ^C O g M e 
H .HCI 
114
r ^ c o g H
N'^H
SAc
106
+ HgN 1  
.CF3CO2H O '^'O M g 
155
IV
%
HC ' N. .H
COgMe
Cl
156 A c s
BOCO
SAc
154
Reagents and conditions: i, BOP-Cl, DIEA, CH2CI2, 0-5 °C, 5 h then rt, 4 
days, 55%; ii, DIAD, PPhg, AcSH, THF, 0 °C, 2.5 h then rt, 15 h, 92%; 
iii, TFA, CH2CI2, 0 °C, 90 min; iv, BOP-Cl, DIEA, CH2CI2, 0-5 °C, 3 h 
then rt, 2 days, 68% (2 steps).
Scheme 3.17: Synthesis of linear precursor 156
Surprisingly, mild alkaline hydrolysis of the thiolester 156 to the free thiol 157 
did not give a pure product. It appeared that some other process had occurred in 
addition to cleavage of the thiolester. Apparently, some thiolate alkylation had 
already taken place. The impure material 157 was taken straight on and subjected to
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cyclisation conditions using caesium carbonate in DMF under high dilution 
conditions at room temperature over 4 days (Scheme 3.18). Column chromatography 
of the crude product again enabled isolation of a compound displaying NMR spectra 
corresponding to those expected of the 12-membered macrocycle 151. Gratifyingly, 
mass spectroscopy revealed this to be the desired monomeric cyclic compound 151 
([M + H]+ = 384). Some cyclic dimer was also formed, but was easily separated by 
chromatography. This methodology allowed a 25% conversion of thiolacetate 156 to 
the macrocyclic compound 151 Optimisation of the process established that 
compound 151 could be produced directly from the thiolacetate via action of a dilute 
solution of potassium hydroxide in methanol-water at 65 °C for 2.5 h in an excellent 
69% yield.
Acs HS
H
Me
Me..
151
Reagents and conditions: i, KOH, MeOH, H2O, 2.5 h; ii, CS2CO3, DMF, 
4 days, 25%.
Scheme 3.18: Synthesis o f macrocycle 151
110
3.7.3 Conformational Studies
Macrocycle 151 proved conducive to analysis by X-ray diffraction of a crystal 
grown as a hemihydrate from ethyl acetate-hexane. The solid-state structure of the 
compound is shown below (Fig. 3.9).
Figure 3.9: Crystal structure of macrocycle 151
All amide bonds take the trans configuration, fulfilling our first objective. 
However, the ttt substate adopted is incapable of helix initiation, with the carbonyl 
groups lacking the required alignment. In fact, the molecule lacks any significant 
dipole. Although the carbonyl group in the mercaptopropionyl bridge possesses an 
approximately a-helical geometry, the Pro  ^ carbonyl has roughly opposite alignment, 
and the Ala^ carbonyl is splayed out from the desired position, as the cartoon 
depiction in Fig. 3.10 demonstrates.
I l l
ideal a-helical geometry 
‘ of carbonyl groups
geometry of carbonyl groups 
experimentally observed for 
macrocycle 151
Figure 3.10: Ideal and actual carbonyl alignments o f macrocycle 151
In ^Hg-DMSO solution, the macrocycle 151 displays only one conformation, 
which corresponds almost exactly to that found in the solid state. Any other 
conformation must be present in less than -10% abundance, or NOES Y crosspeaks 
derived from this second conformation would be observable. The diagnostic NOE's 
which indicate the “up” alignment of the Pro^ carbonyl group all involve the Ala^ 
amide proton. This shows interactions with the Pro  ^ aCH and both of the Pro^ ÔCH2 
protons (Fig. 3.11). The absence of NOE's to either Pro  ^ PCH2 proton argues against 
any significant population of the a-helical conformation with the Pro  ^ carbonyl 
“down”.
H ' / - N  
S  "(^"COgM e
Figure 3.11: NOE’s observed for macrcocycle 151 in solution
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3.8 Evaluation of Macrocycle 151 as an a-Helix Initiator
Is the template 151 capable of initiating helical structure in an attached peptide? 
At first glance, the arrangement of carbonyl groups does not appear favourable. The 
Pro  ^ carbonyl has exactly the opposite alignment to that required, and the Ala^ 
carbonyl is also appreciably displaced from the position expected for an a-helix. 
However, the mercaptopropionyl carbonyl is in approximately the correct position to 
accept a hydrogen bond from the first amide group of an attached peptide and thus 
induce an a-helical geometry in at least the first appended residue. If it does so, the 
next NH group along the attached peptide chain will be in the correct position to 
hydrogen bond to the Pro^ carbonyl if the carbonyl group flips alignment (Fig. 3.12). 
A similar effect may then occur for the Ala^ carbonyl group which requires less 
movement to form a hydrogen bond with the next amide group of the growing helix.
Figure 3.12: Potential complementary conformational changes in macrocycle and 
attached peptide
In this way, changes in conformation of both template and peptide would be 
complementary, in an analogous way to the changes in both receptor and ligand
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conformation upon binding of bioactive peptides. Like Kemp’s first template 51 
(p. 46), NMR-observable changes in the macrocycle conformation might thus be used 
as a “reporter” on the conformation of the peptide, since the population of the a- 
helix-initiating conformation of the macrocycle would be directly proportional to the 
degree of a-helicity of the attached peptide.
This “conformational co-operativity” is favoured by the formation of hydrogen 
bonds, but disfavoured on entropie grounds and by repulsive dipolar interactions. It 
was also unclear if the large change in the Pro* \\f dihedral angle required to bring its 
carbonyl group into the correct alignment possessed a prohibitively large activation 
energy due to hindered rotation within the cyclic structure.
This study of the feasibility of a-helix induction by template 151 requires 
synthesis of derivatives with appended peptide chains. The hydrogen bond donors of 
the attached peptide may be able to trigger conformational changes in the template 
and therefore the peptide itself.
One hydrogen bond donor was introduced upon conversion of the methyl ester 
151 to the methylamide 158 (Scheme 3.19).
Me., A o
CONHMe
151 158
Reagents and conditions: NH2CH3, MeOH, 2 days, 100%.
Scheme 3.19: Synthesis of macrocycle methylamide 158
Conformational analysis of compound 158 in H2O -2H2O (9:1) indicated that 
there was no change in the conformation of the macrocycle upon addition of the 
hydrogen bond donor. The Pro* carbonyl group does not flip round to take part in a
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310-helical hydrogen bond with the methylamide NH. Experiments to establish 
whether there is an a-helical hydrogen bond from this NH to the mercaptopropionyl 
carbonyl were inconclusive; weak NOE’s show that the methylamide group may 
spend some time folded underneath the macrocycle, but the presence of a hydrogen 
bond could not be firmly established. In aqueous solution, the solvent may sequester 
the hydrogen bond donor so that the time it spends taking part in an a-helical 
hydrogen bond is greatly reduced.
Attachment of more than one hydrogen bond donor site required hydrolysis of the 
methyl ester 151 to the free acid 159. The acid was coupled to (25)-phenylalanine 
methyl amide 160 to give the template-peptide conjugate 161 (Scheme 3.20).
Me
H
Me
O
151
COgMe
Me
H
H
S  Iff 4 
159
Ph 'V ^C O N H M e  
+ NHz 
160
Me Ph
NHMe
161 O
Reagents and conditions: i, NaOH, MeOH, H2O, 2 h, 83%; ii, BOP-Cl, DIEA, 
CH2CI2, 0-5 °C, 2 h then rt, 20 h, 62%.
Scheme 3.20: Synthesis o f macrocycle-peptide conjugate 161
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In C^HCis solution, the macrocycle in compound 161 shows no change in 
conformational preference relative to that in the methyl ester 151. However, several 
NOE effects suggest some interaction between the lower face of the macrocycle and 
the attached peptide. This implies that the phenylalanine residue spends an 
appreciable amount of time folded underneath the macrocycle in a position conducive 
to the presence of a hydrogen bond between the phenylalanine amide proton and the 
mercaptopropionyl carbonyl. Such a hydrogen bond necessitates an a-helical position 
for the phenylalanine residue. This model is supported by a 0.2 ppm upfield shift of 
the mercaptopropionyl methyl protons, consistent with a ring current effect caused by 
the close proximity of the phenyl ring. There is also a 0.8 ppm downfield shift of the 
phenylalanyl amide proton relative to its position in a peptide known to lack 
intramoleculai' hydrogen bonding.
Although this folded conformation may be populated to some extent, other 
evidence suggests that there is still significant mobility associated with the attached 
peptide. Some NOE's are present which are not possible for the folded conformation, 
and the ^JaN value for the phenylalanine residue is 8.0 Hz, which implies 
conformational averaging and not a fixed a-helical geometiy.
In order to provide hydrogen bond donors for each acceptor carbonyl in the 
macrocycle, one further derivative was required. The peptide component was 
synthesised by mixed anhydride coupling of BOC-(2S)-Ala-OH 162 and (2S)- 
phenylalanine methylamide 160 to afford dipeptide 163. TEA mediated removal of 
the BOC group yielded the trifluoroacetate salt 164. This was coupled to the 
macrocycle acid 159 to give the desired conjugate 165 (Scheme 3 .2 1 ).
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Ph
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Reagents and conditions: i, IBCF, NMM, THF, -15 °C rt, 2 h, 67%; ii, 
TFA, CH2CI2, 0 °C, 2 h; iii, 159, BOP-Cl, DIEA, CH2CI2, 0-5 °C, 2 h then 
rt, 18 h, 33% (2 steps).
Scheme 3.21: Synthesis o f macrocycle-peptide conjugate 165
NMR studies in C^HClg solution supply no evidence to suggest that the attached 
hydrogen bond donors are altering the conformation of the macrocycle. However, 
there is fairly convincing evidence for the presence of an intramolecular hydrogen 
bond between the NH of the appended alanine residue and the thiapropionyl carbonyl. 
There is a relatively strong set of NOE's similar to those found for compound 161, 
indicative of folding of the peptide under the macrocycle. The value for the 
attached alanine residue is 3.9 Hz, which corresponds exactly with the value expected 
for an a-helical geometry, and the high-field position of the NH resonance is 
indicative of involvement in a hydrogen bond. These results suggest that the 
macrocycle may be inducing a-helical character in the first attached amino acid 
residue, but not in any of the subsequent residues. The more convincing data for this
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conjugate compared with derivative 161 may reflect the higher intrinsic a-helical 
propensity of alanine in comparison with phenylalanine.
3.9 Effect of a C-terminal Cation on the Conformation of Macrocycle 151
The enthalpic benefit of hydrogen bonding between the appended peptide and the 
template in the “helical” conformation appears unable to counterbalance the repulsive 
dipolar forces and entropie losses associated with this conformation.
However, hydrogen bonds are not the only stabilising force acting upon peptide 
and protein a-helices in nature. Another common feature of these a-helices is the 
presence of an associated charge of the appropriate sign near one of the helix teimini, 
which interacts favourably with the helix macrodipole. The desired alignment of 
carbonyl groups in our macrocycle is disfavoured by repulsive dipole-dipole 
interactions. This repulsive force could be replaced by a favourable effect if a 
negatively charged group could be attached over the //-terminal face of the 
macrocycle (as found in Bartlett’s template 54, p 47 or if a positively charged 
group could be attached under the C-terminal face, as shown in Fig. 3.13. The latter 
effect was demonstrated by Gellman et al. who appended a tetraalkylammonium 
group at the C-terminus of a short depsipeptide with resultant induction of essentially^ 
complete a-helical stmcture.
Figure 3.13: Charge-template models for control of macrocycle conformation
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Introduction of an anionic group on the //-terminal face is synthetically 
challenging and cannot be accomplished from macrocycle 159. Therefore, we chose 
to attach a cationic group at the C-terminus via the carboxyl group of macrocycle 159. 
This proved to be straightforward, with mixed anhydride coupling of acid 159 to N,N- 
dimethylethylenediamine affording macrocycle 166 with a pendant tertiary amine 
(Scheme 3.22).
"  H
Me
H S-.„
m CIM /— OCOgH ^
159 /  166
N ' NM02
N " NHM02 
167 CFaCO^
Reagents and conditions: i, //,iV-dimethylethylenediamine, IBCF, NMM, 
THF, DMF, -15 °C -> rt, 4 h, 78%; ii, TFA, CH2CI2, 100%.
Scheme 3.22: Synthesis o f macrocycle-cation conjugate 167
The amine 166 was converted to its trifluoroacetate salt 167 to produce the 
positively charged group intended to interact with the set of carbonyl groups in the 
macrocycle; two hydrogen bond donors are also present which may assist in 
stabilisation of a-helical macrocycle conformations.
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In organic solution, the macrocycle-cation conjugate 167 behaves in a different 
manner to any of the previous systems. In this case, the macrocycle equilibriates 
between two conformations. One set of resonances was observed at room 
temperature, but the  ^H NMR resonances of both conformations could be frozen out 
at -8 0  °C in C2H2CI2. The rapid rate of interconversion between the two 
conformations resulted in significant complications even at this low temperature, but 
sufficient NOE constraints were obtained to allow simulated annealing and generation 
of reliable structures for both conformations.
The major conformation, accounting for -60% of the population, was found to be 
similar to those observed in previous cases, although the Ala^ carbonyl appears to 
have been pulled down from its previous position, presumably to interact with the 
appended positive charge (Fig. 3.14).
Figure 3.14; Major conformation of macrocycle-cation conjugate 167
In contrast, the minor conformation, accounting for -40% of the population 
possesses an a-helical arrangement of carbonyl groups (Fig. 3.15). This conclusion is 
based on a set of NOE’s involving the Ala^ amide proton and protons on the upper 
face of Proi which are only possible for a conformation with the Pro' carbonyl 
correctly aligned in an a-helical geometry.
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Figure 3.15: Minor conformation of macrocycle-cation conjugate 167
Dynamic modelling of the minor conformation using a dielectric constant of 4 
(approximating to a non-polar environment) showed no evidence of hydrogen 
bonding between the macrocycle and the pendant chain. Instead, the 
trialkylammonium cation was positioned directly underneath the centre of the 
macrocycle, allowing maximum charge-dipole interaction with the aligned carbonyl 
groups. When the dielectric constant was increased to simulate an aqueous 
environment, the trialkylammonium group was found to drift away from the position 
directly beneath the macrocycle.
This striking change in macrocycle conformation shows that the generation of 
potential a-helix initiating templates is possible by judicious use of charge-dipole 
interactions. Modelling studies suggest that these initiating forms are stabilised solely 
by the charged group effect without contribution from hydrogen bonding.
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3.10 Conclusions and Future Work
Under the influence of a C-terminal cationic group, the Pro-(2/?)-Ala-Pro template 
has been demonstrated to adopt a significant population of the desired a-helical 
conformation in organic solution. Further derivatives of macrocycle 151 are under 
study, whçre additional amino acid residues are incorporated between the template 
and the pendant cation to establish the effect of the charge-template system on the 
conformational preference of an attached peptide. This may also allow us to 
determine if the NMR signature of the template in the a-helical state can act as a 
“reporter” on the degree of helicity adopted by the attached peptide. Experiments will 
be designed to calculate the dependence of the peptide conformation on the charge 
alone Le, is it possible that any helical character induced in a peptide is caused solely 
by the charge-dipole interaction without the template exerting any significant 
stabilising influence? The solvent dependence of the conformational equilibrium 
exhibited by these systems will also be assessed, since the template must ideally be 
able to function in aqueous media which may lessen the beneficial charge-dipole 
interactions and disrupt intramolecular hydrogen bonding.
A more useful template would carry an anionic group at its ‘W-terminus”, 
allowing for general use in conjunction with any peptide of interest without the need 
for synthesis of peptide derivatives with pendant amine groups. The anion-stabilised 
model also allows for the maximum possible ion-dipole effect to be exerted upon the 
template; this favourable influence is likely to be significantly diminished in the 
cation-stabilised model if longer peptides are inserted between the macrocycle and the 
pendant ammonium ion.
The first design 168 incorporates a side-chain carrying a phosphate group on of 
ProT This side-chain can fold over the A^-terminus of the helix to allow the doubly- 
charged anionic group to be positioned directly over the axis of the helix barrel where 
it can exert the maximum influence.
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The alternative designs 169 and 170 are synthetically more accessible and could 
be made using the well-established methodology by substituting Ala^ for a protected 
form of aspartic acid (macrocycle 169) or glutamic acid (macrocycle 170). This 
template follows nature’s lead; Pro is the most common residue at the A-terminal 
position of a-helices, whilst Asp and Glu are the most common residues at the next 
C-terminal position. Although the negative charge attached to these templates is less 
likely to be positioned directly over the helix, they can also favour the “down” 
alignment of the Pro^ carbonyl by forming a hydrogen bond from the carboxyl side- 
chain to the Ala^ NH.
The optimised template can then be applied to a variety of peptide conjugates 
under various conditions to determine whether the template is an efficient “reporter” 
system (showing quantifiable spectral changes as a function of peptide helicity) 
and/or an efficient a-helix initiator (calculation of the helix initiation constant a  for 
the template).
Further into the future, an a-helix template might be applied to study of the 
mechanism of the FMDV 2A peptide. The template could be attached to the N- 
terminus of 2A analogues, resulting in stabilisation of a-helical structure. If the 
proposed bioactive structure involving a functional helical segment is correct, such 
stabilisation should allow the cleavage reaction to take place, allowing study of the 
cleavage mechanism catalysed by this protein fragment.
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4. EXPERIMENTAL
Melting points were taken on an Electrothermal melting point apparatus and are 
uncorrected.
Optical rotations were measured at 22 °C on an Optical Activity AA-1000 
polarimeter using a 10 cm path length cell.
Elemental microanalyses were performed in the departmental microanalytical 
laboratoiy.
IR spectra were recorded on a Perkin-Elmer 1710 f.t. IR spectrometer. The 
samples were prepared as Nujol mulls, thin films between sodium chloride discs or 
solutions in the specified solvent. The frequencies (t>) of absorption maxima are given 
in wavenumbers (cm~^) relative to a polystyrene standard.
NMR spectra were recorded on a Brüker AM-300 (^H, 300 MHz;
74.76 MHz), Varian 300 (^H, 300 MHz; 75.44 MHz) or Varian gemini 200 (^H, 
200 MHz; 50.31 MHz) spectrometers. Chemical shifts are described in parts per 
million downfield from SiMe^ and are reported consecutively as position or <^ ), 
relative integral, multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; dd, doublet of 
doublets; m, multiplet and br, broad), coupling constant (7/Hz) and assignment 
(numbering according to the lUPAC nomenclature for the compound).  ^H-NMR
spectra were referenced internally on ^HOH (5 4.68), CHCI3 (J  7.27) or DMSO {ô)
2.47). l^c-NMR spectra were referenced on CH3OH {S 49.3), C2HCI3 (577.5), or 
DMSO (5 39.7). Carbon and proton resonances of amino acids in NMR spectra are 
assigned as a , p, y and Ô according to normal convention. Where more than one 
conformational isomer is present due to the presence of a tertiary amide bond, these 
are assigned as c (cis) or t {trans), according to the isomeric state of the amide bond. 
If the isomeric states of the amide bonds are not known, the conformations are 
assigned as A, C etc.
Mass spectra and accurate mass measurements were recorded on a VG 70-250 SE, 
a Kratos MS-50 or by the SERC service at Swansea using a VG AZB-E. Fast atom 
bombardment spectra were recorded using glycerol as a matrix. Major fragments were 
given as percentages of the base peak intensity (100%).
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All experiments were performed at room temperature (20-25 °C) unless 
otherwise stated. Flash chromatography was performed according to the method of 
Still et al. using Sorbsil C 60 (40-60 mm mesh) silica gel. Analytical thin layer 
chromatography was carried out on 0.25 mm precoated silica gel plates (Macherey- 
Nagel SIL g/UV254) and compounds were visualised using UV fluorescence, iodine 
vapour or ninhydrin.
The solvents used were either distilled or of analar quality. Light petroleum ether 
refers to that portion boiling between 40 and 60 °C and ether refers to diethyl ether. 
Solvents were dried according to literature procedures. Ethanol and methanol were 
dried using magnesium turnings. DMF, CH2CI2 and pyridine were distilled over 
CaH2. THF and ether were dried over sodium/ benzophenone and distilled under 
nitrogen. Thionyl chloride was distilled over sulfur and the initial fractions were 
always discarded. A-Methylmorpholine was distilled over ninhydrin. All other 
reagents were used without further purification.
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(25)-iV-(Chloroacetyl)proline 65
O c CO2H
Cl
A stirred suspension of (25)-proline 6 (7.5 g, 65.1 mmol) in ethyl acetate (150 cm^) 
was treated dropwise with chloroacetyl chloride (8.0 cm^, 99.7 mmol), and heated at 
reflux for 50 min. Upon cooling, colourless crystals were formed which were filtered 
off and washed with cold ethyl acetate to afford acid 65 (7.9 g, 64%), mp 106-108 °C
(lit., 112 °C) (Found; C, 43.85; H, 5.15; N, 7.2. Calc, for C7H10CINO3; C, 43.9; H, 
5.25; N, 7.3%); [a]p  -110.6  (c 0.9 in HjO) [lit., -  114 (c 2 in HjO)];
t)„ax(Nujol)/cm-> 2900 (OH), 1722 (acid CO), 1620 (amide CO) and 690 (C-Cl); 
0h(200 MHz; C^HsO^H) 1.90-2.13 (3 H, m, ^pCHjand -yCHî), 2.18-2.35 (1 H, m, 
IPCH2), 3.51-3.74 (2  H, m, 8CH2), 4.28 (2 H, AB quartet, J  13.6, CH2CI), 4.41-4.48 
(1, 1 H, m, aCH) and 4.62-4.69 (c, 1 H, m, aCH); 8c(74.76 MHz; C^HsO^H) 23.49 
(c, 7CH2), 25.99 (i, )CH2), 30.51 (t, pCHj), 32.37 (c, PCH2), 43.12 (c, CHjCl), 43.23 
(t, CH2CI), 48.46 (t, 8 CH2), 48.73 (c, 8CH2) 60.98 (aCH), 167.76 (t, amide CO), 
168.17 (c, amide CO), 174.87 (c, acid CO) and 175.34 (f, acid CO); m/z (El) 193 and 
191 (2 and 6 %, chlorine isotopes, M+), 148 and 146 (26 and 52, chlorine isotopes, [M 
-  C0 2 HJ+), 112 (36, [M -  Cl -  COgH + H]+) and 70 (100, C4HgN+).
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N-(ter^Butoxycarbonyl)-A^'-phenylhydrazine 67
Di-rerf-butyl dicarbonate (11,1 g, 50.8 mmol) was added to a solution of 
phenylhydrazine 66  (5.0  cm^, 30.8 mmol) in ether (125 cm^) and the mixture stirred 
at room temperature for 3 days. The solvent was removed under reduced pressure and 
the residual solid washed with light petrol, aqueous HCl (0.5 mol dm“3) and water to 
afford hydrazide 67 (9.1 g, 8 6%); a small portion was recrystallised from light petrol- 
ethyl acetate to afford colourless needles, mp 88-90 °C (lit., 91-93 °C); (Found: 
C, 63.55; H, 7.75; N, 13.65. Calc, for CnHigNsOs: C, 63.45; H, 7.75; N, 13.45%); 
Vrnax(Nujol)/cm-i 3354 (amine NH), 3278 (amide NH) and 1700 (CO); % 200 MHz; 
C2HCI3) 1.48 [9 H, s, C(CHg)3], 5.90 (1 H, s, amine NH), 6.64 (1 H, s, urethane NH), 
6.80 (2 H, d, J  7.8, Ar-H ortho), 6.89 (1 H, t, 7 7.8, Ar-H para) and 7.23 (2 H, t, J 
7.8, A r-H  metay, ^ (74 .76  MHz; C^HClg) 28.15 [C(CH^)^], 81.03 [C(CH3)3)], 
112.88 (Ar-CH ortho), 120.56 (Ar-CH para), 129.00 (Ar-CH meta), 148.33 (Ar-C 
quaternary) and 156.25 (urethane CO); m/z (El) 208 (9%, M+), 152 (81, [M -  
C4H9 + H]+), 108 (57, [M -  CO2C4H9 + H]+), 92 (44, C^H^NH^), 77 (52, C6H5+), 65 
(31, C5H5+) and 57 (100, C4H9+).
1
A-(te/7-Butoxycarbonyl)-iV'-[(25)-iV-(chIoroacetyl)prolyI3-A^-phenylhydrazine 69
r v . H  fh
O BOC O
Cl
Thionyl chloride (1.00 cm^, 13.9 mmol) was added dropwise to a stirred solution of 
(25)-7/-(chloroacetyl)proline 65 (2.20 g, 11.5 mmol) and pyridine (1.27 cm^, 
15.8 mmol) in dichloromethane (50 cm^). After 10 min, a solution of hydrazide 67 
(2.00 g, 9.6 mmol) and DMAP (2.60 g, 21.4 mmol) in dichloromethane (50 cm^) was 
added in one portion. The dark brown solution was stirred for 3-4 days, then washed
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with aqueous HCl (0.5 mol dm“3, 2 x 70 cm^), aqueous sodium hydrogen carbonate 
solution (5%, 2 X 70 cm^) and brine (100 cm^). The organic phase was dried 
(MgSO^), and the solvent removed under reduced pressure to yield a brown oil 
which was purified by column chromatography using light petrol-ethyl acetate (3 :2 ) 
as the eluent to afford hydrazide 69 as a tan oil (2.09 g, 57%); Rf 0.17; (Found: C, 
56.05; H, 6.2; N, 10.75. C^gH^^ClNgO^ requires C, 56.6; H, 6.35; N, 11.0%); (HRMS: 
found [M -  0 C4H9]+, 308.0808. Cj^Hig^lNgOg requires 308.0802); [a\y -21.5 (c 
0.4 in MeOH); t)max(lhin film)/cm“i 1733 (urethane CO), 1694 (amide CO), 1654 
(amide CO) and 1162 (C-O); ^ (200  MHz; C^HClg) (2 conformations, A and B) 1.28 
[9 H, s, C(CH3)3l, 1.66-2.02 (4 H, m, gCH^and yCHz), 3.28-3.53 (2 H, m, SCHg),
3.90-3.99 (2 H, m, CH2CI), 4.30 (A, 1 H, m, aCH), 5.05 (B, 1 H, m, aCH), 6.96-
7.42 (5 H, m, Ar-H), 8.95 (A, 1 H, br. s, NH) and 9.25 (B, 1 H, br. s, NH); %(74.76 
MHz; C2HCI3) 25.28 (A, 1CH2), 25.42 (B, 1CH2), 28.60 [0 (013)3], 28.95 (B, pCHg), 
29.20 (A, PCH2), 42.50 (CHgCl), 47.86 (ÔCH2), 58.17 (B, aCH), 58.39 (A, aCH), 
81.86 [C(CH3)3l, 125.15 and 126.95 (Ar-CH ortho), 128.37 and 128.87 (Ar-CH 
para), 129.11 and 129.95 (Ar-CH meta), 141.56 and 142.14 (Ar-C quaternary), 
154.97 {B, urethane CO), 155.96 (A, urethane CO), 165.39 {B, COCH2CI), 165.83 (A, 
COCH2CI) and 173.47 (CONPh); m/z (El) 382 (2%, [M + H]+), 310 and 308 (2 and 6 , 
chlorine isotopes, [M -  OC4H93+), 283 and 281 (4 and 14, chlorine isotopes, [M -  
CO2 -  C4Hg]+), 176 and 174 (32 and 55, chlorine isotopes, C7H9NO2CI+), 148 and 
146 (46 and 100, chlorine isotopes, C6H9NOCI+), 70 (77, C4H8N+) and 57 (57,
C4H9+).
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(9a5)-2-Phenyl-2,3,4,5,7,8,9,9a-octahydro-lH-pyrrolo-[2,l-^[l,2,5]triazepine- 
1,5-dione 64
J N-Ph 
H
Dry HCl gas was bubbled through a solution of dipeptide 69 (0.84 g, 2.2 mmol) in 
ethyl acetate (25 cm^) for 40 min. The solvent was removed under reduced pressure 
to give amine hydrochloride salt 70, which was redissolved in aqueous HCl 
(0.5 mol dm~3, 25 cm^). This solution was washed with ether (30 cm^), and basified 
with aqueous sodium hydroxide solution (1.0 mol dm^^, 35 cm^). The solution was 
allowed to stand for 30 min and then extracted with ethyl acetate (3 x 50 cm^). The 
organic phase was washed with water (50 cm^), dried (MgSO^.), and the solvent
removed under reduced pressure to yield the triazepinedione 64 as an orange oil 
(0.36 g, 6 8 %); (HRMS: found M+, 245.1170. Ci3Hi5N302  requires 245.1164);
-27.9 (c 1.0 in MeOH); t>max(thin film)/cm“i 3336 (NH) and 1650 (CO); ^h(300 
MHz; C^HClj) 1.90-2.04 (3 H, m, igCHz and 7CH2), 2.30-2.45 (1 H, m, IPCH2),
3.48-3.64 (2 H, m, ÔCH2), 4.17-4.35 (2 H, m, CH2NH), 5.57 (1 H, m, aCH) and 
7.19-7.52 (5 H, m, Ar-H); ^(74.76 MHz; C2HCI3) 25.55 (7CH2), 29.84 (PCH2), 
42.65 (CH2NH), 48.04 (ÔCH2), 58.17 (aCH), 127.99 (Ar-CH ortho), 128.93 (Ar-CH 
para), 130.08 (Ar-CH meta), 142.35 (Ar-C quaternary), 165.28 (COCH2N) and
171.15 (CONPh); m/z (El) 245 (15%, M+), 217 (33, [M -  CO]+), 110 (40, 
C6HgNO+), 93 (57, PhNHi^), 77 (42, Ph+) and 70 (100, C4H8N+).
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(25)-N-Acetylprolmanilide 71
o
Sodium metal (70 mg, 3.0 mmol) was added to a solution of triazepinedione 64 
(0.20 g, 0.82 mmol) in liquid ammonia (10 cm^) under nitrogen at -50°C, such that a 
dark blue colour persisted for 10 min. The solution was allowed to warm up to room 
temperature, after which methanol (10  cm^) and aqueous ammonium chloride 
solution (0.4 mol dm~3, 10 cm^) were added. The mixture was stirred overnight to 
allow evaporation of ammonia, and the remaining solvent removed under reduced 
pressure. The residue was purified by column chromatography using ethyl acetate as 
the eluent to yield (2^)-7/-acetylprolinanilide 71 as pale yellow crystals (40 mg, 21%), 
mp 168-170 °C; Rf 0.23; (HRMS: found M+, 232.1212. C 13H 16N2O2 requires 
232.1203); -66.7 (c 0.5 in MeOH); t)max(Nujol)/cm-i 3270 (NH), 3132 (NH),
1695 (secondary amide CO) and 1628 (tertiary amide CO); ^ (3 0 0  MHz; C2HCI3) 
1.80-2.19 (3 H, m,|pCH2 and 7CH2), 2.14 (3 H, s, COCH3), 2.54-2.61 (1 H, m. 
îPCHa), 3.39-3.60 (2  H, m, SCH2), 4.76 (1 H, d, J 7.2, aCH), 7.04 (1 H. t, J 7.5, 
Ar-H para), 7.26 (2 H, t, J  7.5, Ar-H ortho), 7.51 (2 H, d, J  7.8, Ar-H meta) and 
9.68 (1 H, s, NH); ^(74.76 MHz; C^HC^) 22.88  (COCH3), 25.45 (7CH2), 27.05 
(PCH2) 48.90 (ÔCH2), 60.88 (aCH), 120.20 (Ar-CH ortho), 124.36 (Ar-CH para), 
129.34 (Ar-CH meta), 138.90 (Ar-C quaternary), 169.48 (acetyl CO) and 172.33 
(anilide CO); m/z (El) 232 (32%, M+), 140 (23, [M -  NHPh]+), 112 (76, [M -  
CONHPh]+), 70 (100, C4H8N+) and 43 (35, COCH3+).
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(2S)-2-Benzylhydantoic acid 77
Ph
HOgC,
H,N^NH2
o
Potassium cyanate (22.9 g, 0.28 mol) was added to a stirred suspension of (25)-
phenylalanine 76 (5.0 g, 30.3 mmol) in water (80 cm^). The resulting mixture was
heated at 60 °C for 4 h. The solution was cooled to 0 °C and carefully acidified with
concentrated HCl (50 cm^). The precipitate thus formed was filtered off, washed with
cold water and dried under vacuum to yield (25)-2-benzylhydantoic acid 77 as a white 
solid (5.4 g, 8 6%), mp 189-190 °C (lit., 4^? ig9 °C); +38.5 (c 1.0 in MeOH)
[lit., 247 +45.0 (c 1.0 in EtOH)]; Dmax(Nujol)/cm-i 3450 (NH), 3297 (NH), 2926 
(OH), 1693 (acid CO) and 1659 (urea CO); ^ (200  MHz; % 6-DMSO) 2.85 (1 H, dd, 
7i 13.7, 72 7.9, ipCHi), 3.01 (1 H, dd, 7i 13.9, 7z5.1, ipCHi), 4.35 (1 H, m, aCH),
5.70 (2 H, s, NHz), 6.23 (1 H, d, 7 8.0, NH) and 7.19-7.45 (5 H, m, Ar-H); %(50.31 
MHz; 2H6-DMSO) 37.79 (pCHz), 53.92 (aCH), 126.65 (Ar-CH para), 128.41 
(Ar-CH ortho), 129.47 (Ar-CH meto), 137.70 (Ar-C quaternary), 158.53 (urea CO) 
and 174.17 (acid CO); m/z (El) 208 (6 %, M+), 148 (86 , [M -  NHCONH2 + H]+), 120 
(41, CgHioN+), 91 (100, C7H7+), 74 (61, C2H4NO2+) and 65 (28, C5H5+).
(25)-A-Aminophenylalanine 78
A solution of (25)-2-benzylhydantoic acid 77 (8.00 g, 38.4 mmol) in aqueous 
potassium hydroxide solution (2.5 mol dm~3, 56 cm^) at 0 °C was treated with 
aqueous potassium hypochlorite solution (2.1 mol dm~ ,^ 25 cm^). The solution was 
heated at 70-80 °C for 1.5 h, after which toluene (100 cm^), hydrazine hydrate 
(2.4 cm^) and concentrated HCl (32 cm^) were added. The mixture was cooled to 
room temperature, the phases separated, and the solvent removed from the aqueous
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phase under reduced pressure. The residual salts were extracted with hot ethanol (3 x 
20 cm3) and the extracts brought to pH 6.3 by addition of diethylamine, resulting in 
formation of a white solid which was filtered off, washed with ethanol and dried 
under vacuum to yield (25)-N-aminophenylalanine 78 (2.99 g, 43%), mp 199-201 °C 
(lit., 283 197-200 °C); (Found: C, 58.2; H, 7.1; N, 15.05. Calc, for C9H12N2O2 IH2O: 
C, 58.5; H, 6 .8 ; N, 15.15%); (HRMS: found M+, 180.0904. Calc, for C9H12N2O2: 
180.0899); [aj^ -10.0 (c 1.2 in 5 mol dm"3 HCl) [lit., 247 _ i 5 .g (c 0.5 in 6 mol dm-3 
HCl)]; t>max(Nujol)/cm-i 2900 (OH), 1735 (CO) and 1377 (C-O); ^ (2 0 0  MHz; 
2H2O) 2.96-3.16 (2 H, m, PCH2), 3.67 (1 H, t, J  6.2, aCH) and 7.16-7.42 (5 H, m, 
Ar-H); 6^(74.76 MHz; 2H2O) 33.49 (PCH2), 63.46 (aCH), 125.54 (Ar-CH para), 
127.03 (Ar-CH ortho), 127.36 (Ar-CH meta), 133.67 (Ar-C quaternary) and 172.76 
(acid CO); m/z (El) 180 (5%, M+), 91 (100, C7 H7 +), 89 (100, [M -  C7 H7 M , 77 
(23, Ph+), 71 {91, [C0 CH(CH2)NH + H]+} 65 (35, C5H5+) and 43 (46, [CH2CHNH 
+ H]+).
(25)“A-(Benzyloxycarbonylamino)phenylalanine 80
Ph
H O 2C ,
z
A solution of (25)-A^-aminophenylalanine 78 (1.50 g, 8.3 mmol) in aqueous sodium 
hydroxide solution (0.2 mol dm~3, 40 cm3) at 0 °C was treated with benzyl 
chloroformate (1.42 g, 8.4 mmol) and the mixture stirred vigorously whilst warming 
to room temperature over 1 h. Additional sodium hydroxide solution (1.0 mol dm-3, 
10 cm3) was then added to redissolve the white precipitate. The solution was washed 
with ether (2 X 30 cm3) and the aqueous phase acidified with aqueous HCl 
(0.5 mol dm-3) pH 3. The white solid thus formed was filtered off, washed with
cold  w ater and dried  under vacuum  to affo rd  (25)-
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A^-(benzyloxycarbonylamino)phenylalanine 80 (2.06 g, 79%), mp 163-165 °C;
(Found: C, 64.7; H, 5.75; N, 8.85. C17H 18N2O4 requires C, 64.95; H, 5.75; N, 8.9%); 
[a]p -3.9 (c 0.5 in MeOH); Dmax(Nujol)/crn-i 3365 (NH), 3287 (NH), 2900 (OH),
1749 (acid CO), 1710 (amide CO) and 1273 (C-O); ^(200 MHz; C^HsO^H) 2.96-
3.01 (2 H, m, pCHa), 3.85 (1 H, m, aCH), 5.10 (2 H, s, OCH2PI1) and 7.21-7.34
(10 H, m, Ar-H); 6c(74.76 MHz; C^HgO^H) 38.07 (PCH2), 65.92 (OCH2Ph), 68.12
(aCH), 127.99, 129.23, 129.40, 129.78, 130.67 (Ar-CH), 138.26, 138.71 (Ar-C
quaternary), 159.51 (urethane CO) and 176.13 (acid CO); m/z (El) 314 (13%, M+),
223 (42, [M -  CH2Ph]+), 179 (22, [M -  CO2CH2PW+), 91 (100, C7 H7 +), 77 (22,
Ph+) and 65 (34, C5H5+).
Methyl (25)-A"-(benzyloxycarbonylamino)phenylalaninate 81
PhMe02C..^
Thionyl chloride (0.62 cm^, 8.5 mmol) was added dropwise to methanol (15 cm^) at 
0 °C. Hydrazide 80 (1.80 g, 5.73 mmol) was added and the resulting solution heated 
under reflux for 40 min, cooled to room temperature, and the solvent and excess 
thionyl chloride removed under reduced pressure to yield a pale yellow oil. The crude 
oil was redissolved in ethyl acetate (80 cm^) and the solution washed with aqueous 
sodium hydrogen carbonate solution (5%, 2 x 40 cm^) and water (2 x 20 cm^). The 
organic phase was dried (MgSO^) and the solvent removed under reduced pressure to 
yield a pale yellow solid (1.63 g, 87%). A small portion of this was recrystallised 
from ethyl acetate-light petrol to afford the methyl ester 81 as colourless crystals, mp 
62-64 °C; (Found: C, 65.55; H, 6.0; N, 8.45. C18H20N2O4 requires C, 65.85; H, 6.15; 
N, 8.55%); (HRMS: found M+, 328.1414. C18H20N2O4 requires 328.1423); [a]^
+10.9 (c 0.2 in MeOH); t;max(Nujol)/cm-i 1735 (CO), 1261 and 1080 (C-O); 6^(200
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MHz; C2HC13) 2.95 (1 H, dd, J\ 14.0, h  8.0, ipCHz), 3.11(1 H, dd, h  14.0, J2 5.4, 
IpCHa), 3.70 (3 H, s, CO2CH3), 4.00(1 H, t, aCH), 4.20 (1 H, br. s, amine NH), 5.09 
(2 H, s, OCHiPh), 6.52 (1 H, br. s, urethane NH) and 7.22-7.31 (10 H, m, Ar-H); 
Ôc(50.31 MHz; C^HCla) 37.34 (pCH;), 52.48 (CO2CH3), 64.43 (aCH), 57.50 
(OCH2Ph), 127.45, 128.66, 128.71, 128.99, 129.06 and 129.61 (Ar-CH), 136.55 and 
136.83 (Ar-C qnatemary), 157.42 (urethane CO) and 173.57 (ester CO); m/z (El) 328 
(5%, M+), 237 (57, [M -  C HzPh]*), 193 (35, [M -  C02CH2Ph]+), 162 (26, 
PhCH2CC0 2 CH3+), 105 (17, [CHCH2Ph + H]+), 91 (100, C7 H7 +) and 65 (22, 
C5H5+).
Methyl (25)4V-(benzyloxycarbonylamino)-lV-acetylphenylalaninate 8 6
MeOaÇ
o  z
A solution of hydrazide 81 (100 mg, 0.3 mmol) in dichloromethane (15 cm^) was 
treated with acetyl chloride (70 mg, 0.9 mmol) and the mixture stirred for 4 days. The 
solution was washed with aqueous HCl (0.5 mol dm-3, 2 x 10 cm^), aqueous sodium 
hydrogen carbonate solution (5%, 2 x 10 cm^) and water (2 x 1 0  cm^). The organic 
phase was dried (MgSO^) and the solvent removed under reduced pressure to yield a 
light yellow solid, which was washed with methanol and dried under reduced pressure 
to yield compound 86  as a white solid (30 mg, 27%), mp 130-132 °C; (Found: C, 
65.05; H, 5.95; N, 7.55. C20H22N2O5 requires C, 64.85; H, 6.0; N, 7.55%); [aj^
-112.5 (c 0.2 in MeOH); ümax(CH2Cl2)/cm-i 3388 (NH), 3054 (CH), 1751 (ester 
CO), 1685 (amide CO) and 1272 (C-O); ^ (2 0 0  MHz; C^HClg) 2.08 (3 H, s, 
COCH3), 3.09-3.27 (2 H, m, PCH2), 3.62 (3 H, s, CO2CH3), 4.68 (1 H, s, NH), 5.19 
(2 H, s, OCH2Ph), 5.51 (1 H, m, aCH) and 7.14-7.65 (10 H, m, Ar-H); 6^(50.31 
MHz; C^HCls) 21.16 (COCH3), 35.17 (PCH2), 52.82 (CO2CH3), 59.33 (aCH), 68.43
134
(OCHaPh), 127.28, 128.78, 128.90, 129.09, 129.28 and 129.49 (Ar-CH), 135.84 and 
136.93 (Ar-C quaternary), 155.57 (urethane CO), 171.70 (amide CO) and 172.90 
(ester CO); m/z (El) 371 (1%, [M + H]+), 313 (38, [M -  C4H9]+), 237 (39, [M -  
COCH3 -  CH2Ph]+), 193 (22, [M -  COCH3 -  NHC0 2 CH2Ph + H]+), 91 (100, 
C7H7+) and 43 (32, COC H3+).
Methyl (2S)-iV-(benzyloxycarbonylamino)-A^-[(2S)-A^-(chloroacetyl)prolyl] 
pbenylalaninate 82
PhMe02Ç
hV
Cl
A solution of (25)-7/-(chloroacetyl)proline 65 (0.53 g, 2.8 mmol) and pyridine 
(0.31 cm^, 3.9 mmol) in dichloromethane (10 cm^) was treated dropwise with thionyl 
chloride (0.26 cm^, 3.6 mmol). After 10 min, a solution of hydrazide 81 (0.60 g,
1.8 mmol) and DMAP (0.49 g, 4.0 mmol) in dichloromethane (10 cm^) was added in 
one portion. After 3-4 days the dark brown solution was washed with aqueous HCl 
(0.5 mol dm~3, 2 x 20 cm^), aqueous sodium hydrogen carbonate solution (5%, 2 x 
20 cm^) and brine (30 cm^). The organic phase was dried (MgS0 4 ), and the solvent 
removed under reduced pressure to yield a brown oil. The crude oil was purified by 
column chromatography using light petrol-ethyl acetate (3:2) as the eluent to afford 
unchanged starting material 81 (0.10 g, 17%) and hydrazide 82 as a light oil 
(0.49 g, 53%); RfO.lO; (HRMS: found M+, 501.1675. C25H2835CIN3O6 requires 
501,1667); [a ]p -66.8 (c 1.1 in MeOH); ümax(thin film)/cm-^ 3241 (NH), 1744 (ester
CO), 1690 (urethane CO) and 1645 (amide CO); &(200 MHz; C2HCI3) 1.92-2.06 
[3 H, m, ^pCH2(Pro) and 7CH2(Pro)], 2.11-2.18 [1 H, m, ipCH2(Pro)], 3.00-3.21
[2 H, m, pCH2(Phe)], 3.55-3.65 [2 H, m, 0CH2(Pro)], 3.70 (3 H, s, CO2CH3), 3.93-
4.08 (2 H, dd, J\ 13.2, J2 4.0, CH2CI), 4.61 [t, 1 H, m, aCH(Pro)], 4.73 [c, 1 H, m,
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aCH(Pro)], 5.10-5.25 [3 H, m, c, aCH(Phe) and OCH^Ph], 5.50 [t, 1 H, m, 
aCH(Phe)], 7.25-7.39 (10 H, m, Ar-H) and 8.10 (1 H, br. s, NH); 5c(74.76 MHz; 
C^HClj) 22.40 [c, TCHzCPro)]. 25.38 [t, ■yCH2(Pro)], 29.11 [t, pCHjCPro)], 31.00 [c, 
pCHzCPro)], 34.79 [pCH2(Phe)], 42.09 (c, C HjCl), 42.16 (t, CH^Cl), 47.74 
[ÔCHjCPro)], 52.51 (c, CO2CH3), 53.02 (f, COjCHj), 60.42 [aCH(Pro) and 
aCH(Phe)], 68.21 (c, OCHjPh), 68.80 (r, OCHjPh), 127.10-129.63 (Ar-CH), 136.15 
and 137.09 (Ar-C quaternary), 155.94 (urethane CO), 165.62 (COCH^Cl), 169.93 
(amide CO) and 174.37 (ester CO); m/z (El) 504 and 502 (3 and 9%, chlorine 
isotopes, [M + H]+), 328 (31, [M -  CICH2CONC4H7CO + H]+), 237 (21, [M -  
CICH2CONC4H7CO -  C7H7 + H]+), 176 and 174 (29 and 57, chlorine isotopes, 
CICH2CONC4H7CO+), 148 and 146 (43 and 100, chlorine isotopes, 
CICH2CONC4H7+), 91 (71, C7H7+) and 70 (74, [C4H7N + H]+).
(9aS)-2-[(lS)-l-Methoxycarbonyl-2-phenylethyl]-2,3,4,5,7,8,9,9a-octahydro-lfl'- 
pyrrolo-[2,l-(i][l,2,5]triazepine-l, 5-dione 72
\ - P hH
.CO2M6
Peptide 82 (0.10 g, 0.2 mmol) was treated with 30% HBr in acetic acid (6 cm^). The 
solution was stirred for 2 h and then poured on to ether (100  cm^), resulting in 
formation of a flocculent white precipitate which decomposed to a brown oil if 
exposed to air. The solvents were carefully decanted and the suspension diluted with 
ether, shaken, and the solvent again decanted. The remaining solvents were removed 
under reduced pressure and the residue redissolved in aqueous sodium hydroxide 
solution (0.01 mol dm"^, 20 cm^) to give neutral pH. The solution was allowed to 
stand for 90 min, and extracted with ethyl acetate (3 x 20 cm^). The combined 
organic extracts were washed with water (50 cm^) and dried (MgSO^). The solvent 
was removed under reduced pressure to yield a clear oil (60 mg, 91%); a small
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portion was crystallised from ethyl acetate-light petrol to give the triazepinedione 72 
as pale yellow crystals, mp 114-116 °C; (HRMS: found M+, 331.1523. C^H^iNgO^ 
requires 331.1532); [ajg  -78.3 (c 0.8 in MeOH); ttmax(thin film)/cm-‘ 3353 (NH),
1740 (ester CO), 1672 (amide CO), 1170 (C-O) and 1093 (C-N).
NMR spectra of compound 72 show two conformations. These are defined as follows 
for each of the three spin systems: A and B (pyrrolidine ring); C and D (CH2 in 
triazepinedione ring) and E and F  (phenylalanine).
5h(300 MHz; C ^ C l;)  1.75-2.15 [3 H, ra, |pCH2(Pro) and )CH2(Pro)], 2.18 [A, 1 H, 
m, |PCH2(Pro)], 2.32 [B, 1 H, m, ipCH2(Pro)], 2.61 (C, 1 H, d, 7 11.3, 5COCH2N), 
2.99-3.50 [2 H, m, pCH2(Phe)], 3.09 (C, 1 H, d, 7 11.3, 5COCH2N), 3.50-3.82 [2 H, 
m, 5CH2(Pro)], 3.67 and 3.76 (3 H, s, CO2CH3), 3.78-3.91 (D, 2 H, m, COCH2N), 
5.12 [B, 1 H, dd, 7i 8.9, 7% 3.0, aCH(Pro)], 5.29 [A, 1 H, dd, 7i 8.9, 7z 3.0, 
aCH(Pro)], 5.45 [F, 1 H, dd, 7i 9.2, 7% 6.3, aCH(Phe)], 5.65 [E, 1 H, dd, 7; 12.3, 7%
4.8, aCH(Phe)] and 7.19-7.33 (5 H, m, Ar-H); ^c(300 MHz; C^HCl;) 22.36 [B, 
7CH2(Pro)], 24.66 [A, )CH2(Pro)], 27.29 (C, COCHjN), 27.42 (D, COCH2N), 29.00 
[A, pCH2(Pro)], 31.52 [B, pCH2(Pro)], 33.59 [£, pCH2(Phe)], 34.10 [F, pCH2(Phe)], 
47.80 [B, 8 CH2(Pro)], 48.12 [A, 8 CH2(Pro)], 52.41 and 52.77 (COjCHj), 57.57 [A, 
aCH(Pro)], 57.96 [F, aCH(Phe)], 58.13 [B, aCH(Pro)], 58.69 [E, aCH(Phe)], 127.27’ 
and 127.81 (Ar-CH para), 128.39 and 128.82 (Ar-CH ortho), 129.05 and 129.36 
(Ar-CH meta), 135.90 and 136.42 (Ar-C quaternaiy), 165.14 and 165.25 (COCHIN),
171.42 and 172.05 (amide CO) and 174.71 (ester CO); m/z (El) 331 (53%, M+), 212 
(63, [M -  COCHaPh]+), 168 (38, [M -  PhCH2CHC02CH3]+), 125 (39, 
NC4H7CONCH2+), 112 (51, NC4H8CON+), 91 (48, C7H7+) and 70 (100, C4H8N+).
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(9a5)-2-[(15)-l-Methoxycarbonyl-2-phenylethyl]-3-[(2S)-AT- 
benzyIoxycarbonyIalanyl]-2,3,4,5,7,8,9,9a-octahydro-lflT-pyrrolo- 
[2,l-d][l,2,5]triazepine-l,5-dione 90
4 ..COaMe 
^ P h
Me NH
A solution of (25')-iV-(benzyloxycarbonyl)alanine 89 (76 mg, 0.34 mmol) and 
A^-methylmorpholine (40 mm^, 0.36 mmol) in diy THF (3 cm^) was cooled to -15 °C, 
and wobutyl chloroformate (50 mm^, 0.32 mmol) was added with stirring. After 
2 min, a solution of triazepinedione 72 (100 mg, 0.30 mmol) and 
A-methylmorpholine (40 mm^, 0.36 mmol) in DMF (1 cm^) was added in one portion 
to the stirred suspension. The reaction mixture was allowed to warm to room 
temperature and stirred for a further 5 h. The hydrochloride salts were filtered off and 
the solvent removed under reduced pressure. The residual oil was redissolved in ethyl 
acetate (10 cm^) and the solution was washed with aqueous HCl (0.5 mol dm"3, 2 x 5  
cm3), aqueous sodium hydrogen carbonate solution (5%, 2 x 5 cm^) and brine (5 
cm^). The solution was dried (MgS0 4 ), and the solvent removed under reduced 
pressure to yield a pale yellow oil which was purified by column chromatography 
using ethyl acetate as the eluent to afford the product 90 as a clear oil (6 mg, 4%); Rf 
0.62; (HRMS: found M+, 536.2283. C28H32N4O7 requires 536.2271); t)max(lhin 
film)/cm“  ^ 1742 (ester CO), 1725 (urethane CO), 1680 (secondary amide CO), 1650 
(tertiary amide CO) and 1180 (C-O); ^h(300 MHz; C^HCla) (2 conformations) 1.42 
[3 H, d, 77.1, pCH3(Ala)], 1.79-2.27 [4H, m, pCH2(Pro) andyCH2 (Pro)], 3.18-3.49 
[2 H, m, pCH2(Phe)], 3.62-3.87 [2 H, m, 0CH2(Pro)], 3.71, 3.76 (3 H, s, CO2 CH3 ), 
4.00-4.08 (2 H, m, COCH2N), 4.36 [1 H, m, aCH(Ala)], 5.11 (2 H, s, OCH2Ph),
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5.21-5.42 [2 H, m, (xCH(Pro) and aCH(Phe)], 6.64 and 6.80 (1 H, m, NH) and 7.07-
7.36 (10 H, m, Ar-H); ^(74.76 MHz; C^HCls) 18.65 [pCH3(Ala)], 22.27 and 24.99 
[7CH2(Pro)], 29.03 and 31.61 [PCH2(Pro)], 33.39 and 34.33 [pCH2(Phe)]. 41.79 and
42.01 (COCHjN), 47.67 and 47.97 [SCHjlPro)], 49.70 [aCH(Ala)], 52.68 and 52.97 
(CO2CH3), 58.43 and 58.69 [aCH(Pro)], 64.10 and 64.33 [aCH(Phe)], 67.05 
(OCHzPh), 127.04, 127.48, 128.24, 128.36, 128.70, 128.75, 128.89, 129.16 and 
129.39 (Ar-CH), 136.65 and 137.76 (Ai^C quaternary), 141.71 and 143.09 (Ar-C 
quaternary), 155.83 (urethane CO), 164.95 (amide CO), 169.79 (amide CO) and 
172.33 (ester CO); m/z (Cl) 536 (8 %, M+), 190 [27, 0 CNCH(C0 2 )CH2Ph+], 174 [30, 
OCNCH(CO)CH2Ph+], 146 (6 6 , OCNCHCH2Ph+), 140 (29, CH3CONC4H7CO+), 
112 (45, NC4H8CON+), 91 (100, C7H7+) and 70 (96, C4H8N+).
(25)-Al-(4-ChIorobutyryl)proiine93
rvCO2H
A suspension of (25)-proline 6  (4.0 g, 34.7 mmol) in ethyl acetate (100 cm^) was 
treated with 4-chlorobutyryl chloride (6.0 cm^, 53.5 mmol), and the mixture heated at 
reflux for 75 min. After cooling to room temperature, the solvent was removed under 
reduced pressure. The residual oil was washed with several portions of ethyl 
acetate-light petrol (1:1) to remove unreacted acid chloride, affording (25')-A-(4-
chlorobutyryl)proline 93 as a pale yellow oil (7.2 g, 94%); (HRMS: found M+, 
220.0740. C9H1535CINO3 requires 220.0736); [aj, -19.9 (c 1.0 in MeOH); t>max(thin
film)/cm-i 2966 (OH), 1735 (acid CO) and 1605 (amide CO); 6^(300 MHz; C^HCb)
1.93-2.27 (6 H, m, PCH2, 7CH2 and CH2CH2CI), 2.47-2.55 (2  H, m, PCH2 and 
CH2CI), 3.47-3.69 (4 H, m, 6CH2 and CH2CO), 4.50 (1 H, m, aCH) and 10.14 (1 H,
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br. s, CO2H); ^c(74.76 MHz; C^HClg) 24.96 (YCH2), 27.82 (CH2CH2CI), 28.92 
(PCH2), 31.33 (CH2CI), 44.83 (CH2CO), 48.03 (ÔCH2), 59.78 (aCH), 173.34 (amide 
CO), 174.76 (acid CO); m/z (El) 222 and 220 (2 and 5%, chlorine isotopes, M+), 176 
and 174 (13 and 25, chlorine isotopes, [M -  CO2H -  H]+), 157 (14, [M -  
CH2CH2C1]+), 140 (26, [M -  CO2H -  Cl]+), 107 and 105 [4 and 14, chlorine isotopes, 
C0 (CH2)3C1+], 70 (100, C4H8N+) and 41 (37, C3H5+).
Methyl (2S,2’5)-A^-[A^-(ter^-butoxycarbonyl)prolyl]alaninate 96
N ^CH g
B O C ^  COglVle
A solution of (2S)-iV-(rerf-butoxycarbonyl)proline 94 (2.5 g, 11.6 mmol) and 
AT-methylmorpholine (1.3 cm^, 11.6 mmol) in dry THE (20 cm^) was cooled to 
“ 15 °C, and w<?butyl chloroformate (1.55 cm^, 11.4 mmol) was added with stirring. 
After 2 min, a solution of (2S)-alanine methyl ester hydrochloride 95 (1.6 g,
11.6 mmol) and//-methylmorpholine (1.3 cm^, 11.6 mmol) in THF (10 cm^) and 
DMF (26 cm^) was added in one portion to the stirred suspension. The reaction 
mixture was allowed to warm to room temperature over 2 h and left standing 
overnight. The hydrochloride salts were filtered off and the solvent removed under 
reduced pressure. The residual oil was redissolved in ethyl acetate (50 cm^) and the 
solution washed with aqueous HCl (0.5 mol dm~3, 2 x 30 cm^), aqueous sodium 
hydrogen carbonate solution (5%, 2 x 30 cm^) and brine (30 cm^). The solution was 
dried (MgSO^), and the solvent removed under reduced pressure to afford the product 
as a white solid which was recrystallised from ethyl acetate-light petrol to yield the 
dipeptide 96 as colourless crystals (2.4 g, 65%), mp 78-79 °C (lit., 79-81 °C); 
[a]j3 -94.8 (c 1.1 in MeOH) [lit., 8^4 . 92.3 (c 1.0 in MeOH)]; Vmax(Nujol)/cm-i 3267
(NH), 1752 (ester CO), 1695 (urethane CO), 1658 (amide CO) and 1163 (C-O); 
6h(200 MHz; C^HCb) 1.33 [3 H, d, J 7.2, pCH3(Ala)], 1.41 [9 H, s, C(CH3)3],
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1.73-1.98 [3 H, m, ipCH2(Pro) and ^CHzCPro)], 2.01-2.27 [I H. m, |pCH2(Pro)], 
3.31-3.50 (2 H, m, 8CH2), 3.68 (3 H, s, CO2CH3), 4.23 [1 H, m, aCH(Ala)], 4.50 
[1 H, m, aCH(Pro)], 6.61 and 7.34 (c and t, 1 H, br. s, NH); 6c(74.76 MHz; C^HCls) 
17.90 [pCH3(Ala)], 23.64 [c, •yCH2(Pro)]. 24.34 [t, ■yCH2(Pro)], 28.18 [€(013)3  and t, 
pCH2(Pro)], 30.88 [c, pCH2(Pro)], 46.93 [5 CH2(Pro)], 47.88 [aCH(Ala)], 52.15 
(C0 2 O 13), 59.71 and 60.59 [c and t, aCH(Pro)], 80.12 [ € ( ^ 3)3], 154.49 and 155.48 
(c and t, urethane CO), 172.43 (amide CO) and 173.22 (ester CO); m/z (El) 300 (2%, 
M+), 227 (7, [M -  0C4H9]+), 199 (7, [M -  C02C4Hg]+), 170 (31, C8H14N2O2+), 114 
(71, C5H 10N2O+), 70 (100, C4H8N+) and 57 (72, C4H9+).
Methyl (25)-A^-{A^-[A7^-(4-chIorobutyryl)-(25)-prolyl]-(2S)-proIyl}alanmate 92
MeOpC H
Dipeptide 96 (2.09 g, 7.0 mmol) was dissolved in ethyl acetate (75 cm^) at 0 °C and 
dry HCl gas was bubbled through the cold solution for 70 min. The solution was 
allowed to stand at 0 °C for 90 min, after which time the solvent was removed under 
reduced pressure to yield the amine hydrochloride salt 97 as a clear oil (1,64 g, 99%). 
A solution of (25)-7/-(4-chlorobutyryl)proline 93 (1.55 g, 7.1 mmol) and pyridine 
(0.89 cm^, 11.0 mmol) in dichloromethane (40 cm^) was treated dropwise with 
thionyl chloride (0.66 cm^, 9.0 mmol). After 5 min, a solution of the amine 
hydrochloride 97 (1.20 g, 5.1 mmol) and DMAP (1.24 g, 10.2 mmol) in 
dichloromethane (35 cm^) was added in one portion. The solution was allowed to stir 
for 2 days, after which time it was washed with aqueous HCl (0.5 mol dm~3, 2 x 
50 cm^), aqueous sodium hydrogen carbonate solution (5%, 2 x 50 cm^) and brine 
(50 cm^). The solution was dried (MgS0 4 ), and the solvent removed under reduced
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pressure to afford a brown oil, which was purified by column chromatography using 
ethyl acetate-methanol (9:1) as the eluent to yield the peptide 92 as an oil (0.79 g,
39%); Rf 0.20; (HRMS: found M+, 401.1712. CigHag^^ClNsOs requires 401.1717); 
[a][j-84.5 (c 1.6 in MeOH); l)max(thin film)/cm-> 3329 (NH), 2955 (CH), 1739 (ester
CO), 1652 (amide CO) and 1165 (C-O); 0h(300 MHz; C^HClj) (3 conformations)
1.32, 1.38 and 1.45 [3 H, d, 7 7.2, pCHg], 1.89-2.19 [10 H, m, 2 x pCH2(Pro), 2 x
yCH2(Pro) and CH2CH2CI], 2.45-2.49 (2 H, m, CH2CI), 3.50-3.71 [6 H, m, 2 x
5CH2(Pro) and CH2CO], 3.63 (3 H, s, CO2CH3), 3.97 and 4.20-4.58 [3 H, m, 2 x
aCH(Pro) and aCH(Ala)], 7.10, 7.55, and 7.68 (1 H, br. d, NH); 6c(?4.76 MHz;
C^HCls) 16.35, 17.23 and 17.90 [pCH3(Ala)], 22.41, 22.78, 24.22, 24.94, 25.27 and
25.43 [2 X yCH2(Pro)], 27.58 and 28.01 (CH2CH2CI), 28.53 and 28.95 [2 x
pCH2(Pro)], 31.26 and 31.54 (CH2CI), 44.51 and 44.73 (CH2CO), 47.15, 47.34 and
47.62 [2 X SCH2(Pro)], 48.25 and 48.89 [aCH(Ala)] 52.17 and 52.40 (CO2CH3),
57.91, 58.17 and 58.85 [aCH(Pro)], 59.82, 60.45 and 61.11 [2 x aCH(Pro)], 170.76,
171.50, 171.73 and 171.99 (amide CO), 173.18 and 173.52 (ester CO); m/z (El) 403
and 401 (1 and 4%, chlorine isotopes, M+), 204 and 202 (9 and 29, chlorine isotopes,
C9H13NO2CI+), 174 (51, CgHi3NOCl+) and 70 (100, C4H8N+).
1
Methyl (2S,4S)-4-hydroxyprolinate hydrochloride 101
rv "COgMe 
H .HCl
Thionyl chloride (0,35 cm^, 4,1 mmol) was added dropwise to methanol (10 cm^) at 
0 °C. (25,45)-4-Hydroxyproline 100 (0,40 g, 2.3 mmol) was added and the resulting 
solution heated under reflux for 90 min. The solvents were removed under reduced 
pressure to afford the hydrochloride 101 as a white solid in quantitative yield. A small 
portion was recrystallised from ethyl acetate-hexane to yield colourless needles, mp 
79-80 °C; (Found: C, 36.4; H, 6,75; N, 7,5, CeHnNOs HChHzO requires C, 36,3; H,
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7.1; N , 7.05%); [a]j^ -49.2 (c 0.5 in MeOH); Umax(Nujol)/crn-i 3327 (OH), 2921 
(CH), 1732 (CO), 1252 (OH def.) and 1182 (C-O); 4(300 MHz; ^HiO) 2.27-2.39 
(2 H, m, PCH2), 3.34 (2 H, br. s, ÔCH2), 3.72 (3 H, s, CO2CH3) and 4.51-4.60 (2 H, 
m, aCH and yCH); 4(74.76 MHz; 2H2O) 36.76 (PCH2), 53.55 (ÔCH2), 53.93 
(CO2CH3), 58.45 (aCH), 69.00 (^CH) and 170.93 (ester CO); m/z (El) 145 (11%, [M 
-  HC1]+), 101 (13, [M -  HCl -  CH2NH -  CHg]+), 86 (100, [M -  HCl -  C0 2 CH3]+), 
68 (44, C4H6N+) and 58 (16, NHCH2CHO+).
(25)-2-Chloropropionic acid 104
A stirred suspension of (25)-alanine 103 (15.0 g, 0.17 mol) in saturated potassium 
chloride solution (36 cm^) was treated dropwise with concentrated HCl (60 cm^). The 
mixture was cooled to 0 °C, and sodium nitrite (23.3 g, 0.34 mol) was added in 
portions over 75 min. After completion of addition, the brown solution was stirred at 
0-5 °C for a further 1 h, then allowed to reach room temperature overnight. The 
solution was extracted with ether (3 x 100 cm^), the organic phase dried (MgS0 4 ),
and the solvent removed under reduced pressure to yield acid 104 as a pale yellow oil 
(13.4 g, 73%), bp 80 °C/-15 mmHg (lit., 285 77  «c/10 mmHg); [a ^  -17.7 (c 0.8 in
MeOH) (lit., 285 -1 8 .2 ) ;  t>max(thin film)/cm-i 3110 (OH), 1735 (CO), 1457 (C H 3
def.), 1210 (C-O) and 668  (C-Cl); 4 (300 MHz; C^HC^) 1.73 (3 H, d, J  7.2, PCH3),
4.45 (1 H, q, J  6.9, aCH) and 10.70 (1 H, br. s, CO2 H); 4(74.76 MHz; C2HCI3)
21.71 (PCH3), 52.63 (aCH) and 176.75 (acid CO); m/z (Cl) 111 and 109 (3 and 11%,
chlorine isotopes, [M + H]+) and 57 (100, CHCO2+).
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(2S,2^SyN -(2 * -Chloropropionyl)proline 106
r v COjH
Me' Cl
A stirred solution of (25)-2-chloropropionic acid 104 (6.0 g, 55.3 mmol) and 
A^-methylmorpholine (6.2 cm^, 55.3 mmol) in dry THF (100 cm^) at -15  °C was 
treated dropwise with w<?butyl chloroformate (7.40 cm^, 54.5 mmol), followed after 
2 min by a solution of (25)-proline methyl ester hydrochloride 102 (9.2 g, 55.5 mmol) 
and A^-methylmorpholine (6.2 cm^, 55.3 mmol) in DMF (30 cm^). The mixture was 
allowed to reach room temperature and stirred for 18 h. The hydrochloride salts 
formed were filtered off and the solvents removed under reduced pressure to yield an 
orange oil, which was redissolved in dichloromethane (140 cm^). The solution was 
washed with aqueous HCl (0.5 mol dm~8, 2 x 100 cm^), aqueous sodium hydrogen 
carbonate solution (5%, 2 X 100 cm^) and brine (50 cm^). The solvent was removed 
under reduced pressure to yield a pale yellow oil which was purified by gradient 
column chromatography using light petrol-ethyl acetate as the eluent to give the 
dipeptide methyl ester 104 as a pale yellow oil (4.9 g).
The above oil was dissolved in methanol (45 cm^), and aqueous sodium hydroxide 
solution (1.0 mol dm~8, 55  cm^) was added. The mixture was stirred at room 
temperature for 2 h, after which time aqueous HCl (1.0 mol dm“ ,^ 55 cm^) was 
added. Methanol was removed under reduced pressure, the solution further acidified 
to pH 1, and the solution extracted with ethyl acetate (3 x 80 cm^). The combined 
organic extracts were dried (MgSO^), and the solvent removed under reduced
pressure to yield the acid 106 as a white solid (4.05 g, 36%). A small portion was 
recrystallised to give colourless crystals, mp 161-162 °C (lit., 286 164-165 °C); [a]j^
-59.2 (c 1.0 in MeOH) [lit., 286 _62.1 (c 1.0 in MeOH)]; Vmax(Nujol)/cm~i 3000 
(OH), 1739 (acid CO), 1621 (amide CO) and 652 (C-Cl); 4(200 MHz; C^HCb) 1.64 
(3 H, d, J  6 .6 , CUCH3), 1.97-2.29 (4 H, m, pCHa and 7CH2), 3.60-3.89 (2 H, ÔCH2),
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4.46-4.56 (2 H, m, aCH and Œ C H 3) and 10.05 (1 H, s, CO2H); 4(50.31 MHz; 
C2HCI3) 20.89 (CHCH3), 25.25 (7CH2), 29.25 (PCH2), 47.69 (ÔCH2), 51.53 
(CHCH3), 60.03 (aCH), 169.13 (amide CO) and 175.78 (acid CO); m/z (El) 208 and 
206 (4 and 15%, chlorine isotopes, M+), 170 (39, [M -  HC1]+), 162 and 160 (22 and 
60, chlorine isotopes, [M -  CO2H -  H]+), 126 (49, [M -  CO2 H -  Cl]+), 114 (51, 
C5HgN0 2 t), 70 (100, C4H8N+) and 57 (29, [CH3CHCO + H]+).
Methyl {2S)-N -{AT-[(2S)-2-chloropropionyl]-(2S)-prolyl}prolinate 107
This was prepared in an identical manner to hydrazide 69, using (25',2’5)-A- 
(2’-chloropropionyl)proline 106 (0.70 g, 3.4 mmol) and methyl (25)-prolinate 
hydrochloride 102 (0.51 g, 3.08 mmol) to yield a pale brown oil which was purified 
by gradient column chromatography using ethyl acetate-light petrol as the eluent to 
afford methyl ester 107 as colourless crystals (0.32 g, 33%), mp 126-128 °C; Rf 0.25
(ethyl acetate); (Found: C, 53.25; H, 6 .8 ; N, 8 .6 . C14H21CIN2O4 requires C, 53.1; H, 
6.7; N, 8.85%); [a]p -131.0 (c 0.9 in MeOH); t>max(Nujol)/cm“  ^ 1735 (ester CO) and
1652 (amide CO); 4 (3 0 0  MHz; C^HC^) 1.54 (3 H, d, J  6 .6 , CHCJY3), 1.90-1.98 
[6 H, m, 2 X |pCH2(Pro) and 2 x )CH2(Pro)], 2.10-2.15 [2 H, m, 2 x îpCH2(Pro)], 
3.56-3.78 [4 H, m, 2 x SCHzffro)], 3.62 (3 H, s, CO2CH3), 4.44-4.48 [2 H, m, 
txCH(Pro) and CHCHs] and 4.53 [1 H, dd, J\ 7.8,7 2  3.9, aCH(Pro)]; %(74.76 MHz; 
C^HCls) 20.71 (CHCH3), 24.93 and 25.13 [2 x yCH2(Pro)], 28.49 and 28.99 [2 x 
pCH2(Pro)], 46.89 and 47.44 [2 x SCHzfPro)], 51.49 (CHCH3), 52.31 (CO2CH3),
58.52 and 58.91 [2 x aCH(Pro)], 167.90 (COCHCH3), 170.70 (amide CO) and
173.06 (ester CO); m/z (El) 318 and 316 (14 and 36%, chlorine isotopes, M+), 280 
(14, [M -  HC1]+), 225 {11, [M-ClCH(CH3)CO]+}, 190 and 188 [7 and 21, chlorine
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isotopes, C1CH(CH3)C0 NC4H7C0 '^ ], 162 and 160 [52 and 96, chlorine isotopes, 
C1CH(CH3)C0 NC4H7+], 128 (29, NC4H7CO2CH3+) and 70 (100, C4H8N+).
(25)-A^-{A^-[(25)-2-Chloropropionyl]-(2S)-prolyl}proline 108
A solution of methyl ester 107 (0.30 g, 3.0 mmol) in methanol (2 cm^) was treated 
with aqueous sodium hydroxide solution (1.0 mol dm~3, 2 cm^) and the mixture 
stirred for 90 min. The solution was treated with aqueous HCl (0.5 mol dm~3, 2 cm^) 
and the methanol removed under reduced pressure. The solution was further acidified 
to pH 1-2 and extracted with ethyl acetate (5 x 20 cm^). The combined organic 
extracts were dried (MgS0 4 ), and the solvent removed under reduced pressure to 
yield acid 108 as a white solid (0.28 g, 98%), mp 84-86 °C; (Found: C, 50.9; H, 6.55; 
N, 8.65. C13H19CIN2O4 4 H2O requires C, 50.8; H, 6.4; N. 9.1%); [a]g-104.5 (c 0.9 
in MeOH); Unia)i(Nujol)/cm"* 2922 (CH), 1702 (acid CO) and 1642 (amide CO); 
5h(300 MHz; C^HCb) 1.57 (3 H, d, J  6 .6 , CHCH3), 1.97-2.08 [6 H, m, 2 x 
îpCH2(Pro), 2 x-yCH2(Pro)], 2.11-2.22 [2 H, m, 2 x jpCH2(Pro)], 3.52-3.59 and 
3.63-3.84 [4 H, m, 2 x 8 CH2(Pro)], 4.46-4.53 [2 H, m, aCH(Pro) and CHCH3], 
4.59-4.63 [1 H, m, aCH(Pro)] and 9.34 (1 H, br. s, CO2H); SdlA.16  MHz; C^HClg) 
20.60 (CHCH3), 25.07 [2 x yCH2(Pro)], 28.57 and 28.76 [2 x pCHzffro)], 47.31 and 
47.58 [2 X 8CH2(Pro)], 51.52 (CHCH3), 58.68 and 59.31 [2 x aCH(Pro)], 168.47 
(COCHCH3), 171.77 (amide CO) and 174.23 (acid CO); m/i (El) 304 and 302 (4 and 
14%, chlorine isotopes, M+), 266 (7, [M -  HC1]+), 260 and 258 (4 and 11, chlorine 
isotopes, [M -  C0 2 ]+), 162 and 160 [46 and 8 6 , chlorine isotopes, 
C1CH(CH3)C0 NC4H7C0 +], 128 (14, NC4H7CO2CH3+) and 70 ( 100 , C4 HgN+).
146
Methyl (2S,45)-iV-(A^-{A^-[(2S)-2-chloropropionyl]-(2S)“prolyl}“(2S)-prolyi)-4-
hydroxyproUnate 99
«  o
HO
This was prepared in an identical manner to hydrazide 69, using acid 108 (0.23 g, 
0.76 mmol) and methyl (25,46')-4-hydroxyprolinate hydrochloride 101 (0.12 g, 0.66 
mmol) to yield the peptide 99 as a brown oil (0.12 g, 42%) which defied further 
purification; (HRMS: found M+, 429.1662. Ci9H28^^ClN30 6  requires 429.1667); 
Vmax(thin film)/cm-l 3441 (OH), 2981 (CH), 1746 (ester CO), 1649 (amide CO), 1435 
(CH def.) and 1066 (C-O); ^ (300 MHz; C^HCla) 1.61 (3 H, d, /  6.3, CHC/^a),
1.91-2.38 [10 H, m, 2 X |3CH2(Pro), pCH2(Hyp) and 2 x yCH2(Pro)], 3.56-3.86 [6 H. 
m , 2 X 0 CH2(Pro) and 0CH2(Hyp)], 3.68 (3 H, s, CO2CH3), 4.47-4.69 [4 H, m, 
CHCHs,  2 X aCH(Pro) and aCH(Hyp)] and 5.10-5.21 [1 H, m, yCH(Hyp)]; ^(50.31 
MHz; C%Cl3) 20.78 (CHCH3 ), 25.08 and 25.17 [2 x 7CH2(Pro)], 28.36 and 28.52 [j2 
X pCH 2(Pro)], 37.04 [pCH2(Hyp)j, 47.37 and 47.61 [2 x 6CH 2(Pro)], 51.56 
(CHCH3), 52.94 (CO2CH3), 55.85 [0CH2(Hyp)], 57.80, 58.21 and 58.77 [2  x 
aCH(Pro) and aCH(Hyp)], 71.41 ['yCH(Hyp)], 168.08 (COCHCH3 ), 170.56 and 
171.56 (2 X amide CO) and 174.75 (ester CO); m/z (El) 431 and 429 (1 and 3%, 
chlorine isotopes, M+), 393 (6 , [M -  HC1]+), 287 and 285 {4 and 7, chlorine isotopes, 
[M -  NCH2CH(0 H)CH2CHC0 2 CH3 + H]+}, 259 and 257 {4 and 13, chlorine 
isotopes, [M -  C0 NCH2CH(0 H)CH2CHC0 2 CH3 + H]+}, 190 and 188 (17 and 53, 
chlorine isotopes, CgHnN0 2 Cl+), 162 and 160 (34 and 87, chlorine isotopes, 
C7H11NOCI+), 130 {69, [NCH2CH(0 H)CH2CHC0 2 H + H]+}, 86  (84, C4H8NO+) 
and 70(100, C4H8N+).
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Methyl (2iS,4i?)-4-hydroxyprolinate hydrochloride 114
HO
r vN C02Me 
H .HCl
This was prepared in an identical manner to methyl (25',45)-4-hydroxyprolinate
hydrochloride 101, using (25',4i?)-4-hydroxyproline 113 (10.0 g, 76,3 mmol) to give
the hydrochloride 114 as a white solid (13.5 g, 98%). A small portion was 
recrystallised to afford white needles, mp 162-164 °C (lit., 8^7 162-164 °C); [a]^
-25.3 (c 1.0 in MeOH) [lit., -24.3 (cl.05 in MeOH)]; u„,ax(Nujol)/em-i 3325 
(OH), 1742 (CO), 1246 (OH def.) and 1180 (C-O); ^ (2 0 0  MHz;2H2 0 ) 2.19 (1 H, 
ddd, Ji 14.8, Ji 8 .8 , Jj 4.2,&pCHz), 2.40 (1 H, dd, Ji 14.8, 7% 8 .8 , IPCH2), 3.25 (1 H, 
d, J  12.6,18CH2), 3.35 (1 H, dd, Ji 12.6, J2 3 .6 , | 8 CH2), 3.68 (3 H, s, CO2CH3) and
4.48-4.58 (2H, m, aCH and 7CH); 8^(50.31 MHz; 2H2O) 37.07 (PCH2), 53.87 
(ÔCH2), 54.23 (CO2CH3), 58.65 (aCH), 69.85 ("jCH) and 170.62 (ester CO); m/z (El) 
146 (11%, [M -  HC11+), 86  (100, OC4 H8N+), 68  (44, C4H6N+) and 58 (21, 
NHCH2COH+).
Methyl (25,4i?)-A-(iV-{iV-[(25)-2-chloropropionyI]-(25)-proIyl}-(25)-prolyl)-4- 
hydroxyprolinate 115
0 - O ' V
HO
This was prepared in an identical manner to hydrazide 69, using acid 108 (1.27 g, 4.2 
mmol) and methyl (2S',4/?)-4-hydroxyprolinate hydrochloride 114 (0.79 g, 4.4 mmol) 
to afford the product as a brown oil (1.08 g, 60%) which defied further purification;
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(HRMS: found M+, 429.1657. Ci9H28^^ClN306 requires 429.1667); 6h(300 MHz; 
C^HCis) 1.56 (3 H, d, J  6.6, C H Œ 3), 1.90-2.42 [10 H. m, 2 x P CHzCPro), 
pCH2(Hyp) and 2 x 'YCH2(Pro)], 3.54-3.82 [6 H, m, 2 x 0CH2(Pro) and 0CH2(Hyp>] 
3.63 (3 H, s, CO2CH3) and 4.40-4.65 [5 H, m, C//CH3, 2 X aCH(Pro), aCH(Hyp) 
and yCH(Hyp)]; ^(74.76 MHz; C^HCb) 20.52 (CHCH3), 24.75 and 24.79 [2 X 
7CH2(Pro>], 28.01 and 28.32 [2 x pCH2(Pro)], 37.27 [pCH2(Hyp)], 47.13 and 47.37 
[2 X 6CH2(Pro)], 51.34 (CHCH3), 52.22 (CO2CH3), 54.57 [0CH2(Hyp)], 57.63, 58.01 
and 58.55 [2 x aCH(Pro) and aCH(Hyp)], 69.91 ['yCH(Hyp)], 167.85 (COCHCH3),
170.52 and 170.89 (2 X amide CO) and 172.91 (ester CO); m/z (El) 431 and 429 (2 
and 7%, chlorine isotopes, M+), 287 and 285 {2 and 9, chlorine isotopes, [M -  
NCH2CH(0 H)CH2CHC0 2 CH3 + H]+}, 259 and 257 {3 and 11, chlorine isotopes, 
[M -C 0 NCH2CH(0 H)CH2CHC0 2 CH3 + H]+}, 190 and 188 (17 and 61, chlorine 
isotopes, CgHiiN0 2 Cl+), 162 and 160 (24 and 79, chlorine isotopes, C7H11NOCI+) 
and 70 (100, C4H8N+).
Methyl {2S,4R)-N-[A^-(terf-butoxycarbonyl)-(2S)-prolyl]-4-hydroxyprolinate 119
o  OMe
A solution of (25)-A-(^err-butoxycarbonyl)proline 94 (4.0 g, 18.6 mmol) and N,N-di- 
ffopropylethylamine (9 .0  cm^, 52.0 mmol) in dry dichloromethane (115 cm^) was 
treated with BOP-Cl (4.92 g, 19.3 mmol) and the resulting suspension stirred under 
nitrogen at 0 °C for 20 min. A suspension of methyl (25,4/?)-4-hydroxyprolinate 
hydrochloride 114 (2.93 g, 16.1 mmol) in dry dichloromethane (35 cm^) was then 
added. The mixture was allowed to warm to room temperature and stirred for a 
further 6 days. The solution was washed with aqueous HCl (0.5 mol dm~3, 2 x 
100 cm^), aqueous sodium hydrogen carbonate solution (5%, 2 x 100 cm^) and brine
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(100 cm^), then dried (MgSO^). The solvent was removed under reduced pressure, 
and the residual oil purified by column chromatography using ethyl acetate as the 
eluent to afford the dipeptide 119 as colourless crystals (3.41 g, 62%), mp 92-94 °C; 
Rf 0,24; (Found: C, 55.95; H, 7.8; N, 8.15. CigHzeNzOg requires C, 56.15; H, 7.65; N, 
8.2%); [a]j3 - 112.6 (c 0.8 in MeOH); UmaxCCHzCWcm-i 3458 (OH), 2981 (CH) 
1748 (ester CO), 1690 (urethane CO), 1662 (amide CO), 1407 (alcohol C-O) and 
1165 (ester C-O); ^ (200  MHz; C^C lg) (2 conformations, ct and tt) 1.17 [ct, 9 H, 
C(CH3)3], 1.21 [tt, 9 H, C(CH3)3], 1.61-2.06 [6 H, m, pCH2(Pro), pCHzCHyp) and 
7CH2(Pro)], 3.14-3.89 [4 H, m, 8CH2(Pro) and 6CH2(Hyp)], 3.47 (3 H, s, CO2 CH3) 
and 4.16-4.42 [3 H, m, aCH(Pro), aCH(Hyp) and yCH(Hyp)]; %(50.31 MHz; 
C2HCI3) 23.47 [cr,7CH2(Pro)], 23.98 [tt, yCH2(Pro)], 28.26 [ct, 0 (0 1 3 )3], 28.38 [tt, 
0 (0 1 3 )3)], 29.00 [tt, pCH2(Pro)], 29.73 [ct, pCH2(Pro)], 36.95 [tt, pCH2(Hyp)],
37.15 [ct, pCH 2(Hyp)], 46.51 [ct, 6CH2(Pro)], 46.86 [tt, 5CH2(Pro)], 52.08 
(CO2O I 3), 54.45 [6CH2(Hyp)], 57.70 [aCH(Pro)], 57.93 [aCH(Hyp)], 69.68 [ct, 
yCH(Hyp)], 69.99 [tt, yCH(Hyp)], 79.71 [C(CH3)3], 153.96 (ct, urethane CO), 154.47 
(tt, urethane CO), 171.36 (tt, amide CO), 171.78 (ct, amide CO), 172.65 (ct, ester CO) 
and 172.75 (tt, ester CO); m/z (Cl) 343 (42%, [M + H]+), 287 (48, [M -  C4H8 + H]+), 
243 (100, [M -  CO2 -  C4H8 + H]+) and 57 (84, [C4H8 + H]+).
Methyl (25,4/î)r/V-[(25)-prolyI]-4-(acetyIthio)prolinate trifluoroacetate 118
SAc
Pro^  
H
^  ° 0 "^  'OMe
.CF3CO2H
Di-wopropyl azodicarboxylate (0.46 g, 2.3 mmol) was added to a solution of 
triphenylphosphine (0.61 g, 2.3 mmol) in dry THF (15 cm^) at 0 °C, and the resulting 
suspension stirred under nitrogen at 0 °C for 30 min. A solution of alcohol 119
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(0.69 g, 2.0 mmol) and thiolacetic acid (0.17 cm^, 2.5 mmol) in dry THF (10 cm^) 
was then added dropwise to this solution. The mixture was stirred at 0 °C for 2 h, and 
then at room temperature for 18 h. The solvent was removed under reduced pressure 
to yield a pale orange oil which was paitially purified by column chromatography, 
using ethyl acetate-light petrol (2 :1) as the eluent, to afford the thiolester 120  as an 
oil (1.12 g).
The above oil was redissolved in dichloromethane (20 cm^), the solution cooled to 
0 °C, and trifluoroacetic acid (10 cm^) was added. The solution was stirred at 0 °C for 
2 h, and the solvents were removed under reduced pressure. The residual oil was 
redissolved in water (20 cm^) and the solution washed with ether (2 x 1 0  cm^). The 
aqueous phase was concentrated under reduced pressure and lyophilised to yield the 
amine trifluoroacetate salt 118 as a clear colourless oil (0.58 g, 69%); (Found: C, 
42.0; H, 5.3; N, 6.35. C13H20N2O4S CF3CO2H.H2O requires C, 41.65; H, 5.35; N, 
6.5%); (HRMS: found [M - CF3C0 2 ]+, 301.1222. C13H21N2O4S requires 301.1222); 
[a]p -93.8 (c 0.2 in MeOH); %iax(CH2Cl2)/cm-i 2956 (CH), 1750 (ester CO), 1696
(thiolester CO), 1663 (amide CO) and 1200 (C-O); 4i(300 MHz; C^HCb) 1.90-2.15 
[4H, m, pCH2(Proi) and yCH2(Proi)], 2.31 (3 H, s, SCOCH3), 2.44 [1 H, m, 
iPCH2(Pro2)], 2.73 [1 H, dt, Ji 13.2, y2 7.8,ipCH2(Pro2)], 3.35 [1 H, dd, 7, 10.2, h
7.8, î 5CH2(Pro2)], 3.41-3.58 [2H, m, SCH2(Prol)], 3.71 (3 H, s, CO2CH3), 4.00 
[1 H, quintet, J  7.8, yCH(Pro2)], 4.12 [1 H, dd, 7; 10.2, J2 7.2, | 5CH2(Pro2)] and
4.49-4.69 [2 H, m, 2 x oCH(Pro)], 7.71 (1 H, br. s, NH) and 11.80 (1 H, br. s, 
CO2H); 5c(50.51 MHz; C^HCls) 24.70 ['yCH2(Pro')], 29.01 [pCH2(Pro>)]. 30.77 
(SCOCH3), 34.45 [pCH2(Pro2)], 39.87 [YCH(Pro2], 47.27 [5CH2(Proi)l, 52.56 
(CO2CH3), 53.09 [8 CH2(Pto2)], 59.05 [aCH(Pro')], 60.15 [aCH(Pro2>], 116.46 (q, 
7cf 286, CF3CO2H), 161.93 (q,7cF 38, CF3CO2H), 167.95 (amide CO), 171.49 (ester 
CO) and 195.04 (thiolester CO); m/z (Cl) 301 (70%, [M -  CF3C021+), 269 (100, [M 
-  CF3CO2 -  OCH3I+), 160 [30, NC4H7(S)C0 2 CH3+] and 70 (17, C4H8N+).
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Methyl (2S,4S)-A^-(A^-{A^-[(2S)-2-chloropropionyl]-(2S)»prolyl}-(25)-proIyl)-4- 
(acetylthio)prolmate 117
V Pro^
Acs
This was prepared in an identical manner to dipeptide 119, using (2S,2'S)-N~{T-
chloropropionyl)proline 106 (0.38 g, 1.85 mmol) and amine trifluoroacetate 118
(0.50 g, 1.21 mmol) to afford thiolacetate 117 as a white foam (0.53 g, 90%); (Found;
C, 49.95; H, 6.0; N, 8.65. C21H 30CIN3O6S requires C, 49.85; H, 6.35; N, 8.3%); 
(HRMS: found M+, 487.1552. C21H3035CIN3O6S requires 487.1544); [aj, -133.1 (c
0.3 in MeOH); Dmax(thin film)/cm"i 1748 (ester CO), 1695 (thiolacetate CO), 1652 
(amide CO), 1435 (CH def.) and 1200 (C-O); %(200 MHz; C2HCI3) 1.63 (3 H, d, J 
6.6, CHCH3), 1.85-2.20 [9H, m, pCHjCProi), pCH2(Pro2), (Pro3),
7CH2(Pro') and 7CH2(Pro2)], 2.31 (3 H, s, SCOCH3), 2.60-2.80 [1 H, m. 
èpCH2(Pro3)], 3.42 [1 H, dd, Ji 10.1, J2 7 .2 , | 5 CH2(Pio3)], 3.57-3.84 [4 H, mj 
5CH2(Proi) and 8CH2(Pro2)], 3.70 (3 H, s, CO2CH3), 4.01-4.10 [1 H, m, 7CH(Pro3)], 
4.30 [1 H, dd, Ji 10.1, J2  7.2, ï8CH2(Pro3)] and 4.48-4.71 (4 H, m, CHCE .3 and 3 x 
aCH(Pro)]; Jc(?4.76 MHz; C^HCIs) 20.88 (CHCH3), 25.19 and 25.26 [■yCHiCPro') 
and 7CH2(Pro3)], 28.39 and 28.66 [pCHalPro') and pCHaCPro^)], 30.87 (SCOCH3),
35.13 [pCH2(Pro3)l, 40.38 [7 CH2(Pro3)], 47.35 and 47.71 [8CH2(Pro‘) and 
5CH2(Pro2)], 51.68 (CHCH3), 52.57 [5CH2(Pro3)], 52.76 (CO2CH3), 58.29, 58.54 
and 58.84 [3 x aCH(Pro)], 168.16 (COCHCH3), 170.71 and 171.14 (2 x amide CO),
172.36 (ester CO) and 194.84 (thiolester CO); tn/z (El) 489 and 487 (7 and 16%, 
chlorine isotopes, M+), 451 (7, [M -  HC1]+), 327 {14, [M -
C1CH(CH3)C0 NC4H7]+}, 287 and 285 (6  and 21, chlorine isotopes, [M -  
CH3COSC4H6NC02CH31+), 190 and 188 [32 and 100, chlorine isotopes.
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C1CH(CH3)C0 NC4H7C0 +], 162 and 160 [26 and 77, chlorine isotopes, 
C1CH(CH3)C0 NC4H7+] and 70 (53, C4H8N+).
Methyl (25,4S')-A^-(iV-{A^-[(2S)-2-chIoropropionyl]-(2S)-prolyl}-(25)-prolyl)-4- 
mercaptoprolinate 1 2 1
HS
Thiolacetate 117 (0.15 g, 0.31 mmol) was dissolved in methanol (10 cm^) and the 
solution treated with aqueous potassium hydroxide solution (0.05 mol dm~3, 10 cm^). 
The mixture was stirred for 4 h, after which time aqueous HCl (0.05 mol dm“3, 10 
cm^) was added and the methanol removed under reduced pressure. The solution was 
further acidified to pH 1-2 and extracted with ethyl acetate (5 x 30 cm^). The 
combined organic extracts were dried (MgS0 4 ) and the solvent removed under 
reduced pressure to yield the thiol 121 as a clear colourless oil (0.13 g, 95%); 
(HRMS: found [M + H]+, 446.1506. C19H2835CIN3O5S requires 446.1516); [ a ^
-135.5 (c 0.4 in MeOH); Umax(thin film)/cm~^ 2954 (CH), 2539 (SH), 1744 (ester 
CO), 1654 (amide CO), 1434 (CH def.) and 1199 (C-O); 4^(200 MHz; C^HCb) 1.60 
(3 H, d, J  6.6, CHCHj), 1.80-2.20 [9 H, m, pCH2(Prol), pCH2(Pro2),lpCH2(Pro3), 
7CH2(Prol) and 7CH2(Pro2)], 2.64-2.71 [I H, m, |pCH2(Pro3)], 3.32-3.45 [2 H, m, 
7CH(Pro3) andî8CH2(Pro3)], 3.58-3.86 [4 H, m, 8CH2(Pro') and 5CH2(Pro2)], 3.69 
(3 H, s, CO2CH3), 4.27 [1 H, dd, Ji 8.4, J2 5.7, i5CH2(Pro3)], 4.49 [2 H, m, Œ C H 3 
and aCH(Pro)] and 4.67 [2H, m, 2 x aCH(Pro)]; 8^(74.76 MHz; C^HCls) 20.61 
(CHCH3), 24.97 and 25.04 [yCH2(Pro') and -yCHaCProî)], 28.27 and 28.43 
[pCH2(Pro‘) and pCH2(Pro2)], 35.82 [pCH2(Pro3)], 39.26 [7CH2(Pro3)], 47.22 and 
47.50 [5CH2(Pro>) and 0CH2(Pro2)], 51.43 (CHCH3), 52.53 (CO2CH3), 56.20
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[ÔCH2(Pro3)], 58.10, 58.63 and 58.74 [3 x aCH(Pro)], 167.96 (COCHCH3), 170.67 
and 170.83 (2 X amide CO) and 172.25 (ester CO); m/z (CI) 448 and 446 (21 and 
60%, chlorine isotopes, [M + H]+), 412 (100, [M -  Cl + H]+), 380 (32, [M -  Cl -  
OCH3 + H]+), 227 {49, [M -  ClCH(CH3)CONC4H? -  CO2CH3 + H]+}, 154 (31, 
[CH3CHCONC4H7CO + H]+), 126 (26, OCNC4H8CO+) and 70 (24, C4H8N+).
Dimethyl (35,95,15/î,175,205,235,295,35/f,37S,405)-15,35-dimethyl- 
2,8,14,22,28,34-hexaoxo-16,36-dithia-l,7,13,21,27,33-hexaazaheptacyclo- 
[24.2.2.1.1.1.1.03,7.09,13 Q23,27 029,33]t0^racontane-2O,4O-dicarboxylate 122
MeOpC
°  NL'COzMe
40
Pro
Sodium hydride (60% dispersion in mineral oil, 11 mg, 0.29 mmol) was added to a 
stirred solution of thiol 121 (105 mg, 0.24 mmol) in dry THF (40 cm^) and the 
mixture heated at reflux under nitrogen for 2 h. The suspension was cooled to room 
temperature, and the solvent removed under reduced pressure. The residual oil was 
purified by gradient column chromatography using dichloromethane-methanol as the 
eluent to yield the cyclic product 122 as a pale oil (21 mg, 22%); Rf 0.65 
(dichloromethane-methanol, 9:1); (HRMS: found [jM + H]+, 410.1742. 
C19H27N3O5S requires 410.1750); [aj, -64.1 (c 0.3 in MeOH); Umax(lhin film)/cm~^
1742 (ester CO), 1634 (amide CO) and 1200 (C-O); 5h(300 MHz; C2HCI3) 1.35 
(6 H, d, J 6 .6 , 2 X CHCH3), 1.85-2.35 [18 H, m. pCH2(Proid’), pCH2(Pro2.2’),
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îPCH2(Pro3.3'), •yCH2 (Pro'.l') and •yCH2 (Pro2 .2 ’)], 2.76 [2 H, dt, Ji 13.2, h  8.4, 
îPCH2(Pro3.3’)], 3.25 [2 H, dd, 7i 10.2, 7% 7.5, |8CH2(Pro3.3’)], 3.45-3.92 [10 H, m, 
7 CH(Pro3 .3 ), SCH2 (Prol.l') and 6 CH2 (ProW)], 3.69 (6 H, s, 2 x CO2CH3 ), 4.23 [2 H, 
dd, 7, 10.2, h  7.9,î8CH2(Pro3.3')] and 4.62-4.71 [8 H, m, 2 x CT/CHs and 6  x 
aCH(Pro)]; 8c(74.76 MHz; C^HCla) 17.56 (2 x CHCH3), 25.11 and 25.54 
[7CH2(Prol4’) and 'yCH2 (Pro2 .2 ')], 28.20 and 28.58 [pCH2 (Prol l ') and 
PCH2(Pro2.2')], 38.42 [PCH2(Pro3.3’)], 40.45 ['yCH2(Pro3.3 )], 40.90 (2 x CHCH3), 
47.35 and 48.36 [8 CH2(Pro>4 ') and 8 CH2 (Pro2 .2 ’)], 52.39 (2 x CO2CH3), 52.68 
[8 C H 2 (P r o 3 .3 ') ] ,  58.58, 58.82 and 59.06 [6 x aCH(Pro)], 170.63 and 170.78 (4 x 
amide CO), 172.08 (2 x COCHCH3) and 172.67 (2 x ester CO); m/i (ES+) 857 (8%, 
[M + K]+), 841 (57, [M + Na]+), 819 (16, M+) and 364 (96, |m  -  2 CH3 -  OCHs]+).
(3S,9S,15fi,175,205,23S,295,35«,37S,40S)-15,35-Dimettiyl-2,8,14,22,28,34- 
hexaoxo-16,36-dithia-l,7,13,21,27,33-hexaazaheptacycïo- 
[24.2.2.1.1.1.1.03»’^ .0^»i3.023»27.029,33]|etracontane-20,40-dicarboxylic acid 123
Pro'
Pro
Pro
ProHO2C
Pro Me
Pro^
A solution of methyl ester 122 (11 mg, 27 pmol) in methanol (0.2 cm^) was treated 
with aqueous sodium hydroxide solution (1.0 mol dm-^, 0.2  cm^) and the solution 
stirred for 2 h. The solvents were removed and the residue redissolved in water (5 
cm^). The aqueous solution was acidified to pH 1 with aqueous HCl (1 mol dm-3) and
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washed with dichloromethane ( 2 x 4  cm^). The solvent was removed from the 
aqueous phase and the residual solids extracted several times with hot 
dichloromethane. The combined extracts were filtered and the solvent removed under 
reduced pressure to afford the acid 123 as a colourless glass (7 mg, 65%); [ajj^ -33.9 
(c 0.4 in MeOH); Vmax(CH2Cl2)/cm-i 2978 (CH), 1754 (acid CO), 1642 (amide CO) 
and 1437 (CH def.); %(300 MHz; 2H2O) 1.32 (6 H, d, 77.2, 2 x CHCffg), 1.86-2.01 
[4H, m, ^pCH2(Prol4 ') and èpCH2(Pro2.2')], 2.00-2.13 [10 H, m, èpCH2(Pro3.3 ), 
7CH2(ProC i’) and 'yCH2(Pro2.2 ')] 2.31-2.44 [4 H, m, îpCH2(Pro>.i') and 
|pCH2(Pro2’2’)], 3.02 [2 H, dt, 7i 12.6, 7 ; 7.8, |pCH2(Pro3.3 )], 3.35 [2H, m, 
ï5CH2(Pro3.3’)], 3.60 [2 H, m, 'yCH(Pro3 3')], 3.62-3.91 [8 H, m, BCHiCPmi i ) and 
6 CH2(Pro2.2')], 4.17 [2 H, dd, 7i 9.0, Jj 6.0, 8^CH2(Pro3.3’)], 4.27 (2 H, q, 7 7.2. 2 x 
CT/CHs), 4.51 [2 H, t, 77.8, aCH(Pro3.3’)] and 4.71^.78 [4 H, m, aCH(Pro'.i’) and 
aCH(Pro2.2’)]; 8c(75.44 MHz; % 2 0 ) 16.13 (2 x CHCH3), 24.58 and 24.78 
[7CH2(P ro l.l’) and 7CH2(Pro2 .2 ’)], 27.71 and 28.25 [pCH2(Prol ' ) and 
pCH2(Pro2.2')], 37.96 [pCH2(Pro3.3 )], 40.30 [2 x CHCH3 and 3CH(Pro3.3')], 47.83 
and 48.94 [BCHalPro'd') and 8 CH2(Pro2.2’)], 51.34 [8CH2(Pro3.3’)], 58.73 and 59.51 
[6 X aCH(Pro)], 171.56 and 171.97 (4 x amide CO), 174.13 (2x  COCHCH3) and 
175.27 (2 X acid CO).
(2/?,55)-2-fer/-Butyl“5“methyl-l-aza-3-oxabicycIo[3.3.0]octan-4-one 127
VÇo
h -
Pivalaldehyde (25 cm^, 0.23 mol) was added to a suspension of (25")-proline 6 (14.0 g, 
0.12 mol) in pentane (400 cm^) and the mixture heated under reflux, using a Dean- 
Stark apparatus, for 7 days. During this time three further 25 cm^ portions of 
pivalaldehyde were added at 2 day intervals. The solvent and excess pivalaldehyde
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were removed under reduced pressure to afford the bicyclooctanone 126 as a pale 
orange-brown oil (21.5 g). A portion of this oil (6.3 g, 34.4 mmol) was redissolved in 
dry THF (140 cm^) and the solution cooled under nitrogen to -78 °C. A solution of 
lithium di-wopropylamide in hexanes-THF (1 mol dm~3, 36 cm^) was added and the 
mixture stined for 1 h at -78 °C. Methyl iodide (2.4 cm^, 38.6 mmol) was then added 
dropwise and the suspension allowed to warm to -30 over 2 h. The suspension 
was poured into a mixture of water (100 cm^) and dichloromethane (250 cm^). The 
organic phase was separated, dried (MgSO^) and the solvents removed under reduced 
pressure to give a yellow-orange solid. The crude solid was redissolved in 
dichloromethane and the solution was filtered. The filtrate was concentrated under 
reduced pressure to yield a brown semi-solid mass; Kugelrohr distillation of this
residue under reduced pressure afforded bicyclooctanone 127 as a clear colourless oil 
(3.9 g, 55%), bp 110 -C/-0.05 mmHg (lit., 275 85 “C/0.05mmHg); [a j, -28.7 (c 1.05
in CHCI3) [lit., 275 -29.8 (c 0.7 in CHCI3)]; Umax(thin film)/cm-> 2973 (CH), 1784 
(CO) and 1192 (C-O); 8h(200 MHz; C2HCI3) 0.90 [9 H, s, C(CH3)3], 1.37 (3 H, s, 
pCHs), 1.64-1.86 (3 H, m, IpCHj and -yCHa), 2.12-2.19 (1 H, m, ipCHj), 2.76-2.87 
(1 H, m, Ï8CH2), 3.05-3.18 (1 H, m, I8CH2) and 4.25 (1 H, s, OCHN); 8c(75.44 
MHz; C2HCI3) 24.54 [C(CH3)J, 25.84 and 25.96 (PCH3 and 7CH2), 36.86 [C(CH3)3)]
39.14 (pCHz), 58.34 (8 CH2), 69.30 (aC), 106.36 (NCO) and 179.76 (CO); m/z (Cl) 
198 (82%, [M + H]+), 140 (6 , [M -  C4H9I+), 130 (100, [M -  C5H7 + H]+) and 84 (14, 
NC4H7CH3+).
Methyl (2S)-2-methylproIinate hydrochloride 128
rvCOgMeMe 
H .HCl
An ice-cooled solution of bicyclooctanone 127 (6.6  g, 33.5 mmol) in dry methanol 
(75 cm^) was treated dropwise with thionyl chloride (4.0 cm^, 54.6 mmol). The
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solution was heated under reflux for 2  h, then cooled and the solvents removed under 
reduced pressure to yield a dark brown solid. The crude solid was recrystallised from 
ethyl acetate-methanol to afford the amine hydrochloride 128 as colourless crystals 
(3.5 g, 58%), mp 106-108 °C; (Found: C, 46.5; H, 8.15; N, 7.7. C7H 14CINO2 requires 
C, 46.8; H, 7.85; N, 7.8%); [a|j, -31.6 (c 1.3 in MeOH); t)„jx(CH2Cl2)/cm-‘ 2995
(CH) and 1747 (CO); 4,(200 MHz; % 2 0 ) 1.68 (3 H, s, PCH3), 1.99-2.21 (3 H, m, 
IPCH2 and 7CH2), 2.36-2.46 (1 H, m,|pCH2), 3.41-3.51 (2  H, m, 8CH2) and 3.84 
(3 H, s, CO2CH3); 8c(75.44 MHz; C^HaO^H) 21.86 (PCH3), 23.97 (7CH2), 36.75 
(PCH2), 46.75 (6CH2). 54.68 (CO2CH3), 70.50 (<xC) and 173.17 (ester CO); m/z (Cl) 
144 (100%, [M -  Cl]+) and 84 (26, [M -  HCl -  C0 2 CH3]+).
(2S,2’S)-A^-(2’-ChloropropionyI)-2-methylproline 130
r v ^
Cl
A solution of (25)-2-chloropropionic acid 104 (1.21 g, 11.1 mmol), methyl {2S)-2- 
methylprolinate hydrochloride 128 (1.00 g, 5.5 mmol) and A ^,A -di-
zjopropylethylamine (3.3 cm^, 18.9 mmol) in dry dichloromethane (100 cm^) was 
treated with BOP-Cl (2.98 g, 11.7 mmol) and the resulting suspension stirred under 
nitrogen at 0-5 °C for 4 h. The mixture was allowed to warm to room temperature 
and stirred for a further 15 h. The solution was washed with aqueous HCl (0.5 
mol dm“3, 2 X  50 cm^), aqueous sodium hydrogen carbonate solution (5%, 2 x 50 
cm^) and brine (50 cm^), then dried (MgS0 4 ). The solvent was removed under 
reduced pressure to yield the dipeptide 129 as a colourless oil (0.78 g).
The above oil was redissolved in methanol (7 cm^), treated with aqueous sodium 
hydroxide solution (1.0 mol dm~3, 9  cm^), then stirred for 2 days. Following addition 
of aqueous HCl (1.0 mol dm“ ,^ 9 cm^), the solution was concentrated to -15 cm^
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under reduced pressure and then extracted with ethyl acetate (3 x 25 cm^). The 
combined organic extracts were dried (MgS0 4 ) and the solvent removed under 
reduced pressure to afford the product as a tan solid (0.53 g, 43%); a small portion 
was recrystallised to yield the acid 130 as colourless crystals, mp 136-137 °C;
(Found: C, 49.5; H, 6 .8 ; N, 6.45. C9H14CINO3 requires C, 49.2; H, 6.4; N, 6.4%); 
[a]jy -3.9 .(c 0.3 in MeOH); Umax(CH2Cl2)/crn-i 3000 (OH), 2989 (CH), 1758 (ester
CO), 1674 (amide CO) and 1260 (C-0); %(300 MHz; C^HClg) 1.53 (3 H, s, PCH3),
1.57 (3 H, d, J  6 .6 , CHCH3), 1.85-2.06 (3 H, m.ipCH; and 7CH2), 2.21-2.30 (1 H, 
m, îpCHz), 3.57-3.69 (1 H, m, I8 CH2), 3.78-3.85 (1 H, m, jSCHa), 4.42 (1 H. q, 7 
6 .6 , C/ÏCH3) and 7.13 (1 H, br. s, CO2H); 6^(75.44 MHz; C^HCls) 20.49 (PCH3),
20.90 (CHCHs), 24.26 (■yCH2), 38.66 (PCH2), 48.46 (S Œ 2), 51.80 (CHCH3), 67.00 
(aC), 168.33 (COCHCH3) and 177.61 (acid CO); m/z (El) 222 and 220 (1 and 4%, 
chlorine isotopes, M+), 176 and 174 (32 and 56, chlorine isotopes, [M -  CO2H + 
H]+), 140 (45, [M -  CO2H -  HCl + H]+), 128 (21, [M -  ClCH(CH3)CO]+} and 84 
(100, C5H10N+).
Methyl (2S,45)-iV-(A^-{Ar-[(25)-2-chloropropionyl]-(2S)-2-methylprolyl}-(2S)- 
proIyl)-4-mercaptoprolinate 132
HS
A solution of (25',2’5)-iV-(2’-chloropropionyl)-2-methylproline 130 (0.20 g, 0.91 
mmol) and A, A-di-i.yopropylethylamine (0.50 cm^, 2.87 mmol) in dry 
dichloromethane (15 cm^) was treated with BOP-Cl (0.25 g, 0.98 mmol) and the 
resulting suspension stirred under nitrogen at 0 °C for 20 min. A solution of amine 
trifluoroacetate 118 (0.28 g, 0.83 mmol) in dry dichloromethane (5 cm^) was then
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added. The mixture was stirred at 0-5 °C for 5 h, then at room temperature for 15 h. 
The solution was washed with aqueous HCl (0.5 mol dm~3, 2 x 5  cm^), aqueous 
sodium hydrogen carbonate solution (5%, 2 x 5  cm^) and brine (100 cm^) and dried 
(MgSO^). The solvent was removed under reduced pressure, and the residual oil was 
purified by column chromatography using ethyl acetate-methanol (19:1) as the 
eluent, to yield the thiolacetate 131 as a colourless foam (0.13 g). The crude foam was 
redissolved in methanol (9 cm^) and the solution treated with aqueous potassium 
hydroxide solution (0.05 mol dm~3, 9 cm^). The solution was stirred for 4 h, after 
which time aqueous HCl (0.05 mol dm”3, 10 cm^) was added. The methanol was 
removed under reduced pressure, then the solution was further acidified to pH 1 and 
extracted with ethyl acetate (3 x 25 cm^). The combined organic extracts were dried 
(MgSO^) and the solvent removed under reduced pressure to afford the thiol 132 as a
colourless oil (0.11 g, 29%); (HRMS: found [M + H]+, 460.1682. CzoHgi^^clNgOgS 
requires 460.1673); [ajj^-108.4 (c 1.1 in MeOH); t)max(CH2Cl2)/crn-i 2546 (SH),
1747 (ester CO), 1662 (amide CO), 1423 (CH def.) and 1200 (C-O); 5h(300 MHz;
C^HCls) 1.57 (3 H, d, J  6 .6 , CHCT/g), 1.78 [3 H, s, pCH3(ProO], 1.80-2.10 [8 H, m,
\F(i,2)pCH2(Proi), pCH2(Pro2), VF(i.2)pCH2(Pro3), 'yCH2(Proi) and yCH2(Pro^)], 2.35
[1 H, m, ipCH2(Pro2)], 2.63 [1 H, dt, Ji 13.3, /2  8 .0 ,ipCH2(Pro3)], 3.30-3.41 [2 H,
m, 7CH(Pro3) and | 8 CH2(Pro3)], 3.52-3.80 [4 H, m, 8 CH2(Prol) and 8 CH2(Pro2)],
3.62 (3 H, s, CO2CH3), 4.20 [1 H, dd, 7, 10.0, J2 7.6, &8CH2(Pro3)], 4.42 [2 H, m,
Œ C H 3 and aCH(Pro)] and 4.71 [1 H, m, aCH(Pro)]; 8fc(75.44 MHz; C2HCI3) 20.62
(CHCH3), 23.52 and 23.60 [pCH3(Prol) and YCH2(Pm^)], 25.55 [■yCHzCProi)]. 27.26
[pCH2(Pro2)], 36.00 [pCH2(Pro3)], 38.23 [PCH2(Pro')], 39.36 [7CH2(Pro3)], 48.36
[8CH2(Pro3)], 48.69 [8CH2(Pro>)], 52.22 (CHCH3), 52.65 (CO2CH3), 56.32
[8CH2(Pro3)], 58.75 [aCH(Pro^)], 60.51 [aCH(Pro3)], 68.58 [aC(Proi)], 167.90
(COCHCH3), 171.09 and 171.71 (2 x amide CO) and 172.58 (ester CO); m/z (Cl) 462
and 460 (33 and 100%, chlorine isotopes, [M + H]+), 426 (13, [M -  HCl + H]+), 392
(13, [M -  Cl -  SH + H]+), 301 and 299 {3 and 7, chlorine isotopes, [M -
NC4H6(SH)C02CH3]+)}.
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Dimethyl (3S,95,15/2,175,205,235,295,35/î,375,405)-9,15,29,35-tetramethyl- 
2,8,14,22,28,34-hexaoxo-16,36-dithia-l,7,13,21,27,33-hexaazaheptacydo 
[24.2.2.1.1.1.1.0^»7.0^»13^023,27^ 029,33]tet|.acontane-20,40-dicarboxylate 133
Pro
Pro
Pro
Pro
Pro Me
Pro*'
Caesium carbonate (210 mg, 0.65 mmol) was added to a solution of thiol 132 
(150 mg, 0.33 mmol) in DMF (80 cm^) and the mixture strirred with heating at 
80-90 °C for 2.5 h. The suspension was cooled and the solvent removed under 
reduced pressure. The residual orange-brown oil was purified by column 
chromatography using dichloromethane-methanol (19:1) as the eluent to afford the
macrocycle 133 as a white foam (41 mg, 30%); RfO.43; (Found: C, 54.4; H, 7.1; N,
9.5. C4oH58N6 0 ioS2*2H2 0  requires: C, 54.4; H, 7.0; N, 9.8%); -58.4 (c 0.1 in
MeOH); i>max(CH2Cl2)/cm-* 2983 (CH), 1747 (ester CO), 1658 (amide CO), 1626 
(amide CO) and 1200 (C-O); ^(300 MHz; 2H2O) 1.31 (6 H, d, 7 6.9, 2 x CHC//3), 
1.80 [6 H, s, pCH3(Prohi’)], 1.93-2.21 [18 H, m, pCH2(Proi-i’), pCH2(Pro2.2 ), 
îpCH2(Pro3 .3 ’), 7CH2(Proi.l ) and TCHaCPro .^^’)], 2 .85-2 .94  [2 H, m,
|pCH2(Pro>.l')], 3.44 [2 H, t, J  9.4, ÿ C H îC P ro ^ .î’)] , 3.58-3.69 [4 H, m, 
iSCH2(Pro'.l') and 'vCH(Pro3.3’)], 3,76 (6  H, s, 2 x CO2CH3), 3.76-3.85 [6 H, m. 
i 8CH2(ProM ’) and 8CH2(Pro2.2 ')], 4.11-4.22 [4 H, m, 2 x CffCHj and 
î 8CH2(Pro3.3’)], 4.56 [2 H, t, J 7.3, aCH(Pro3.3’)] and 4.70-4.79 [4 H, m, 
aCH(Pro'->') and aCH(Pro2.2’)]; ^t(75.44 MHz; 2H2O) 16.41 (2 x CHCH3), 23.01
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a n d  23.24 [ p C H ^ m ' 4  )  a n d  'y C H z C P r o 'd ') ] ,  25.20 ['v C H 2 (P ro 2 .2 ')], 26.66 
[pCH2(Pro2.2')], 37.55 [pCH2(Pro3.3')], 38.00 [pCH2(Proid’)], 40.87 [7CH2(Pro3.3’)], 
41.58 (2 X CHCHs), 49.20 a n d  49.41 [8CH2(P ro ''')  a n d  5 C H 2 (P r o 2 .2 ’) ] ,  52.08 (2 x 
CO2CH3). 53.17 [8CH2(Pro3.3')], 59.38 [aCH(Pro3.3’)], 61.03 [aCH(Pro2.2’)], 69.31 
[aCH(ProM’)], 172.55, 173.15 a n d  173.52 (6  x a m id e  CO) a n d  174.45 (2 x e s te r  
C O ); m /z  (C l)  847 ( 8 %, [M + H ]+ ), 452 {72,
[CONC4H6(CH3)COCH(CH3)SC4H6(C02CH3)NCOC4H7NCO + H]+), 354 (80, 
[CONC4H6(CH3)COCH(CH3)SC4H6(C02CH3)]+ ) a n d  145 { 100,
[NC4H«(S)C02H]+).
(3S,9S,15fi,17S,20S,23S,29S,35«,37S,40S)-9,15,29,35-Tetramethyl- 
2,8,14,22,28,34-hexaoxo-16,36-dlthia-l,7,13,21,27,33-hexaazaheptacyelo 
[24.2.2.1.1.1.1.03,7.09>l3.023,27_o29,33]tetfa£ontane-20,40-dicarboxylic a d j  1 3 4
,1 ■ ^  p . .
oHO2C
o
Pro’’ A  N.^ „.C02H
rA P o.
This was prepared in an identical manner to acid 123, using methyl ester 133 (20 mg,
4.7 p,mol) to give the acid 134 as a clear colourless oil (15 mg, 78%); (HRMS: found 
[M -  2H + 2Na]+, 863.3084. C3gHs3N6 0 ioS2Na2 requires 863.3060); [aj^ -45.8 (c
0.1 in MeOH); i^maxC^Cy/cm-i 2971 (CH), 1749 (acid CO), 1647 (amide CO) and 
1456 (CH def.); 5h(500 MHz; 2H2O) major conformation: 1.30 (6 H, d, J  7.2, 2 x 
CHCH3), 1.79 [6 H, s, pCHsCProl.P)], 1.86-2.00 [4 H, m, jpCHzCProM ) and
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^ H 2(ProW )], 2 .00-2.15 [8 H, m, ^pCHa ( P f  o3.3’), ■yCH2(Pro2.2’) and 
hCH 2(Pro‘d’)], 2.15-2.26 [4 H, m,lpCH2(Pro‘.>’) and |pCH2(Pro2.2')], 2.88-2.97 
[2 H, m, ^pCH2(Pro3.3’)], 3.37-3.42 [2 H, m, | 8CH2(Pro3.3’)], 3.49-3.68 [4 H. m, 
î8CH2(Pro3 .3 ')  and 7CH(Pro3.3 ')], 3.72-3.86 [6 H, m. 8CH2(Pro'.>’) and 
î8CH2(Pro2.2')], 4.10-4.15 [2 H, m ,j8CH2(Pro3.3’)], 4.18 (2 H, q, 77.2, 2 x CHCH3), 
4.49 [2 H, t, 7 7.8, aCH(Pro3.3’)] and 4.70-4.75 [2 H, m, aCH(Pro2.2')]; minor 
conformation: 1.42 [6 H, s, pCH3(Pro' 1 )], 1.48 (6  H, d, 7 7.2, 2 x C H C H 3), 
1.68-1.73 [2 H, m, &yCH2(Pro2 2 ')], 1.83-2.03 [6  H, m, YCH2(Pro‘.>') and 
hCH 2(Pro2.2')l, 2.04-2.15 [4 H, m,|pCH2 (Proi.i’) and ipCH2(Pro2.2’)], 2.15-2.33 
[6  H, m, |pCH2(Pro>.i’),ipC H 2(Pro2.2’) and ÿC H 2(Pro3.3’)], 3.02-3.08 [2 H, m, 
|pCH2(Pco3.3’)], 3 .49-3.56 [2 H, m, ^C H 2(Pro3.3 ')], 3.37-3.42 [4 H, m, 
8CH2(Pro2,2')], 3.49-3.68 [2 H, m, 8CH2(Prol.l’)], 3.99-4.06 [2 H, m, 7CH(Pro3.3')], 
4.10-4.22 [4 H, m, 2 X C/ÎCH3 and i8CH2(Pro3.3’)], 4.48 [2 H, t, 7 7.8, aCH(Pro3.3')] 
and 4.92 [2 H, d, 7 7.8, aC H (Pro '' )]; 8c(75.44 MHz; 2H2O) 16.77 and 19.57 (2 x 
CHCH3), 20.10 and 22.15 [pCH3(Pro'4 ’)], 23.04, 23.28 and 25.23 ['vCH2(Pro'4 ') and 
7CH2(Pro2.2’)], 26.80 and 30.84 [pCH2(Pro:4  )], 34.96 and 38.10 [pCH2(Pro33’)],
38.86 and 39.86 [pCH2(Prol4 ’)], 40.41 and 41.30 [7CH(Pro3.3’)], 43.61 and 43.95 (2 
X CHCH3), 47.62, 49.03, 49.30 and 49.63 [8CH2(Prol' ) and 8CH2(Pro2 2')], 51.70 
and 52.04 [8 CH2(Pro3 3')], 59.31, 61.22, 62.25 and 63.10 [aCH(Pro22') and 
0iCH(Pro3'3’)], 68.32 and 69.41 [aC(Prot' )], 171.40, 171.57, 172.78, 173.15 and 
173.95 (6  X amide CO), 178.31 and 179.18 (2 x acid CO); m7z (FAB) 885 (53%, [M -  
2H + 3Na]+), 863 (100, [M -  H + 2Na]+) and 817 (18, [M -  H]+).
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(25)-iV-(ter/-Butoxycarbonyl)-2-methyIproIine 137
r y COaH
Me
BOC
A suspension of (25')-2-methylproline methyl ester hydrochloride 128 (1.00 g, 
5.6 mmol) in dry dichloromethane (30 cm^) at 0 °C was treated with N,N-di- 
wopropylethylamine (2.40 cm^, 13.8 mmol), DMAP (0.20 g, 1.9 mmol) and d\-tert- 
butyldicarbonate (1.85 g, 8.4 mmol). The mixture was allowed to reach room 
temperature and stirred for 3 days. The solution was washed with aqueous HCl (0.5 
mol dm~3, 2 X 20 cm^), aqueous sodium hydrogen carbonate solution (5%, 2 x  20 
cm3) and brine (20 cm^). The organic phase was dried (MgSO^), and the solvent was 
removed under reduced pressure to yield the methyl ester 136 as a brown oil (1.24 g). 
The crude oil was redissolved in methanol (15 cm^) and aqueous sodium hydroxide 
solution (1.0 mol dm"^, 25 cm^) was added. The solution was stirred for 2 days, 
concentrated to -20 cm^ and acidified to pH 2 with aqueous HCl (0.5 mol dm~3). The 
solution was extracted with ethyl acetate (3 x 25 cm^) and the combined organic 
extracts dried (MgSO^). The solvent was removed under reduced pressure to afford 
the acid 137 as pale yellow crystals (0.78 g, 61%), mp 129-130 °C [lit., 
129-132 °C]; (Found: C, 57.75; H, 8.4; N, 6.15. Calc, for C 1 1H 1 9NO4 : C, 57.6; H, 
8.35; N, 6.1%); [a]p -50.6 (c 1.4 in CHCI3 ) [lit., -41.4 (c 1.45 in CHCI3)];
t)max(CH2Cl2)/cm-i 2982 (CH), 2664 (OH), 1749 (acid CO), 1692 (urethane CO) and 
1165 (C-O); ^h(200 MHz; C^HCls) 1.40 [t, 9 H, s, C(CH3)3], 1.44 [c, 9 H, s, 
C(CH3)3], 1.50 (f, 3 H, s, pCHj), 1.57 (c, 3 H, s, PCH3), 1.84-2.00 (3 H, m.&pCHz 
and 7CH2), 2.18-2.43 (1 H, m.IpCHa), 3.42-3.60 (2 H, m, SCHj) and 10.05 (1 H, s, 
CO2H); 6k(75.44 MHz; C^HCla) 22.45 (c, PCH3), 23.09 (t, pCHs), 23.14 (t, 7CH2), 
23.39 (c, YCH2), 28.61 [t, 0 (0 3 3 )3], 28.75 [c, 0 (0 1 3 )3], 39.35 (c, POH2), 40.67 (t, 
POH2), 48.14 (I, 6 OH2), 48.63 (c, 8OH2), 65.17 (t, aO), 6 6 .0 0  (c, aO), 81.06 
[C(CH3)3], 154.26 (t, urethane CO), 155.50 (c, urethane CO), 179.34 (c, acid CO) and
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181.11 (t, acid CO); m/z (El) 229 (0.5%, M+), 184 (27, [M -  C0 2 H]+), 128 (100, [M 
-  CO2H -  C4Hg]+), 84 (78, NC4H7CH3+) and 57 (79, C4H9+).
Methyl (25,41î)WV-(tert-butoxycarbonyI)-4-hydroxyprolinate 138
HO
COgMe
BOC
A stirred suspension of methyl (25,4/?)-4-hydi*oxyprolinate hydrochloride 114 (7.0 g,
38.5 mmol) in dry THF (90 cm^) was treated with A-methylmorpholine (8.8 cm^,
78.7 mmol) and the mixture stirred for 1 h. Di-fgrf-butyl dicarbonate (9.3 g, 42.7 
mmol) was added and the mixture stirred for a further 18 h. The hydrochloride salts 
were filtered off and the solvent removed from the filtrate under reduced pressure to 
give a brown oil which was redissolved in ethyl acetate (100 cm^). The solution was 
washed with aqueous HCl (0.5 mol dm~^, 2 x 70 cm^), aqueous sodium hydrogen 
carbonate solution (5%, 2 x 70 cm^) and brine (70 cm^), then dried (MgS0 4 ). The 
solution was then concentrated under reduced pressure to yield compound 138 as a 
clear colourless oil (7.5 g, 79%); (Found: C, 53.6; H, 8.05; N, 5.8. C11H 19NO5 
requires C, 53.85; H, 7.8; N, 5.75%); (HRMS: found [M + H]+, 246.1341. 
C11H20NO5 requires 246.1334); [a ^  -60.2 (c 1.0 in MeOH) [lit, -51.0 (c 1.0 in
MeOH)]; Umax(thin film)/cm“i 3443 (OH), 1750 (ester CO), 1683 (urethane CO) and 
1160 (C-O); 0h(200 MHz; C^HCH) 1.36 [r, 9 H, s, C(CH3)3], 1.41 [c, 9 H, s, 
C(CH3)3], 1.98-2.07 (1 H, m ipCH 2), 2.22-2.32 (1 H, m, ipCHz). 3.19-3.61 (2H, 
m, SCH2). 3.69 (3 H, s, CO2CH3) and 4.31-4.43 (2 H, m, aCH and -yCH); 8c(75.4 
MHz; C^HCls) 28.21 [t, C(CH3)3], 28.35 [c, CCCHs)], 38.36 (c, PCH2), 39.12 {t, 
PCH2), 52.03 (t, CO2CH3), 52.18 (c, CO2C H3), 55.60 (l, 8CH2), 55.73 (c, 5CH2), 
58.09 (c, aCH), 58.17 (f, aCH), 68.96 f t iCH), 69.66 (c, 7CH), 80.20 [c, C(CH3)3],
80.33 [r, C(CH3)], 154.13 {t, urethane CO), 154.75 (c, urethane CO), 173.68 (c, ester 
CO) and 173.92 (^ ester CO); m/z (El) 246 (6 %, [M + H]+), 186 (60, [M -
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C02CH3]+), 144 (54, [M -  C0 2 C4H,]+), 130 (71, [M -  CO2CH3 -  C4Hg]+), 86  (88 , 
[M -  CO2CH3 -  COzCaHsl+l and 57 (100, C4H9+).
Methyl (25,45)-4-(acetylthio)pro!inate trifluoroacetate 140
AcS
h t " COgMe 
H .CF3CO2H
Di-ijopropyl azodicarboxylate (3.75 g, 19.0 mmol) was added to an ice-cooled 
solution of triphenylphosphine (4.97 g, 19.0 mmol) in dry THF (70 cm^) and the 
resulting suspension stirred at 0 °C for 30 min. A solution of alcohol 138 (4.04 g,
16.5 mmol) and thiolacetic acid (0.48 cm^, 20.4 mmol) in dry THF (70 cm^) was then 
added dropwise to this solution. The mixture was stirred with ice-cooling for 2 h, and 
at room temperature for 18 h. The solvent was removed under reduced pressure to 
yield a pale orange oil which was partially purified by column chromatography using 
light petrol-ethyl acetate (6 :1) as the eluent to yield the thiolacetate 139 in an impure 
state as a colourless oil (4.05 g).
The above oil (1.1 g) was redissolved in dichloromethane (20 cm^), the solution ice- 
cooled, and trifluoroacetic acid (7 cm^) added. The solution was stirred with cooling 
for 90 min, and the solvents were removed under reduced pressure. The residual oil 
was redissolved in water (10  cm^) and the solution washed with ether ( 2 x 7  cm^). 
The aqueous phase was concentrated under reduced pressure and lyophilised to give
the amine trifluoroacetate 140 as a clear colourless oil (1.03 g, 72%); (HRMS: found 
[M -  CF3C0 2 ]+, 204.0691. CgHo^^ClNOgS requires 204.0694); [0(  ^-25.9 (c 1.0 in
MeOH); t>max(CH2Cl2)/cm-i 2996 (CH), 1751 (ester CO), 1698 (thiolacetate CO) and 
1199 (C-O); 5h(300 MHz; C^HCls) 2.19 (1 H, dt, 7; 13.9,72 7.8, ÎPCH2), 2.32 (3 H, 
s, SCOCH3), 2.85 (1 H, dt, 7, 13.9, 72 7.8, jpCHz), 3.37 (1 H, dd, 7| 12.2, 72 7.7, 
&5CH2), 3.81 (3 H, s, CO2CH3), 3.86 (1 H, dd, 7j 12.2, J2 7.7, jPCHz), 4.08 (1 H, 
quintet, 7 7.7, 7CH), 4.53 (1 H, t, 7 8.1, aCH) and 8.43 (2 H, br. s, NH;); 5c(50.51
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MHz; C2HC13) 30.50 (SCOCH3), 34.25 (pCHz), 38.97 (7CH2), 50.87 (CO2CH3), 
53.84 (ÔCH2), 59.06 (aCH), 116.40 (q,7cF 290.8, CF3CO2 H), 161.91 (q, 7cf36.5, 
CF3 CO2H), 169.06 (ester CO) and 194.85 (thiolester CO); m/z (CI) 204 (100%, [M -  
CF3C021+), 162 (26, [M -  CF3CO2 -  COCH3 + H]+) and 146 (19, [M -  CF3CO2 -  
CO2CH3 + H]+).
Methyl (25,4iS)-A-[A-(^er^-butoxycarbonyl)-(2S)-2-inethylproiyl]-4- 
(acetylthio)prolinate 141
SAc
This was prepared in an identical manner to dipeptide 119, using acid 137 (0.15 g, 
0.65 mmol) and amine trifluoroacetate 140 (0.23 g, 0.73 mmol) to yield a yellow oil 
which was purified by column chromatography using ethyl acetate-light petrol (1:1) 
as the eluent to afford the thiolacetate 141 as colourless crystals (0.21 g, 55%); Rf 
0.64 (ethyl acetate); mp 112-114 °C; (Found: C, 55.05; H, 7.3; N, 6.75. C 19H30N2O6 
requires: C, 55.1; H, 7.55; N, 6.75%); [a]p -109 .8  (c 1.2 in MeOH);
t>max(CH2Cl2)/cm~i 2980 (CH), 1752 (ester CO), 1694 (urethane CO), 1640 (amide 
CO) and 1174 (C-O); 4,(300 MHz; C^HC^) 1.43 [9 H, s, C(CH3)3], 1.49 [3 H, s, 
pCHsCProi)], 1.72-2.07 [5 H, m, pCH2(Proi),iPCH2(Pro2) and ■vCH2(Prol)), 2.29 
(3 H, s, SCOCH3), 2.51 [1 H, dt, Ji 13.7, J2 7.4, jpCH2(Pro7)], 3.15 [1 H, t, J 10.3, 
i8CH2(Pro2)], 3.31 [1 H, m.^CHjCProl)], 3.50 [1 H, m ,|5CH2(Pro‘)], 3.69 (3 H, s, 
CO2CH3), 3.80 [1 H, m, 7CH(Pro2)], 4.04 [1 H, m.^ôCHjCProZ)] and 4.39 [1 H, t, J
8.1, aCH(Pro2)]; dc{15M  MHz; C^HCls) 22.46 [pCHaCPio')], 23.57 [7CH2(Prol)], 
28.16 [tt, C(CH3)3], 28.69 [ct, C(CH3>3], 30.84 (SCOCH3), 33.72 [pCH2(Pro2)],
39.79 and 40.21 [pCH2(Pro') and 7CH(Pro2)], 47.61 [SCH2(Pro')], 52.28 (CO2C H 3),
52.51 [5CH2(Pro7)], 60.70 [aCH(Pro2)], 66.01 [aC(Pro‘)], 81.25 [C(CH3)3], 154.06
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(urethane CO), 172.57 (amide CO), 173.62 (ester CO) and 195.51 (thiolester CO); 
m/z (El) 415 (13%, M+), 341 (14, [M -  SCOCH3 + H]+), 315 (17, [M -  CO2C4H9 + 
H]+), 184 [80, C4H9 0 C(0 )NC4HôCH3+], 128 (100, CH3C4H7NCO2+), 84 (65, 
NC4H7CH3+) and 57 (53, C4H9+).
(2S,5aS,10a5)-2-(Acetylthio)-5a-methyl-5,10-dioxoperhydrodipyrrolo 
[l,2-fl;l,2-d]pyrazine 143
Pro ,.Ma
Pro
SAc
A solution of thiolester 141 (0.15 g, 0.36 mmol) in dichloromethane (3 cm^) at 0 °C 
was treated with trifluoroacetic acid (1 cm^). The mixture was stirred for a further 90 
min, then the solvents were removed under reduced pressure to supply the amine 
thiolacetate 142 as a colourless oil.
A solution of (25,2’5')-A-(2’-chloropropionyl)-2-methylproline 130(0.16 g, 0.73 
mmol) and 7/, A-di-fjopropylethylamine (0 .2 2  cm^, 1.26 mmol) in dry 
dichloromethane (6 cm^) was treated with BOP-Cl (0.19 g, 0.75 mmol) and the 
resulting suspension stirred at 0 °C for 35 min. A solution of amine trifluoroacetate 
142 (0.17 g, 0.36 mmol) in dry dichloromethane (2 cm^) was then added. The mixture 
was stirred at 0-5 °C for 9 h, then at room temperature for 14 h. The solution was 
diluted with dichloromethane to -20 cm^ and washed with aqueous HCl (0.5 
mol dm~3, 2 x 5  cm^), aqueous sodium hydrogen carbonate solution (5%, 2 x 5  cm^) 
and brine (5 cm^) then dried (MgS0 4 ). The solvent was removed under reduced 
pressure, and the residual oil purified by column chromatography using ethyl acetate 
as the eluent to afford the dioxopiperazine 143 as a white solid (50 mg, 49%); Rf 0.25 
(ethyl acetate); (Found: C, 51.55; H, 6.55; N, 9.2. Ci3HigN2 0 3 S H2 0  requires: C, 
52.0; H, 6.7; N, 9.35%); Dmax(CH2Cl2)/cm-i 2982 (CH), 1695 (thiolester CO), 1664
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(amide CO) and 1428 (CH def.); 5h(300 MHz; C^HCIs) 1.41 [3 H, s, pCH3(Proi)], 
1.93-2.29 [5 H, m, pCH2(Pro>), |pCH2(Pro2) and yCH2(Pro>)], 2.30 (3 H, s, 
SCOCH3), 2.67 [1 H, dt, Ji 12.9, 72 6 .9 ,îPCH2(Pro2)], 3.42 [1 H, dd, Jy 12.0, /2  8.1, 
|SCH2(Pro2)], 3.48-3.58 [2 H, m, 8CH2(Pro')], 3.84-3.89 [1 H, ra, )CH(Pro2)], 3.99 
[1 H, dd, Jx 10.2, 72 6 .6 , |8CH2(Pro2)] and 4.30 [1 H, dd, 7, 9.3, J2 7.2, aCH(ProZ)]; 
6c(75.44 MHz; C^HCb) 21.56 [pCH3(Pm')], 23.20 [7CH2(Proi)], 30.84 (SCOCH3),
3 4 .34  [pCH2(Pro2)l, 35.57 (PCH2(Prol)], 38.33 [■vCH(Pro2)), 45.50 [6CH2(Pro>)], 
51.22 [8 CH2(Pro2)l, 59.61 [aCH(Pro2)], 66.59 [aC(Prol)], 165.60 and 169.89 (2 x 
amide CO) and 195.44 (thiolacetate CO); m/z (Cl) 283 (100%, [M + H]+), 241 (8 , [M 
-  COCH3 + 2H]+) and 206 (9, [M -  COCH3 -  H2S + H]+).
Methyl (25)-A^-[A^-(2-chloropropionyl)-(2S)-2-methylprolyI]-2-methylprolinate 
144 and (25,2’S)-iV-(2’-chloropropionionyl)proline 7-azabenzotriazolyi ester 145
!— V Me
H OOMe
A solution of (25,2’5)-A-(2’-chloropropionyl)-2-methylproline 130 (68  mg, 0.31 
mmol), methyl (25)-2-methylproliiiate hydrochloride 128 (37 mg, 0.21 mmol) and N- 
A^-di-fjopropylethylamine (110 mm^, 0.63 mmol) in dry DMF (1 cm^) under nitrogen 
at 0 °C was treated with HATU (120 mg, 0.32 mmol) and the mixture stirred at 0 °C 
for 4 h, then at room temperature for 40 h. The solution was diluted to 30 cm^ with 
ethyl acetate and washed with aqueous HCl (0.5 mol dm“3, 2 x 10 cm^), aqueous 
sodium hydrogen carbonate solution (5%, 2 x 10 cm^) and brine (10 cm^). The 
organic phase was dried (MgSO^), and the solvent was removed under reduced 
pressure. The residual oil was purified by column chromatography using ethyl 
acetate-light petrol (3:2) as the eluent, enabling isolation of two products, the peptide
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144 as a white solid (21 mg, 30%) and the 7-azabenzotriazolyl ester 145 as a 
colourless gum (38 mg, 37%).
Data for 144: mp 124-126 °C; Rp 0.45 (ethyl acetate); (HRMS: found [M + H]+, 
345.1586. C 16H2535CIN2O4 requires 345.1581); [a j, -42.5 (c 0.8 in MeOH);
"rnaxCCHzCW /cm-i 2985 (C H ), 1737 (ester C O ), 1666 (amide C O ), 1636 (amide 
C O ), 1402 (C H  def.) and 1193 (C -O ) ; 4;(300 MHz; C^HCla) (2 conformations, A 
and B) 1.51 (A, 3 H , d, /  6.6, C H C H 3), 1.53 (3 H , s, P C H 3), 1.61 (B, 3 H , d, 7 6.6, 
C H C H s), 1.64 (3 H , s, p C H s), 1.75-2.21 (8 H , m, 2 x PCH; and 2 x yCHz),
3.38-3.49 (1 H , m,|5CH2), 3.60-3.68 (2 H , m, SCH z), 3.70 (B, 3 H , s, C O 2C H 3),
3.74 (A, 3 H, s, C O 2C H 3), 3.87-3.95 (1 H , m,ySCH2), 4.35 (A, 1 H, q, 76.6, C H C H s) 
and 4.45 (B, 1 H , q, 7 6.6, C H C H 3); ^(75.44 MHz; C ^H C ls) 20.68, 21.79 and 22.70 
(C H C H s and 2 x p C H s), 23.67 and 25.28 (2 x 7C H 2), 37.39 and 37.69 (2 x P C H 2), 
47.89 and 49.06 (2 x 8C H 2), 52.18 (C H C H 3), 52.82 (C O 2C H 3), 68.46 (2 x aC), 
167.55 (C O C H C H 3), 170.83 (amide C O ) and 175.29 (ester C O ); m/z (C l) 347 and 
345 (23 and 70% , chlorine isotopes, [M  +  H]+), 315 and 313 (33 and 97, chlorine 
isotopes, [M  -  2 CH3 +  H ]+ ), 204 and 202 [32 and 100, chlorine isotopes, 
C1CH(CH3)C0NC4H6(CH3)C0+], 176 and 174 [26 and 82 , chlorine isotopes, 
C1CH(CH3)C0NC4H6CH3+].
Data for 145; (Found: C, 47.45; H, 5.1; N, 19.55, C14H 16CIN5O3 H2O requires C, 
47.25; H, 5.1; N, 19.7%); Umax(CH2Cl2)/crn-i 2987 (CH), 1750 (ester CO) and 1661 
(amide CO); 4&(300 MHz; C2HCI3) 1.73 (3 H, d, 76.6, CHCH3), 1.81 (3 H, s, PCH3), 
2 .2 0 - 2 .35  (3 H, m, ipCHzand 7CH2), 2.71-2.81 (1 H, m, IpCHj), 3.75-3.83 (1 H, 
m ,|8CH2), 3.95-4.03 (1 H, m ,|8CH2), 4.52 (1 H, q, 76.6, CHCH3), 7.40 (1 H, dd, 7,
6.5, 72 4.4, Ar-CH 5), 8.39 (1 H , dd, 7i 8.3, J2 1.4, Ar-CH 6) and 8.71 (1 H, dd, 7, 
4.4,7 2  1.4, Ar-CH 4); 8fc(75.44 MHz; C^HCls) 20.64 (C H C H s), 21.34 (PCHs), 24.86 
(7CH2), 38.80 (PCH2), 48.15 (8CH2), 51.60 (CHCH3), 66.00 (aC), 121.32 (Ar-C 5),
129.90 (Ar-C 4), 135.51 and 141.18 (2 x quaternary Ar-C), 152.39 (Ar-C 6), 168.14 
(amide CO) and 170.02 (ester CO).
170
(2S,4lî)-A^-[A^-(ter^-Butoxycarbonyl)-(2S)“prolyl]-4-hydroxyproUne 
methylamide 147
O ^ 'NHMe
Methyl ester 119 (0.63 g, 1.84 mmol) was dissolved in a saturated solution of 
methylamine in methanol (35 cm^) at 0 °C. The flask was stoppered, allowed to warm 
to room temperature, and left standing for 1 day. The flask was cooled to 0 °C and the 
stopper removed. Excess methylamine was driven off by bubbling nitrogen through 
the solution for 30 min. The solvent was removed under reduced pressure to yield the 
methylamide 147 as a white foam (0.63 g, 100%), mp 187-188 °C (Found: C, 56.6;
H, 8.25; N, 12.45. C16H27N3O5 requires C, 56.3; H, 7.95; N, 12.3%); [a]^ -99.4 (c
I.1 in MeOH); Umax(CH2Cl2)/cm-i 3448 (NH), 3342 (NH), 2981 (CH), 1677 (CO) 
and 1164 (C-O); 5h(200 MHz; C^HCla) (3 conformations, ct, tt and to) 1.20 [ct, 9 H, 
C(CH3)3], 1.24 [tt and tc, 9 H, C(CH3)3], 1.63-1.91 [4 H, m, IpCHjCPro), 
|pCH2(Hyp) and TCHzCPro)], 1.95-2.09 [1 H, m, èpCH2(Hyp)], 2,54 (3 H, d, J 4.4 
NHC/Î3), 3.20-3.62 [4 H, m, 5CH2(Pro) and 8CH2(Hyp)], 4.22-4.43 [3 H, m, 
aCH(Pro), aCH(Hyp) and TCH(Hyp)], 7.36 [tt and ct, 1 H, q, 7 4.8, NTfCHa) and 
7.76 (tc, 1 H, q, 74.8, NTfCHs); £fc(50.31 MHz; C^HCla) 23.75 [ct, yCH2(Pro)], 24.43 
[tt, ■yCH2(Pro)], 24.76 [tc, ïCH2(Pro)], 26.40 (tt, NHCH3), 26.47 (ct, NHCH3), 28.31 
[tc, C(CH3)3], 28.36 [rt, € (0 1 3 )3], 28.57 [tt, € (0 1 3 )3], 29.34 [tt, p€H2(Pro)], 29.52 
[tc, P€H 2(Pto)], 30.24 [ct, P€H2(Pro)], 36.64 [tt and ct, P€H2(Hyp)], 37.50 [tc, 
P€H2(Hyp)], 46.79 [ct, 5 €H 2(Pro)], 47.17 [tt, 8 €H 2(Pro)], 47.29 [tc, 8 €H 2(Pro)], 
54.26 [tc, 8€H 2(Hyp)], 54.57 [ct, 8 €H 2(Hyp)], 55.33 [tt, 8 €H 2(Hyp)], 57.82 (tc, 
a€H ), 58.31 (ct, a€H ), 58.60 (tt, a€H), 59.26 (tt, a€H), 60.00 (ct, a€H), 67.87 [tc, 
'y€H(Hyp)], 69.97 [ct, 7€H(Hyp)], 70.56 [tt, y€H(Hyp)], 79.98 [ct, C(€H3)3], 80.26 
[tt and tc, C(€Ha)3], 154.00 (ct, urethane € 0 ), 155.02 (tt and tc, urethane €0),
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172.04 {tt, amide CO), 172.10 {ct, amide CO), 172.40 {ct, amide CO), 172.71 {tt, 
amide CO) and 172.92 {tc, amide CO); m/z (Cl) 342 (98%, [M + H]+), 286 (100, [M 
-  C4H8 + H]+) and 242 (83, [M -  CO2C4H8 + H]+).
(25,4S)-A^ -[^ '^ “(^ ^^ “^Butoxycarbonyl)-(2S)-prolyl]-4-(acetylthio)proline 
methylamide 148
Di-wopropyl azodicarboxylate (0.33 g, 1.6 mmol) was added to a solution of 
triphenylphosphine (0.44 g, 1.7 mmol) in THF (5 cm^) at 0 °C. The resulting 
suspension was stirred at 0 °C for 30 min, after which a solution of alcohol 147 
(0.50 g, 1.5 mmol) and thiolacetic acid (0.13 cm^, 1.8 mmol) in THE (5 cm^) was 
added dropwise. The mixture was stirred at 0 °C for 2.5 h, then at room temperature 
overnight. The solvent was removed under reduced pressure and the residual oil 
purified using column chromatography with light petrol-ethyl acetate (2 :1) as the 
eluent to afford the thiolacetate 148 as a clear colourless oil (0.29 g, 50%); Rf 0.10 
(ethyl acetate); (HRMS: found [M + H]+, 400.1898. C18H30N3O5S requires 
400.1906); t>max(CH2Cl2)/cm-i 3346 (NH), 2980 (CH), 1688 (urethane and thiolester 
CO), 1666 (amide CO) and 1166 (C-O); ^(300  MHz; C%Cl3) (3 conformations, ct, 
tt and tc) 1.31 [ct, 9 H, s, C(CH3)3], 1.34 [tt and tc, 9 H, s, C(CH3)3l, 1.71-2.52 [6 H, 
m, pCH2(Proi), pCH2(Pro^) andyCH2(Proi)], 2.20 {tc, 3H, s, SCOCH3), 2.22 {tt, 3 H, 
s, SCOCH3), 2.24 {ct, 3 H, s, SCOCH3), 2.65 {tt and ct, 3 H, d, 74.7, NHCH3), 2.71 
(tc, 3 H, 7 4.7, NHCH3), 3.18-3.46 [3 H. m, 0 CH2(Pro') and ISCHalPro^)], 
3.81-4.17 [2 H, m, -yCH(Pro2) and |ôCH2(Pro2)], 4.21-4.53 [2 H, m, 2 x aCH(Pro)],
7.10 (1 H, tt and ct, q, J  4.4, NHCH3) and 8.02 (1 H, tc, q, J  4.4, NHCHs); 6^(75.44 
M H z; C^HCb) 23.75, 24.50 and 24.80 ['vCHzffro')]. 26.45 and 26.65 (N H C H 3),
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28.57 and 29.31 [€(0 1 3 )3], 29.55, 30.62 and 30.65 [pCH2(Proi)], 32.37 and 32.86 
(SCOOI3), 37.57 {tt and ct, pCHiCPro^)], 38.84 {tc, pCHzCPro^)], 40.09 {tc, 
TCHCPro^)], 40.28 {tt and ct, 'yCH(Pro2)], 46.79, 46.96 and 42.28 [6CH2(Proi)j, 53.37 
and 53.56 [0CH2(Pro2)], 58.11, 58.17, 59.23, 59.67, 60.02 and 60.48 [2 x aCH(Pro)], 
79.87, 80.13 and 80.40 [ € ( ^ 3)3], 153.99, 154.96 and 155.13 (urethane CO), 171.00, 
171.50, 171.74, 172.12, 172.16 and 173.12 (2 x amide CO), 195.27, 195.77 and 
196.03 (thiolester CO); m/z (Cl) 400 (82%, [M + H]+), 344 (63, [M -  C4H8 + H]+), 
300 (100, [M - C O 2C4H8 + H]+), 170 (21, C4H9OCONC4H7+), 114 (21, 
[NC4H8CONH + H]+) and 70 (22, C4H8N+).
(2iS,4S)-iV-(iV-{iV-[(2S)-2-ChIoropropionyl3-(2S)-prolyl}-(2S)-prolyl)-4- 
(acetylthio)proline methylamide 150
CONHMeN
AcS
A solution of thiolester 148 (0.38 g, 0.75 mmol) in dichloromethane (7 cm^) at 0 °C 
was treated with trifluoroacetic acid (3.5 cm^) and the solution stirred at 0 °C for
2.5 h. The solvents were removed under reduced pressure to yield the trifluoroacetate 
salt 149 as a clear colourless oil.
A solution of acid 106 (0.23 g, 1.1 mmol) and di-wopropylethylamine (0.50 cm^, 2.9 
mmol) in dichloromethane (15 cm^) was treated with BOP-Cl (0.29 g, 1.1 mmol) at 
0 °C under nitrogen. After 20 min, a solution of amine trifluoroacetate 149 in 
dichloromethane (5 cm^) was added and the mixture was stirred at 0-5 °C for 2 h, 
then at room temperature for 2 days. The solution was diluted to ~40 cm^ with 
dichloromethane, then washed with aqueous HCl (0.5 mol dm” ,^ 2 x 25 cm^), 
aqueous sodium hydrogen carbonate solution (5%, 2 x 25 cm^) and brine (25 cm^).
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The organic phase was dried (MgSO^), and the solvent removed under reduced 
pressure to afford the thiolester 150 as a clear colourless oil (0.31 g, 69%); (HRMS; 
found [M + H]+, 487.1788. C21H 32^^C1N4 0 5 S requires 487.1782);
Vtnax(CH2Cl2)/cm“i 3331 (NH), 1690 (thiolester and secondary amide CO), 1662 
(tertiary amide CO) and 1433 (CH def.); ^ (300  MHz; C^HC^) (2 conformations, ttt 
and ttc) 1,51 and 1.53 (3 H, d, J 6.3, C R C m ,  1.72-2.18 [9 H, m, pCH2(Pro'), 
pCH2(Pro2), jpCH2(Pro3), yCH2(Pro') and yCHaCPro^)], 2.19 and 2.21 (3 H, s, 
SCOCH3), 2.33-2.45 [1 H, m, jpCHzCProî)], 2.63 and 2.65 (3 H, d, J  5.5, NHCH3), 
3.25-3.35 [1 H, m, i 8CH2(Pro3)], 3.46-3.60, 3.61-3.81 [4 H, m, 6CH2(Pro>) and 
5CH2(Pro2)], 3.89-3.97 [ttc, 1 H, m, yCH(Pro3)], 4.05 [ttt, 1 H, dd, J\ 7.2, 7% 13.2, 
yCH(Pro3)], 4.21-4.51 and 4.52-4.62 [4 H, m, 3 x aCH(Pro) and &8CH2(Pro3)], 6.81 
(ftt, NHCH3) and 8.11 {ttc, NffCHs); 8c(75.44 MHz; C^HCb) 20.62 and 20.77 
(CHCH3), 24.96, 25.11 and 25.43 [■yCH2(Pro') and yCHiCPro^)], 26.48 and 26.65 
(NHCH3), 28.05, 28.46 and 28.51 [pCH2(Pro') and pCH2(Pro2)], 30.62 and 30.66 
(SCOCH3), 33.15 [ttt, pCH2(Pro3)], 37.25 [ttc, pCH2(Pro3)], 38.84 [ttc, yCH(Pro3)],
40.10 [ttt, yCH(Pro3)], 47.19, 47.43, 47.46 and 47.55 [8 CH2(Pro') and 8CH2(Pro2)], 
51.31 and 51.44 (CHCH3), 53.44 and 53.52 [8CH2(Pro3)], 58.26, 58.52, 58.74, 58.87,
59.78 and 60.46 [3 x aCH(Pro)], 167.84 and 167.91 (COCHCH3), 170.58, 170.95, 
171.60 and 171.91 (3 X amide CO), 195.27 and 195.58 (thiolester CO); m/z (Cl) 489 
and 487 (12 and 29%, chlorine isotopes, [M + H]+), 396 (77, [M -  ClCH(CH3)CO + 
H]+), 354 (11, [M - C 1CH(CH3)C0  -  C H3CO + 2H]+}, 322 (11, [M -  
C1CH(CH3)C 0  -  C H3CO -  S + 2H ]+) and 279 (100,
[CH3CHC0NC4H7C0NC4H6C0NHCH3]+).
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(2S,4S)r/V-(A^-{A^-[(2S)-2-Chloropropionyl]-(2S)-prolyl}-(25)-prolyl)-4-
mercaptoproline methylamide 146
l e ^ O ° 0
Cl < J
CONHMe
Pro^
HS
This was prepared in an identical manner to thiol 121, using thiolester 150 (0.25,0.51 
mmol) to afford thiol 146 as a clear oil (0.15 g, 66%); (HRMS: found [M + H] '*, 
445.1676. C19H3035CIN4O4S requires 445.1676); [a ^  -103.7 (c 0.6 in MeOH); 
Vmax(CH2C l2)/crn“ i 3323 (NH), 2985 (C H ), 1657 (CO) and 1435 (C H  def.); ^(300 
MHz; C^HCla) (2 conformations, ttt and ttc) 1.63 {ttc, 3 H, d, 7 6.6, CHC IT3), 1.65 
{ttt, 3 H, d, 7 6.6, CHC7f3), 1.80 (1 H, d, 7 5.8, SH), 1.91-2.32 [9 H, m, pCH2(ProO, 
pCH2(Pro2), 7CH2(Pto1), 7CH2(Pro2) and <«,ïPCH2(Pro3)], 2.47-2.57 [1 H, m, 
îPCH2(Pro3)], 2.67-2.77 [ttc, 1 H, m,|pCH2(Pro3)], 2.74 (ttc, 3 H, d, 74.7, N H C ffs),
2.79 (ttt, 3 H, d, 74.7, NHC%), 3.32-3.41 [2 H, m,|0CH2(Pro3) and ttc, 7CH(Pro3)], 
3.43-3.51 [ttc, 1 H, 7CH(Pro3)], 3.59-3.70 [2 H, m, i8CH2(Pro>) and î8CH2(Pio2)], 
3.77-3.94 [2 H, m, j 0CH2(Pro') and i5CH2(Pro2)], 4.16 [ttc, 1 H, dd, 7, 12.7,7 2 6 .7 , 
jôCH2 (Pro3 )], 4.25-4.35 [2 H, m, frt,i5 CH2(Pro3) and ttc, aCH(Pro3)], 4.38-4.57 
[2H, m, CffCHs and Iff, aCH(Pro3)], 4.64-4.72 [2 H, ra, aCH(Prol) and 
aCH(Pro2)], 6.50 (ttt, 1 H, d, 7 4.1, NHCHj) and 8.13 (ttc, N/ÏCH3); ^(75.44 MHz; 
C^HCls) 20.75 and 20.91 (CHCH3), 25.12, 25.33, 25.40 and 25.61 ['yCH2(Pro') and 
TCH2(Pio2)], 26.79 (NHCH3), 28.28, 28.64, 28.71 and 28.80 [pCH2(Pro') and 
pCH2(Pro2)], 34.26 [fff, pCH2(Pro3)], 35.94 [ffc, pCH2(Pro3)], 38.49 [ffc, 'yCH(Pro3)],
41.52 [ttt, 7CH(Pro3)], 47.55 and 47.69 [5CH2(Pro') and 6 CH2(Pro2)], 51.48 (fff, 
CHCH3). 51.59 (ffc, Œ C H 3), 56.21 [ffc, 6 CH2(Pro3)], 57.26 [fff, 8CH2(Pro3)], 58.55, 
58.81, 59.02, 59.11, 60.60 and 60.73 [3 x aCH(Pro)), 168.33 (COCHCH3), 171.11, 
171.54, 171.70 and 172.17 (3 x amide CO); 5h(300 MHz; 2H2O) 1.45 (3 H, d, 7 6 .6 ,
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CHCHs). 1.61-1.98 [9 H, m, pCHzffro'), pCHzCPro^), ^pCHiCProS), -yCHzCPro') and 
■ïCH2(Pro2)], 2.17-2.30 [1 H, m,ipCH2(Pro3)], 2.60 (3 H, s, NHCHs), 3.30-3.41 
[2 H, m, -yCH(Pro3) andf5CH2(Pro3)], 3.47-3.57, 3.64-3.78 [4 H, m, 8CH2(Prol) and 
6CH2(Pro2)]. 4.16-4.25 [2 H, m, aCH(Pro) and|8CH2(Pro3)], 4.57-4.63 (2 H, m, 2 x 
aCH(Pro)] and 4.74 (1 H, q, 76.6, CHCH3); 8^(75.44 MHz; % 2 0 ) 19.86 (CHCH3), 
24.35, 24.43 [yCHzCPro') and yCHiCPro^)], 25.73 (NHCH3), 27.95, 28.05 
[pCH2(Proi) and pCH2(Pro2>], 34.40 [pCHsffro^)], 39.09 [7CH(Pro3)], 47.54, 47.92 
[8CH2(Pro‘) and 8CH2(Pro2)], 51.49 (CHCH3), 56.05 [6CH2(Pro3)], 58.59, 59.05,
60.78 [3 X aCH(Pro)], 170.43 (COCHCH3), 171.70, 172.00 and 173.67 (3 x amide 
CO); m/z (Cl) 447 and 445 (8 and 18%, chlorine isotopes, [M + H]+), 278 (82, 
CH2CHCONC4H7CONC4H6CONHCH3+), 234 (17, CHCONC4H7CONC4H6CO+), 
208 and 206 {33 and 100, chlorine isotopes, [C1CH(CH3)C0 NC4H7C0 2 H + H]+}.
Methyl (2S,4R)-N -[iV-(^er^-butoxycarbonyl)-(2R)-alanyl]-4-hydroxyprolinate 153
O OMe
This was prepared in an identical manner to alcohol 119, using {2R)-{tert- 
butoxycarbonyl)alanine 152 (8.00 g, 42,3 mmol) to afford the dipeptide 153 as a 
white foam (6.34 g, 55%); (HRMS: found [M + H]+, 317.1721. C 14H25N2O6 requires 
317.1713); [a]o -16.3 (c 1.0 in MeOH); iWx(CH2Cl2)/cm-i 3425 (NH), 2981 (CH),
1747 (ester CO), 1708 (urethane CO), 1653 (tertiary amide CO) and 1171 (C-O); 
^ (3 0 0  MHz; C^HC^) 1.31 [3 H, d, J  6.9, pCH3(Ala)], 1.42 [9 H, s, C(CH3)3], 
2 .00- 2.11 [1 H, m, ipCH2(Hyp)], 2.25-2.37 [1 H, m, |pCH2(Hyp)], 3.56 [1 H, d, J
11.0, l 8CH2(Hyp)], 3.73 (3 H, s, CO2CH3), 3.83 [1 H, dd, J i  11.0, J2 4.4, 
i8CH2(Hyp)], 4.38-4.63 [3 H, m, aCH(Hyp), aCH(Ala) and -yCHCHyp)] and 5.47 
(1 H, d, J  8.0, NHCH3); 5c(50.31 MHz; C^HCls) 18.70 [pCHs(Ala)], 28.64
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[C(CH3)3], 37.65 [pCH2(Hyp)l, 48.22 [aCH(Ala)], 52.65 (CO2CH3), 55.23 
[8CH2(Hyp)], 58.30 [aCH(Hyp)], 68.43 [yCH(Hyp)], 80.02 [CCCHjls], 155.46 
(urethane CO), 172.19 (amide CO) and 173.03 (ester CO); m/z (Cl) 317 (40%, [M + 
H]+), 261 (100, [M -  C4H8 + H]+), 217 (28, [M -  CO2C4HS + H]+) and 57 (10, 
C4H9+).
Methyl (25,45)-iV-[iV-(terf-butoxycarbonyl)-(2fi)-alanyl]-4-(acetyIthio)prolinate 
154
SAc
'OMe
Di-f^opropyl azodicarboxylate (7.30 g, 34.3 mmol) was added to a solution of 
triphenylphosphine (9.7 g, 37.0 mmol) in THF (100 cm^) at 0 °C. The resulting 
suspension was stirred for 30 min, after which time a solution of alcohol 153 (6.10 g, 
19.0 mmol) and thiolacetic acid (2.75 cm^, 37.3 mmol) in THF (50 cm^) was added 
dropwise. The mixture was stirred at 0 °C for 2.5 h, then at room temperature 
overnight after which the solvent was removed under reduced pressure. Excess 
triphenylphosphine and its oxide were removed by crystallisation (from light petrol- 
ethyl acetate) and filtration. The remaining oil was purified with column 
chromatography using light petrol-ethyl acetate as the eluent to afford the thiolacetate
154 as a clear colourless oil (6.64 g, 92%); Rf 0,49 (ethyl acetate); (HRMS: found [M 
+ H]+, 375.1593. C16H27N2O6S requires 375.1590); [a]^ -24.1 (c 0.2 in MeOH);
i>rnax(CH2Cl2)/cm-i 3428 (NH), 2982 (CH), 1749 (ester CO), 1703 (urethane and 
thiolester CO), 1655 (tertiary amide CO) and 1171 (C-O); 6^(300 MHz; C^Clg) (2 
conformations, tt and tc) 1.26 [3 H, d, J 6 .6 , pCH3(Ala)], 1.36 [tc, 9 H, s, C(CH3)3], 
1.38 [«, 9 H, s, C(CH3)3], 1.84-1.95 [1 H, m, |pCH2(Pro)], 2.26 (tc, 3 H, SCOCH3),
2.30 (tt, 3 H, SCOCH3), 2.60-2.72 [tt, 1 H, m,&pCH2(Pro)], 2.72-2.84 [tc, 1 H, m.
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îpCHzCPro)], 3.36 [tc, 1 H, dd, Ji 12.9, J2 4.7, j5CH2(Prd)], 3.52 [«, 1 H, dd, /] 8 .8 , 
J2 7.0, |ôCH2(Pro)], 3.69 (tt, 3 H, s, CO2CH3), 3.74 (tc, 3 H, s, CO2CH3), 3.92-4.19 
[2 H, m, yCH(Pro) and &8CH2(Pro)], 4.35-4.44 [2 H, m, aCH(Ala) and tc, 
aCH(Pro)], 5.00-5.14 [tt, 1 H, m, aCH(Pro)] and 5.33 (1 H, d, J 8.2, NHCH3); 
8c(75.44 MHz; C^HCb) 18.27 [tc, pCH3(Ala)], 18.86 [tt, pCHsCAla)], 28.60 
[C(CH3)3]i 30.79 (SCOCH3), 34.83 [ff, pCHzCPro)], 37.67 [tc, pCHjCPro)], 39.04 [tc, 
TCH(Pro)], 39.83 [tt, y:H(Pro)], 47.55 [tc, aCH(Ala)], 48.15 [tt, aCH(Ala)], 52.38, 
52.70, 52.76 and 53.03 [8 CH2(Pro) and CO2CH3], 58.77 [aCH(Pro)], 79.94 [tt, 
C(CH3)3], 80.18 [tc, C(CH3)3], 155.42 {tt, urethane CO), 155.82 {tc, urethane CO),
171.74 and 172.03 {tt, amide and ester CO), 172.75 and 173.32 {tc, amide and ester 
CO) and 195.09 (thiolester CO); m/z (CI) 375 (41%, [M + H]+), 319 (100, [M -  C4H8 
+ H]+) and 275 (31, [M -  CO2C4H8 + H]+).
Methyl (25,45)-A^-(A-{iV-[(2S)-2-chloropropionyl]-(2S)-prolyI}-(2R)-alanyl)-4- 
(acetylthio)prolinate 156
Pro'—  _ H
.n„ . h
Me Ci Pro 
Acs'
A solution of thiolester 154 (3.25 g, 8.7 mmol) in dichloromethane (30 cm^) at 0 °C 
was treated with trifluoroacetic acid (15 cm^) and the solution stirred at 0 °C for 90 
min. The solvents were removed under reduced pressure to give the trifluoroacetate 
salt 155 as a yellow oil.
A solution of acid 106 (2.37 g, 11.5 mmol) and A,A^ -di-w<9propylethylamine (6.0 cm^,
34.5 mmol) in dichloromethane (120 cm^) was treated with BOP-Cl (3.10 g, 12.2 
mmol) at 0 °C. After 45 min, a solution of amine trifluoroacetate 155 in 
dichloromethane (40 cm^) was added and the mixture was stirred at 0-5 °C for 3 h,
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then at room temperature for 2 days. The solution was washed with aqueous HCl (0.5 
mol dm~3, 2 x  50 cm^), aqueous sodium hydrogen carbonate solution (5%,
2 X 50 cm3) and brine (80 cm^). The organic phase was dried (MgSO^), and the 
solvent was removed under reduced pressure. The residual oil was purified using 
column chromatography with ethyl acetate as the eluent to afford the thiolester 156 as 
a thick yellow oil (2.73 g, 6 8 %), Rf 0.28; (Found: C, 47.85; H, 6.3; N, 8.65.
C19H28CIN3O6S H2O requires: C, 47.55; H, 6.3; N, 8.75%); (HRMS: Found (M + 
H)+, 462.1457. CiçHag^^ClNaOeS requires 462.1466); [aj^ -31.5 (c 0.9 in MeOH);
tJmax(CH2Cl2)/cm-i 3404, 3310 (NH), 2955 (CH), 1748 (ester CO), 1693 (secondary 
amide and thiolester CO) and 1658 (tertiary amide CO); ^ (3 0 0  MHz; C^HCla) (2 
conformations, ttt and ttc) 1.28 [3 H, d, J  6 .6 , pCH3(Ala^)], 1.63 {ttc, 3 H, d, 7 6.3, 
CHCHb), 1.64 {ttt, 3 H, d, 7 6 .6 , CHCTfs), 1.85-2.26 [5 H, m, pCH2(ProJ), 
ipCH2(Pro3) and yCH(Pro')], 2.27 (ttc, 3 H, s, SCOCH3), 2.31 (ttt, 3 H, s, SCOCH3),
2.60-2.72 [ttt, 1 H, m, jpCH2(Pro3)], 2.74-3.08 [ttc, 1 H, m ipCH 2(Pio3)], 3.36 [ttc,
1 H, dd, Ji 12.9, J 2 4 .7 , | 5 CH2(Pro3)], 3.48-3.70 [3 H, m, 8 CH2(Prol) and ttt, 
| 8CH2(Pro3)], 3.68 (ttt, 3 H, s, CO2CH3), 3.74 (ttc, 3 H, s, CO2CH3), 3.92-4.16 [2 H, 
m, yCH(Pro3) and j8CH2(Pro3)], 4.37-4.57 [3 H, m, CHCH3, aCH(Pro') and 
aCH(Pro3)], 4.63 [1 H, quintet, /  6.9, aCH(Ala)] and 7.15 (1 H, tn, NH); 8b(75.44 
MHz; C^HCb) 17.82 [ttc, pCH3(Ala2)], 18.04 [ttt, pCHsCAla^)], 20.98 (CHCH3),
25.06 [ttt, yCH2(Proi)], 25.34 [ttc, yCH2(Pro')], 28.44 [pCH2(Proi)], 30.85 
(SCOCH3), 34.86 [ttt, pCH2(Pro3)), 37.56 [ttc, pCH2(Pro3)], 39.08 [ttc, yCH(Pro3)],
39.87 [ttt, yCH(Pro3)], 46.78, 47.05, 47.40 and 47.60 [aCH(AlaZ) and 8CH2(Pro')],
51.30 (ttc, CHCH3), 51.69 (ttt, CHCH3), 52.33, 52.46, 52.71 and 53.05 [8CH2(Pro3) 
and CO2 CH3 ], 58.75 [aCH(Pro3)], 60.12 [ttc, aCH(Pro')], 60.74 [ttt, aCH(Pro')],
169.10 (COCHCH3), 170.83, 171.03 (2 X amide CO), 171.99 (ttt, ester CO), 172.88 
{ttc, ester CO) and 195.13 (thiolester CO); m/z (Cl) 464 and 462 (21 and 48%, 
chlorine isotopes, [M + H]+), 371 {26, [M ClCH(CH3)CO + H]+}, 208 and 206 {56 
and 100, chlorine isotopes, [C1CH(CH3)C0 NC4H7C0 2 H]+} and 170 (48, 
[CH2 CHCONC4 H7 CO2 H + H]+).
179
Methyl (15,3R,95,12R,155)-3,12-Dimethyl-4,10,13-trioxo-2-thia-5,ll,14- 
triazatricyclo[12.2.1.0^’^ ]heptadecane-15-carboxylate 151
Pro' . H
Ala^
.  W .M eMe.,
Pro"
Thiolester 156 (0.34 g, 0.74 mmol) was dissolved in a mixture of 0.05 mol dm~3 
aqueous potassium hydroxide solution (25 cm^) and methanol (25 cm^). After stilling 
for 2.5 h, aqueous HCl (0.5 mol dm~3, 2.5 cm^) was added and the methanol was 
removed under reduced pressure. The solution was then further acidified to pH 1 and 
extracted with ethyl acetate (6  x 40 cm^). The combined organic extracts were dried 
(MgS0 4 ) and the solvent removed under reduced pressure to afford thiol 150 in an 
impure state as a colourless oil (0.22  g).
The above oil was redissolved in DMF (150 cm^) and the solution treated with 
caesium carbonate (0.34 g, 1.04 mmol). The suspension was stirred under nitrogen for 
4 days after which it was filtered through Celite, and the solvent removed under 
reduced pressure to give a brown oil. The crude oil was purified by column 
chromatography using dichloromethane-methanol (24:1) as the eluent to afford 
macrocycle 151 as colourless crystals (70 mg, 25%), mp 202-204 °C; (Found: C, 
51.9; H, 6.45; N. 10.55. C17H25N3O5S4 H2O requires C, 52.05; H, 6.7; N, 10.7%); 
[a lp -149.9 (e 0.5 in MeOH); «max(CH2Cl2)/cm-l 3308 (NH), 2953 (CH), 1763 (ester
CO), 1682 (secondary amide CO), 1663 (tertiary amide CO) and 1450 (CH def.); 
4,(500 MHz; % 6-DMSO) 1.27 [3 H, d, J  6.5, CHCH3], 1.28 [3 H, d, J  6 .6 , 
PCH3(Ala2)], 1.57-1.62 [1 H, m, ipCH2(Pro3)], 1.80-1.88 [1 H, m, |pCH2(Pro3)], 
1.96-2.00 [1 H, m,57CH2(Pro>)], 2.10-2.14 [1 H, m, |pCH2(Pro')], 2.20-2.28 [1 H, 
m, &yCH2(Proi)], 2.48-2.55 [1 H, m,|yCH2(Pro')], 2.90 [1 H, dd, 7, 11.8, J2 6 .8 , 
| 5CH2(Pro3)], 3.12-3.17 [1 H, m, ■)CH(Pro3)], 3.61-3.67 [2 H, m, 8CH2(Pro')], 3.65
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(3 H, s, CO2CH3), 4.09 (1 H, q, J  6.9, CHCH3), 4.09-4.16 [1 H, m, aCH(Ala2)], 4.31 
[1 H, dd, 7i 11.7,72 4.8, |SCH2(Pro3)], 4.41[ 1 H, dd, 7, 9.3, J2 5.4, aCH(Pro3)], 4.88 
[1 H, d, 77.2, aCH(Prol)] and 8.17 (1 H, d, 74.3, NH); 8b(125.73 MHz; ^Hg-DMSO) 
16.45 [pCH3(Ala2)], 16.73 (CHCH3), 24.41 [yCH2(Pro')]. 25.62 [pCH2(Pro‘)]. 33.56 
[PCH2(Pro3)], 40.26 (CHCH3), 41.56 [yCH(Pro3)], 46.38 [8 CH2(Pro')], 50.85 
[8CH2(Pro3)], 51.08 [aCH(AlaZ)], 51.79 (CO2CH3), 57.12 [aCH(Pro3)], 57.70 
[aCH(Pro')], 169.26 [CO(Ala2)J, 170.17 [CO(Pro‘)], 171.05 [CO(Pro3)] and 171.48 
(ester CO); m/z (FAB+) 406 (5%, [M + Na]+), 384 (64, [M + H]+) and 128 {84, 
(NC4H6(S)C0]+).
iV.lS-Methyl-(lS,3fi,9S,12R,15S)-3,12-Dimethyl-4,10,13-trioxo-2-thia-5,ll,14- 
triazatricyclo[12.2.1.0^’^ ]heptadecane-15-carboxamide 158
r A  H
^  s  CONHMe
Pro"
Methyl ester 151 (42 mg, 0.11 mmol) was dissolved in a saturated solution of 
methylamine in methanol (5 cm^) at 0 °C. The flask was stoppered, allowed to warm 
to room temperature, and left standing for 2 days. The flask was cooled to 0 °C, and 
the stopper removed. The excess methylamine was driven off by bubbling nitrogen 
through the solution for 30 min. The solvent was removed under reduced pressure to 
afford methylamide 158 as white crystals in quantitative yield, mp 280 °C (decomp.); 
(Found; C, 53.85; H, 6 .8 ; N, 14.5. C17H26N4O4S requires C, 53.4; H, 6.85; N, 
14.65%); [ a t -46.3 (c 0.6 in MeOH); t)max(CH2Cl2)/cm-' 3348 (NH), 2940 (CH),
1671 (secondary amide CO), 1621 (tertiary amide CO) and 1532 (NH def.); 5h(300 
MHz; C2HCI3) 1.34 [3 H, d, J 6 .6 , CUCH3],  1.37 [3 H, d, J  7.1, pCH3(Ala2)],
1.88- 2.01 [2 H, m, lpCH2(Pro3) and&yCH2(Pro')], 2.02-2.16 [2 H, m,|pCH 2(Pro')
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andèyCH2(Pro')], 2.37-2.53 [2 H, m,jPCH2(Prol) andyPCHzCProS)], 2.82 (3 H, d, J 
4.9, NHCHs), 3.22 [1 H, d, J 11.0, | 8CH2(Pro3)], 3.49-3.58 [1 H, m, yCH(Pro3)], 
3.61-3.72 [3 H, m, 6 CH2(Pro') and î5 CH2(Pto3)], 3.81 (1 H, q, J  7.1, CHCH3),
4.38-4.51 [2 H, m, aCH(Ala2) and aCH(Pro3)], 4.83 [1 H, d, 77.1, aCH(Prol)], 7.51 
[1 H, d, 7 6.9, NH(Ala2)] and 7.64 (1 H, m, NHCH3); 8^(75.44 MHz; C^HCb) 17.10 
and 17.15 [CHCH3 and pCHsCAla^)], 25.55 [pCH2(Pro') and yCH2(Pmi)], 26.71 
(NHCH3), 34.70 [pCH2(Pro3)], 43.08 and 43.15 [CHCH3 and yCH(Pro3)], 47.49 
[ôCH2(Proi)], 49.43 [aCH(AlaZ)], 51.37 [5CH2(Pro3)], 59.73 (aCH(Pro3)], 61.36 
[aCH(Proi)], 169.66 [CO(Pro>)], 172.19 [CO(Pro3)], 172.69 [COCAla^)] and 174.63 
(COCHCH3); m/z (CI) 383 (100%, [M + H]+) and 351 (23, [M -  S + H]+).
(lS,3«,9S,12R,15S)-3,12-Dimethyl-4,10,13-trioxo-2-thia-5,ll,14- 
triazatricyclo[12.2.1.05»9]heptadecane-15-carboxylic acid 159
Ala^
j— I N
S '" ( ^ u .C 0 2H
Pro^
A solution of methyl ester 151 (0.30 g, 0.79 mmol) in methanol (3 cm^) was treated 
with aqueous sodium hydroxide solution (1.0 mol dm~3, 3.5 cm^), and the mixture 
allowed to stir for 2 h. After addition of aqueous HCl (1.0 mol dm“ ,^ 5 cm^), the 
methanol was removed under reduced pressure. The solution was acidified with 
aqueous HCl, saturated with NaCl, and exhaustively extracted with ethyl acetate (9 x 
20 cm^). The combined organic extracts were dried (MgSO^), and the solvent 
removed under reduced pressure to afford the macrocycle acid 159 as colourless 
crystals (0.24 g, 83%), mp 225-226 °C (decomp.); (Found: C, 52.15; H, 6.5; N, 11.0. 
C16H23N3O5S requires C, 52.0; H, 6.3; N, 11.35%); [ocj -134.4 (c 0.2 in MeOH);
^max(CH2Cl2)/cm~' 3317 (NH), 1751 (ester CO), 1686 (secondary amide CO) and
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1672 (tertiary amide CO); 0h(300 MHz; C^HCls) 1.32 [6 H, m, CHCH3 and 
PCH3(Ala2)], 1.90-2.10 [3 H, m, IpCHjCProl), &pC%(Pro3) and ^CHaCProi)],
2.38-2.43 [3 H, m, IpCHaCPro'), TpCH2(Pro3) and hCH 2(Proi)], 3.11 [1 H. d, 1
11.8, | 5CH2(Pro3)], 3.50-3.66 [3 H, m. ■yCH(Pro3) and SCHaCProi)], 3.83-3.91 [2 H, 
m, CHCH3 an d |5CH2(Pro3)]. 4.46-4.50 [1 H, m, aCH(Ala^)], 4.54-4.58 [1 H, m, 
aCH(Pro3)], 4.81 [1 H, d, 7 7.7, aCH(Pro‘)], 7.63 (1 H, d, 7 6 .6 , NH) and 9.77 (1 H, 
br. s, CO2H); 5c(75.44 MHz; C^HCla) 16.94 and 17.00 [CHCH3 and pCHaCAla^)], 
25.37 and 25.73 [pCHaCPro') and iCHzlProi)], 34.25 [pCHaCPro^)], 42.62 and 42.75 
[CHCH3 and yCH(Pro3)], 47.48 [8CH2(Prol>], 49.47 [aCHCAla^)], 51.54 
[8CH2(Pro3)], 59.82 and 60.13 [aCH(Pro') and aCH(Pro3)], 169.98 [CO(Pro')], 
172.56, 173.02 and 174.63 [COCHCH3, CO(AlaZ) and CO(Pro3)]; m/z (Cl) 370 (77%, 
[M + H]+), 326 (14, [M -  CO2 + H]+), 257 (59, [M -  NC4H7CO2 + H]+) and 170 
(100, SCHCONC4H7CO+).
(2S)-Al-{(lS,3fi,9S,12«,15S)-3,12-Dimethyl-4,10,13-trioxo-2-thia-5,ll,14- 
triazatricyclo[12.2.1.05>9]heptadecane-15-carbonyl}phenylalanine methylamide 
161
Pro'   .. H
Ala
Me
Me.., A n  ,A o  Ph
NHMe
%
Phe" °
A solution of acid 159 (54 mg, 0.15 mmol) and A,A-di-w<?propylethylamine (80 pi, 
0.46 mmol) in dry dichloromethane (2 cm^) was treated with BOP-Cl (40 mg, 0.16 
mmol) and the resulting suspension stirred under nitrogen at 0 °C for 1 h. A solution 
of (2.5)-phenylalanine methylamide 160 (30 mg, 0.17 mmol) in dry dichloromethane 
(1 cm^) was then added. The mixture was stirred at 0-5 °C for 2 h, then allowed to
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warm to room temperature and stirred for a further 20 h. The solution was diluted to 
-15 cm3 with dichloromethane, washed with aqueous HCl (0.5 mol dm~3, 2 x 5  cm^), 
aqueous sodium hydrogen carbonate solution (5%, 2 x 5  cm^) and brine (5 cm^), then 
dried (MgSO^). The solvent was removed under reduced pressure to afford the 
peptide 161 as a white solid (48 mg, 62%). A small portion of this was recrystallised 
from ethyl,acetate to afford colourless needles, mp 258-259 °C; (Found: C, 58.95; H, 
6.65; N, 13.05. C26H35N5O5S requires C, 58.95; H, 6.65; N, 13.2%); [a}y -62.7 (c
0.15 in MeOH); i>max(CH2Cl2)/cm“i 3364 (NH), 2937 (CH), 1679 (secondary amide 
CO), 1642 (tertiary amide CO) and 1531 (NH def.); %(500 MHz; CmClg) 1.14 [3 H, 
d, 7 7 .2 , CHC7Î3], 1.31 [3 H, d, 7 6 .6 , pCHjCAla^)], 1.84-1.96 [2 H, m.ipCHzCProl) 
and îPCH2(Pro3)], 2.04-2.11 [1 H, m, ^ H 2(Proi)], 2.37-2.54 [3 H, m, 
VpCH2(Prol), lpCH2(Pro3) and ^yCHzCPm')], 2.81 (3 H, d, 74.7, NHC//3), 3.12 
[1 H, dd, 7i 15.9, 72 10.0 ,|pCH2(Phe'')], 3.24 [1 H, d, 7 11.9, jSCH2(Pro3)], 3.48 
(1 H, q, 77.9, CffCHj), 3.58-3.67 [5 H, m,|pCH2(Phe4), yCH(Pro3), SCHzCPm') and 
|SCH2(Pro3)], 4.45-4.49 [2 H, m, aCH(Ala2) and aCH(Pro3)], 4.84 [1 H, dd, 7, 7.9, 
h  1.5, aCH(Proi)], 5.02 [1 H, m, aCH(Phe4)], 6.90 (1 H, q, 7 4.3, NHCHs), 7.15 
(1 H, t, 77.1, Ar-H para), 7.23-7.28 (4 H, m, Ar-H ortho and meta), 7.60 [1 H, d, 7 
7.2, NH(Ala2)l and 7.86 [1 H, d, 7 8.0, NH(Phe4)J; 6^(75.44 MHz; C^HCls) 17.01 
(CHCH3), 17.46 [pCH3(Ala2)J, 25.52 [pCH2(Pro‘)], 25.71 [yCHzCPro')], 26.98 
(NHCH3), 34.48 [pCH2(Pro3)], 36.59 [pCH2(Phe'‘)J, 43.34 [yCH(Pro3)], 43.61 
[CHCH3], 47.49 [8 CH2(Prol)], 48.85 [aCH(Ala2)J, 51.19 [8 CH2(Pro3)], 53.60 
[aCH(Phe‘‘)], 59.98 [otCH(Pro>)], 62.36 [aCH(Pro3)], 126.59 (Ar-CHpara), 128.70 
(Ar-CH meta), 129.11 (A r-CH  ortho), 138.78 (Ar-C quaternary), 169.65 
[CO(Prol)], 172.07 [CO(Pro3)], 172.76 [CO(Phe'»)], 173.00 [CO(AlaZ)] and 174.47 
(COCHCH3); m /z  (Cl) 530 (22%, [M + H]+), 243 (100,
[NC4HgCONHCH(CH2Ph)CO]+) and 201 (37, [SCH(CH3)CONC4H7CONH + H]+}.
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(2S)-A-[(^er/-Butoxycarbonyl)-(25)-alanyl]phenyIaIanine methylamide 163
Me H H
X . N ,  XONHMe HN T  X
B O C O  H I 
Ph
A stirred solution of (25)-(terf-butoxycarbonyl)alanine 162 (0.64 g, 3.4 mmol) and 
A-methylmorpholine (0.38 cm^, 3.4 mmol) in dry THF (15 cm^) at -1 5  °C was 
treated dropwise with wobutyl chloroformate (0.46 cm^, 3.4 mmol), followed after 
2 min by a solution of (25')-phenylalanine methylamide 160 (0.60 g, 3.4 mmol) 
and A-methylmorpholine (0.38 cm^, 3.4 mmol) in dry THF (5 cm^).
The suspension was diluted with additional THF to allow efficient stirring, allowed to 
reach room temperature, then stirred for 2 h. The hydrochloride salts formed were 
filtered off and the solvents removed under reduced pressure to yield a solid which 
was redissolved in ethyl acetate (50 cm^). This solution was washed with aqueous 
HCl (0.5 mol dm“3, 2 x 30 cm^), aqueous sodium hydrogen carbonate solution (5%, 2 
X 30 cm^), and brine (30 cm^). The solvent was removed under reduced pressure to 
yield the dipeptide methylamide 163 as a white solid (0.78 g, 67%). A small portion
of this was recrystallised from ethyl acetate to afford colourless needles, mp 
157-158 °C (lit., 157-158 °C); [aJ)-38.7 (c 1.1 in MeOH) [lit., -37.7 (c 1.0
in MeOH]; Umax(CHzCl2)/cm-i 3411 (NH), 2981 (CH), 1701 (urethane CO), 1670 
(amide CO) and 1505 (NH def.); 5h(200 MHz; C^HCls) 1.27 [3 H, d, /  7.0, 
pCH3(Ala)], 1.37 [9 H, s, C(CH3)3], 2.70 (3 H, d, 74.8, N H C H 3), 3.01-3.25 [2 H, m, 
pCH2(Phe)], 4.05 [1 H, m, aCH(Ala)], 4.66 [1 H, m, aCH(Phe)], 5.10 (1 H, m, NH),
6.74 (1 H, m, NH) and 7.14-7.32 (5 H, m, Ar-H); ^(50.31 MHz; C2HCI3) 18.57 
[PCH3(Ala)l, 26.82 (NHCH3), 28.69 [0 (0 1 3 )3], 38.36 [p C H 2(P h e )], 51.56 
[aCH(Ala)], 54.42 [aCH(Phe)], 80.93 [C(CH3)3], 127.39 (Ar-CH para), 129.04 
(Ar-CH meta), 129.70 (Ar-CH ortho), 137.11 (Ar-C quaternary), 156.10 (urethane 
CO), 171.70 and 173.15 (2 X amide CO); m/z (Cl) 351 (100%, [M + H]+), 294 (93, 
[M -  C4Hg]+) and 250 (12, [M -  C0 2 C4Hg]+).
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(25)-A-(A-{(15,3/î,95,12/î,15S)-3,12-Dimethyl.4,10,13-trioxo-2-thia-5,ll,14- 
triazatricyclo[12.2,1.0®’^ ]heptadecane-15-carbonyI}-(25)-phenylalanyl)alanine 
methylamide 165
Pro'   ,, H
Ala
P r o 3  H JTro3  ^  J Ç  NHMe
A solution of methylamide 163 (0.50 g, 1.4 mmol) in dichloromethane (15 cm^) at 
0 °C was treated with trifluoroacetic acid (8 cm^) and the solution stirred for 2 h. The 
solvents were removed under reduced pressure to yield the trifluoroacetate salt 164 as 
a white solid.
A solution of acid 159 (80 mg, 0.22 mmol) and A,A-di-wopropylethylamine (0.12 
cm3, 0.69 mmol) in dichloromethane (5 cm^) was treated with BOP-Cl (60 mg, 0.24 
mmol) at 0 °C. After 50 min, amine trifluoroacetate 164 (90 mg, 0.25 mmol) was 
added and the mixture was stirred at 0-5 °C for 2 h, then at room temperature for 
18 h. The solution was diluted to -15 cm^ with dichloromethane, then washed with 
aqueous HCl (0.5 mol dm"^, 2 x 6  cm^), aqueous sodium hydrogen carbonate solution 
(5%, 2 x 6  cm3) and brine (6  cm^). The organic phase was dried (MgSO^), and the 
solvent removed under reduced pressure. The crude residue was purified by column 
chromatography using dichloromethane-methanol (2 0 :1) as the eluent to afford the 
peptide 165 as a white solid (43 mg, 33%), mp 129-131 °C; (HRMS: Found (M + 
H)+, 601.2798. C29H41N6O6S requires 601.2808); [aj, -25.7 (c 0.3 in MeOH);
^max(CH2Cl2)/cm~  ^ 3338 (NH), 2935 (CH), 1680 (secondary amide CO), 1662 
(tertiary amide CO) and 1536 (NH def.); 4t(300 MHz; C^HClg) 1.16 [3 H, d, J 7.4, 
pCH3(Ala4)], 1.27 [3 H, d, J  6 .6 , pCH3(Ala2)], 1.30 (3 H, d, J  7.4, CHCH3),
1.89-1.98 [2 H, m, jpCH2(Pro>) and ipCH2(Pro3)], 2.02-2.09 [1 H, m,&yCH2(Pro')],
186
2.33-2.40 [1 H, m, 57CH2(Pro')], 2.43-2.55 [2 H, m,ipCH2(Proi) andlpCH2(Pro3)].
2.74 (3 H, d, 74.7, NHCH3), 2.86 [1 H, dd, 7, 14.4, h  11.7, IpCHzCPhe?)], 3.22 [1 H, 
d, 7 11.8, l8CH2(Pro3)], 3.44-3.69 [4 H, m, ^ C H 2(Phe5), 8CH2(Pro>) and 
i8CH2(Pro3)], 3.74-3.85 [2 H, m, CHCH3 and yCH(Pro3)], 4.15-4.19 [1 H, m, 
aCH(Ala4)], 4.37 [1 H, d, 7 10.4, aCH(Pro3)], 4.41-4.46 [1 H, m, aCH(AlaZ)],
4.60-4.68 .[1 H, m, aCH(PheS)], 4.75 [1 H, d, 7 6 .6 , aCH(Proi)], 6.87 (1 H, q, 7 4.7, 
N77CH3), 7.06 [1 H, d, 7 9.1, NH(Phe5)], 7.11-7.22 (5 H, m, Ar-H), 7.58 [1 H, d, 7
7.1, NH(Ala2)] and 8.33 [1 H, d, 7 8.0, NH(Ala4)]; 8c(125.8 MHz; C^HCls) 16.31
[PCH3(Ala4)], 16.79 (CHCH3), 17.03 [pCH3(Ala%)], 25.16 [pCHzCProl)], 25.34
[7CH2(Pro>)], 26.47 (NHCH3), 34.39 [pCH2(Pro3)], 37.31 [pCH2(Phe5)], 43.30
[■VCH(Pro3)], 43.57 [CHCH3], 47.31 [8CH2(Pro>)], 48.24 [aCH(AlaZ)], 50.74
[8CH2(Pro3)], 51.01 [aCH(Ala‘‘)], 54.24 [aCH(Phe5)], 59.88 [aCH(Pro')], 62.11 
[aCH(Pro3)], 126.32 (Ar-CH para), 128.22 (Ar-CH meta), 129.14 (Ar-CH onho), 
138.68 (Ar-C quaternary), 169.20 [CO(Pro')], 171.90, 172.18, 172.48 and 172.60 
[CO(Ala2), CO(Pro3), CO(Ala'>) and CO(Phe5)], and 174.24 (COCHCH3); m/z (CI) 
601 (100%, [M + H]+), 569 (31, [M -  NHzCHs]*), 439 (10, [M -
CH3NHCOCHCH2P h + H]+ ) a n d  3 7 2  { 1 0 0 ,
[CONC4H6CONHCH(CH3)CONHCH(CH2Ph)CONHCH3]+).
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A-{(liS,3/î,95,12/î,15S)-3,12"Dimethyl-4,10,13-trioxo-2^thia-5,ll,14-triazatricyclo 
[12.2,1.0^’^ ]heptadecane-15-carbonyl}-iV’-(dimethyl)ethylenediamine 166
P r o '_ v  . .  H
"  Ala-’
N NM02
Pro^ H
A Stirred solution of acid 159 (0.15 g, 0.41 mmol) and A-methylmorpholine 
(0.10  cm^, 0.91 mmol) in dry THF (3 cm^) and DMF (1 cm^) under nitrogen at 
-15 °C was treated dropwise with isobutyl chloroformate (55 pi, 0.42 mmol), 
followed after 10 min. by a solution of A,A-dimethylethylenediamine (60 pi,
0.55 mmol) in dry THF (1 cm^). The solution was allowed to reach room temperature 
and stirred for 4 h. The solvents were removed under reduced pressure, and the 
residual oil redissolved in ethyl acetate (20 cm^). The solution was washed with 
aqueous sodium hydrogen carbonate solution (5%, 2 x 5  cm^), and brine (5 cm^) then 
dried (MgSO^). The solvent was removed under reduced pressure to afford the amine 
166 as colourless crystals (0.14 g, 78%), mp 174-176 °C; (Found: C, 53.95; H, 7.6;' 
N, 15.25. C20H33N5O4S ÎH2O requires C, 53.55; H, 7.65; N, 15.6%); [a]p-48.0 
(e 0.85 in MeOH); u„ax(CH2Cl2)/cm-> 3337 (NH), 2983 (CH), 1668 (secondary 
amide CO), 1634 (tertiary amide CO), 1531 (NH def.) and 1269 (C-N); 4,(300 MHz; 
CZHCI3) 1.23 [3 H, d, J  6.9, CHCJÏ3], 1.29 [3 H, d, J 7.1, pCH3(Ala2)], 1.81-2.04 
[3 H, m, |pCH2(Proi), |pCH2(Pro3) and ^ H 2(Pro‘)], 2.18 [6 H, s, N(CH3)2],
2.31-2.43 [4 H, m, CH2N(CH3)2, iPCH2(Pro') andfyCH2(Pro')], 2.51-2.60 [1 H, m, 
îPCH2(Pro3)], 3.15-3.22 [2 H, m, yCH(Pro3) and j8CH2(Pro3)], 3.35-3.62 [5 H, m, 
8CH2(Pto>), j8 CH2(Pro3) and CH2NHCO], 3.71 (1 H, q, 7 7.1, CHCH3), 4.37-4.43 
[2 H, m, aCH(Ala2) and aCH(Pro3)], 4.76 [1 H, d, 7 8.2, aCH(Pro')], 7.70 (1 H, t, 7 
7.7, NHCH2) and 7.90 [1 H, d, 7 8.0, NH(Ala2)]; 8b(75.44 MHz; C^HCla) 16.93 and 
17.10 [CHCH3 and pCH 3(Ala2)], 25.47 [pCH2(Pro') and YCH2(Pro')], 34.52
1 8 8
[pCH2(Pro3)], 37.63 (CH2NHCO), 43.02 and 43.10 [CHCH3 and 7CH(Pro3)], 45.49 
[N(CH3)2], 46.97 [8 CH2(Pro')], 48.79 [aCH(Ala2)], 51.16 [8 CH2(Pro3)], 57.96 
[CH2N(CH3)2], 59.59 [aCH(Prol)], 61.41 [aCH(Pn)3)], 169.53 [CO(Pro‘)], 171.92 
and 172.30 [CO(Ala2) and CO(Pro3)] and 173.87 (COCHCH3); m/z (Cl) 440 (100%, 
[M + H]+), 408 (23, [M -  2 CH3 + H]+), 369 ( 19, [M -  CHCH2N(CH3)2 + H]+) and 
241 {82, [CH3CHC0NC4H7C0NHCH2CH2N(CH3)2 + H]+}.
A solution of amine 166 in dichloromethane was treated with a slight excess of 
trifluoroacetic acid, followed by removal of the solvent under reduced pressure to 
afford the amine trifluoroacetate 167 as a colourless oil.
4,(500 MHz; C^HCb) 1.36 [6 H, d, 7 7.1, CHCH3 and pCH3(Ala2)], 2.01-2.08 [2 H, 
m, iPCH2(Pro3) andîYCH2(Proi)], 2.11-2.18 (1 H, m,jPCH2(Pro>)], 2.28-2.33 [1 H, 
m, ipCH2(Pro')], 2.39-2.45 [IH, m, |yCH2(Prol)], 2.45-2.51 [1 H, m, ^pCH2(Pro3)], 
2.98 (3 H, s, NCH3), 3.02 (3 H, s, NCH3), 3.25-3.35 [1 H, m, iC%N(CH3)2], 
3.45-3.57 [4 H, m ,|C 772NHC0 , |CH2N(CH3)2,&8CH2(Pro') an d |8CH2(Pro3)], 3.68 
[1 H, dd, 7, 12.5, 72 4.5, j8CH2(Pro3)], 3.82 (1 H, q, 7 7.3, CHCH3), 3.89-3.98 [3 H, 
m, ÎCH2NHCO, -yCH(Pro3) and |8CH2(Proi)], 4.23-4.33 [1 H, m, aCH(AlaZ)], 4.46 
[1 H, d, 7 10.5, aCH(Pro3)], 4.55-4.62 [1 H, m, aCH(Pro')], 8.24 [1 H, d, 7 6 .8 , 
NH(Ala^)], 8.79 (1 H, br. s, NHCH2) and 9.16 [1 H, br. s, NH(CH3)2]; 4:(125.8 
MHz; C%Cl3) 16.10 and 17.07 [CHCH3 and pCH3(Ala2)], 25.93 [-yCH2(Proi)], 26.84 
[pCH2(Proi)], 34.39 [pCH2(Pro3)], 35,00 (CH2NHCO), 43.16 [7CH(Pro3)], 43.82 
(CHCH3), 44.02 [NCH3], 45.38 [NCH3], 47.24 [8CH2(Pro')], 49.00 [aCH(Ala%)], 
51.81 [8CH2(Pro3)], 57.92 [CH2N(CH3)2], 62.37 [aCH(Pro') and aCH(Pro3)], 
116.12 (q, 7 c f 289, CF3CO2), 160.88 (q, 7 c f 38.5, CF3CO2), 173.43, 174.06 and 
174.32 (4 X amide CO).
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APPENDIX
CRYSTALLOGRAPHIC DATA FOR MACROCYCLE 151
C17H26N3O5.5S, M = 392.47, orthorhombic, space group C222i (#20), a -  9.371(10), 
b = 16.744(9), c = 25.705(7) Â. V = 4033(4) Â3, Z = 8 , Dcaic = 1.293 g/cm3, T = 
293 K. 1511 unique reflections were collected on a Rigaku AFC7S, diffracting with 
graphite monochromated Mo-Ka radiation (1 = 0.71069 Â) of which 1020 [I > 3a(I)] 
were used for refinement. Convergence at R(F) = 4.9%, Rw(F) = 4.6% for 240 
variable parameters. The structure was solved and expanded using Fourier techniques 
and was refined using teXsan.
C12 C13
C14
C17Clf
N3
CIO C1505 C16N2 06
04
C8
ClC4
C9
C7 N1 C21C3
03 C5
01 02
C6
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Table A 1.1 Bond Lengths (Â) for Macrocycle 151
atom atom distance atom atom distance
S(l) C(l) 1.82(1) S(l) C(16) 1.82(1)
0 (1) C(5) 1.17(1) 0 (2) C(5) 1.34(1)
0 (2 ) C(6 ) 1.45(1) 0(3) C(7) 1.21(1)
0(4) C(10) 1.24(1) 0(5) C(15) 1.25(1)
N(l) C(3) 1.47(1) N(l) C(4) 1.49(1)
N(l) C(7) 1.33(1) N(2) C(8) 1.46(1)
N(2) C(10) 1.32(1) N(3) C (ll) 1.48(1)
N(3) C(14) 1.45(1) N(3) C(15) 1.34(1)
C(l) C(2) 1.53(1) C(l) C(4) 1.54(1)
C(2) C(3) 1.54(1) C(3) C(5) 1.51(1)
C(7) C(8) 1.55(1) C(8) C(9) 1.50(1)
C(10) C (ll) 1.52(1) C (ll) C(12) 1.51(1)
C(12) C(13) 1.52(2) C(13) C(14) 1.54(1)
C(15) C(16) 1.52(1) C(16) C(17) 1.56(1)
N(2) H(25) 1.10 C(l) H(l) 0.95
C(2) H(2) 0.95 C(2) H(3) 0.95
C(3) H(4) 0.95 C(4) H(5) 0.95
C(4) H(6) 0.95 C(6 ) H(7) 0.95
C(6) H(8) 0.95 C(6) H(9) 0.95
C(8) H(10) 0.95 C(9) H (ll) 0.95
C(9) H(12) 0.95 C(9) H(13) 0.95
C(ll) H(14) 0.95 C(12) H(15) 0.95
C(12) H(16) 0.95 C(13) H(17) 0.95
C(13) H(18) 0.95 C(14) H(19) 0.95
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C(14) H(20) 0.95 C(16) H(21) 0.95
C(17) H(22) 0.95 C(17) H(23) 0.95
C(17) H(24) 0.95
Table A 1.2 Bond Angles (°) for Macrocycle 151
atom atom atom angle atom atom atom angle
C(l) S(l) C(16) 101.5(5) C(5) 0 (2 ) C(6 ) 116.2(8)
C(3) N(l) C(4) 108.6(7) C(3) N(l) C(7) 119.9(9)
C(4) N(l) C(7) 130.9(9) C(8) N(2) C(10) 124.0(8)
C (ll) N(3) C(14) 111.9(8) C (ll) N(3) C(15) 121.6 (8)
C(14) N(3) C(15) 126.3(9) S(l) C(l) C(2) 112.9(7)
S(l) C(l) C(4) 112.3(7) C(2) C(l) C(4) 100.6 (8)
C(l) C(2) C(3) 104.4(8) N(l) C(3) C(2) 104.2(8)
N(l) C(3) C(5) 110.1(9) C(2) C(3) C(5) 112.1(9)
N(l) C(4) C(l) 99.5(7) 0 (1) C(5) 0 (2) 123.3(9)
0 (1) C(5) C(3) 127(1) 0 (2) C(5) C(3) 109.4(10)
0(3) C(7) N(l) 121(1) 0(3) C(7) C(8) 118.2(10)
N(l) C(7) C(8) 120.1(9) N(2) C(8) C(7) 115.5(8)
N(2) C(2) C(9) 112.9(9) C(7) C(8) C(9) 110.7(9)
0(4) C(10) N(2) 122.1(10) 0(4) C(10) C (ll) 121.4(9)
N(2) C(10) C (ll) 116.5(9) N(3) C (ll) C(10) 107.4(8)
N(3) C (ll) C(12) 104.0(9) C(10) C (ll) C(12) 115.5(9)
C (ll) C(12) C(13) 102.6(9) C(12) C(13) C(14) 107.0(9)
N(3) C(14) C(13) 103.4(9) 0(5) C(15) N(3) 121.4(9)
0(5) C(15) C(16) 121.2(9) N(3) C(15) C(16) 117.3(9)
S(l) C(16) C(15) 10.7(7) S(l) C(16) C(17) 7.1(8)
192
C(15) 0(16) 0(17) 109.2(8)
C(8) N(2) H(25) 115.1 0 (10) N(2) H(25) 116.9
S(l) 0 (1) H(l) 110.2 0 (2) 0 (1) H(l) 110.1
C(4) 0 (1) H(l) 110.4 0 (1) 0 (2 ) H(2) 110.7
C(l) 0 (2) H(3) 110.8 0(3) 0 (2 ) H(2) 110.6
C(3) 0 (2) H(3) 110.7 H(2) 0 (2 ) H(3) 109.5
N(l) 0(3) H(4) 110.1 0 (2) 0(3) H(4) 110.1
C(5) 0(3) H(4) 110.2 N(l) 0(4) H(5) 111.9
N(l) 0(4) H(6) 111.8 0 (1) 0(4) H(5) 111.9
C(l) 0(4) H(6) 111.7 H(5) 0(4) H(6 ) 109.7
0 (2) 0 (6) H(7) 109.5 0 (2 ) 0 (6 ) H(8 ) 109.5
0 (2) 0 (6) H(9) 109.5 H(7) 0 (6 ) H(8) 109.5
H(7) 0 (6 ) H(9) 109.4 H(8) 0 (6) H(9) 109.4
N(2) 0 (8) H(10) 105.5 0(7) 0 (8) H(10) 105.7
0(9) 0 (8) H(10) 105.5 0 (8) 0(9) H (ll) 109.4
C(8) 0(9) H(12) 109.3 0 (8) 0(9) H(13) 109.3
H (ll) 0(9) H(12) 109.7 H (ll) 0(9) H(13) 109.6
H(12) 0(9) H(13) 109.5 N(3) 0 (11) H(14) 109.7
0 (10) 0 (11) H(14) 109.9 0 (12) 0 (11) H(14) 110.1
0 (11) 0 (12) H(15) 111.1 0 (11) 0 (12) H(16) 111.2
0(13) 0 (12) H(15) 111.2 0(13) 0 (12) H(16) 111.3
H(15) 0 (12) H(16) 109.4 0 (12) 0(13) H(17) 110.1
0 (12) 0(13) H(18) 110.0 0(14) 0(13) H(17) 110.0
0(14) 0(13) H(18) 110.1 H(17) 0(13) H(18) 109.7
N(3) 0(14) H(19) 110.0 N(3) 0(14) H(20) 111.0
0(13) 0(14) H(19) 110.9 0(13) 0(14) H(20) 110.9
H(19) 0(14) H(20) 109.6 S(l) 0(16) H(21) 110.1
0(15) 0(16) H(21) 109.7 0(17) 0(16) H(21) 110.0
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C(16) C(17) H(22) 109.6 0(16) 0(17) H(23) 109.3
C(16) 0(17) H(24) 109.3 H(22) 0(17) H(23) 109.8
H(22) 0(17) H(24) 109.5 H(23) 0(17) H(24) 109.4
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